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Primary increased secretion of glucocorticoids causes obesity, and increased
Cortisol secretion has been noted in subjects with idiopathic obesity, especially if
of central distribution. Observations in obese men suggest that peripheral
glucocorticoid metabolism may be altered. The Zucker rat model of obesity has
been utilised in this thesis to assess glucocorticoid metabolism in vitro and in
vivo, and to study the mechanisms of its dysregulation. Of particular interest was
activity of 11 P-hydroxysteroid dehydrogenase type 1, which reactivates
glucocorticoids and thus increases local glucocorticoid receptor activation eg in
liver and adipose tissue.
Obese animals had elevated plasma corticosterone (B), higher urinary B
metabolites and heavier adrenal glands when compared with lean rats. They also
had increased activity of hepatic 5a-reductase, decreased hepatic llp-HSDl and
increased renal 11P-HSD2 activity. By contrast, llp-HSDl activity was not
different in skeletal muscle or subcutaneous fat, and was higher in omental fat of
obese animals. Urinary glucocorticoid metabolite profdes, assessed by GCMS,
confirmed that metabolism of B by 5a-reductase is increased in obese animals
and showed the balance of llp-HSDs lies in favour of inactive 11-
dehydrocorticosterone. Greater inactivation of B by 5a-reductase in liver and
llp-HSD2 in kidney, combined with impaired reactivation by lip-HSDl in
liver, may decrease local B concentrations in these sites, and increase metabolic
clearance rate of glucocorticoids, thus increasing drive to the hypothalamic-
pituitary-adrenal axis (HPA). By contrast, increased lip-HSDl activity in
omental adipose tissue may increase local glucocorticoid receptor activation and
promote obesity.
To gain insight into the mechanisms of tissue-specific dysregulation of 11P-
HSD1 in obesity, two of the primary regulators of lip-HSDl were studied;
glucocorticoids which up-regulate, and insulin which down-regulates, 1 ip-HSDl.
Adrenalectomy (ADX) normalised weight gain in obese animals, and furthermore
normalised lip-HSDl activity in liver and reversed the difference in omental
adipose tissue. This highlights that not only are the abnormalities in 1 lp-HSDl
activity tissue-specific, but the regulation of the enzyme is tissue-specific also.
ADX of obese Zucker rats not only removes adrenal hormones, but also
normalises many of the metabolic abnormalities, including insulin resistance. To
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investigate whether insulin was responsible for the alterations in 11 P-HSD 1
following ADX, glucocorticoid metabolism was assessed in obese animals that
had been sensitised to insulin with either metformin or rosiglitazone. Enhanced
insulin sensitivity did not normalise 1 1 P-HSD 1 activity, suggesting that insulin is
not responsible for dysregulation of 1 lp-HSD in obese animals, or for changes in
enzyme activity following ADX. By contrast, enhanced insulin sensitivity did
reverse adrenal hypertrophy, suggesting that insulin may be a key factor
contributing to activation of the HPA in obesity, independently of tissue-specific
changes in 1 lp-HSDl.
The alterations in lip-HSDl in obesity predict that local glucocorticoid
concentrations will vary between tissues, being lower in liver and higher in
omental fat. To try and dissect which changes are important to obesity and
insulin resistance, animals were treated with carbenoxolone (CBX), an inhibitor
of 11P-HSD. CBX had no effect on obesity, and was associated with a
worsening of insulin sensitivity. However, inhibition of lip-HSDl was only
demonstrable in vitro in liver and kidney, not adipose tissue or skeletal muscle,
and therefore further work is required before the full implications of the results
can be assessed.
Finally, the finding of tissue specific alterations in lip-HSDl activity in
obesity was reproduced in obese humans. 1 lp-HSDl activity in homogenates of
gluteal subcutaneous adipose tissue obtained by biopsy was higher in obese
patients than in lean. By contrast, in vivo hepatic 11 p-HSD 1 activity was
impaired in the same obese patients.
In conclusion, 11 P-HSD 1 activity, and therefore local glucocorticoid
concentration, is altered in obesity. Manipulation of this enzyme, particularly in
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Primary increased glucocorticoid secretion causes obesity, and
glucocorticoid secretion is enhanced in both human and rodent obesity
(Marin et al., 1992; Pasquali et al., 1993; Andrew et al., 1998; Fraser et
al., 1999; Cunningham et al., 1986). However, plasma Cortisol is not
consistently elevated in obesity, suggesting that peripheral clearance of
Cortisol may be enhanced (Strain et al., 1982; Rosmond et al., 1998).
There are several routes of metabolic clearance of glucocorticoids,
including the interconversion of active and inactive glucocorticoids by the
isoenzymes of 11 P-hydroxysteroid dehydrogenase (11 p-HSD). Disruption
of glucocorticoid metabolism may alter local, as well as plasma, levels of
steroid, as the 1 ip-HSDs control glucocorticoid action at a tissue level. It
has been suggested that alterations in local reactivation of glucocorticoids
by 11 P-HSD type 1 may be important both in determining metabolic
clearance of Cortisol and in promoting obesity (Bujalska et al., 1997;
Andrew et al., 1998). This is the hypothesis explored in this thesis.
The following chapter reviews glucocorticoid physiology and metabolism,
with particular emphasis on the 11 P-hydroxysteroid dehydrogenases.
Some of the multiple regulators of body weight are then discussed, and the
Zucker rat described as an animal model used in many studies of obesity.
Finally, evidence for the role of glucocorticoids in obesity is presented and
a list of aims of this thesis is laid out.
1.1 Glucocorticoids
Glucocorticoids (Cortisol in man and corticosterone in rodents) were
originally named for their effects on carbohydrate metabolism. It is now
known that they exert an influence on most systems in the body, including
the immune system, fluid and electrolyte homeostasis and physiological
responses to stress. They are part of a family of steroid hormones that all
have the common precursor cholesterol. The basic steroid structure of
cholesterol, comprising three cyclohexane rings and one cyclopentane
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ring, is conserved throughout the family, with each steroid being given its
unique properties by the substitution of chemical groups at various
positions on the backbone molecule (Figure 1.1).
1.1.1 Glucocorticoid synthesis
Glucocorticoids are synthesised from cholesterol in the zonae fasiculata
and reticularis of the adrenal cortex. Adrenocortical steroid biosynthesis is
catalysed by members of the CYP oxidative enzyme family (Figure 1.2),
characterised by their absorbence maximum of 450nm (Miller, 1988). The
nomenclature of these enzymes has recently been changed and is
summarised in Table 1.1.
Rats lack the enzyme CYP 17 in the adrenal cortex so steroids cannot be
17-hydroxylated. This is why the major glucocorticoid in the rat is
corticosterone rather than Cortisol, and also why rats do not synthesise
adrenal androgens.
Trivial name Previous name Present name
Cholesterol side chain cleavage P450scc CYP11A1
3P-hydroxysteroid dehydrogenase 3PHSD 3pHSDII
17a-hydroxylase / 17,20-lyase P450ci7 CYP 17
21 -hydroxylase P450c2, CYP21A2
11 P-hydroxylase P450cn CYP11B1
Aldosterone synthase P450chas CYP11B2
Table 1.1: Nomenclature of steroidogenic enzymes.
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Figure 1.1: The basic steroid ring structure and conventional labeling.
The four carbon rings are identified by letters, and the individual carbon
atoms by numbers. Chemical groups are designated by the number of the








































Figure 1.2: The adrenocortical steroid biosynthetic pathway.
The names of the enzymes are shown in the boxes.
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1.1.2 Glucocorticoid secretion
The synthesis and release of glucocorticoids from the adrenal cortex is
regulated by hormonal interactions among the hypothalamus, pituitary and
adrenal, which in turn can be influenced by neural and other stimuli, eg
stress. Stimuli to the hypothalamus lead to the release of corticotrophin
releasing hormone (CRH) and arginine vasopressin (AVP) into the
hypothalamic-hypophyseal portal system. This rapidly leads to
adrenocorticotrophic hormone (ACTH) release from the anterior pituitary
into the systemic circulation. ACTH is processed from the polypeptide
pro-opiomelanocortin (POMC) and acts on the adrenal cortex where it
stimulates steroidogenesis and the release of adrenocortical steroids,
including glucocorticoids. Glucocorticoids exert an inhibitory effect on
CRH and AVP synthesis, POMC processing and secretion of ACTH, to
provide a negative feedback loop that helps to maintain physiological
plasma glucocorticoid concentrations. This system as a whole is known as
the hypothalamic-pituitary-adrenal axis (HPA).
Circulating glucocorticoids are predominantly protein bound. Plasma
Cortisol and corticosterone circulate largely bound to corticosteroid-
binding globulin (CBG) and albumin, with only around 5-10% circulating
as free steroid (Hammond et al., 1990). Only free steroid can diffuse
across the cell membrane to bind to the intracellular glucocorticoid
receptor, so corticosteroids bound to CBG cannot cause glucocorticoid
receptor activation. Binding proteins therefore buffer free corticosteroid
levels, but they are saturated at high physiological levels so that free




Glucocorticoids exert their effects by diffusing into cells and binding to
soluble intracellular receptors. Ligand binding leads to receptor activation,
dimerisation and translocation to the nucleus where the glucocorticoid
receptor complex can interact with specific DNA sequences known as
glucocorticoid response elements (GREs). The receptor dimer interacts
with components of the transcription machinery to enhance transcription,
and GREs are therefore normally closely associated with the promoter
region of target genes (Yamamoto, 1985). Gene transcription can also be
repressed by glucocorticoids, eg in the negative feedback loop of the HPA
expression of pro-opiomelanocortin (POMC), the precursor to ACTH, is
decreased by Cortisol via interactions at a negative GRE (Drouin et al.,
1993). Glucocorticoids can also inhibit transcription by a second
mechanism that does not involve GREs. The receptor dimer can interfere
directly with transcription factors to prevent transcription, eg activated
glucocorticoid receptors bind to activating protein-1 and inhibit the
transcription of genes involved in the immune response (Jonat et al., 1990;
Yang-Yen et al., 1990).
Membrane glucocorticoid binding sites have also been described in rodent
neurones and synaptic membrane (Liposits & Bohn, 1993; Guo et al.,
1995) and in rodent lymphoma and human leukaemic cells (Gametchu et
al., 1993; Gametchu et al., 1999). The physiological relevance of these
binding sites is still a matter of dispute (see Brann et al., 1995 for a
review) but they are thought to have a function in controlling
glucocorticoid effects on growth, particularly in lymphoma.
1.1.4 Effects ofglucocorticoids
The effects of glucocorticoids are wide-ranging. As well as their many
direct effects, they also have permissive and modulatory effects on tissue
sensitivity to other hormones, such as catecholamines. The major roles of
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glucocorticoids were discovered initially by clinical observation of the
effects of adrenal disease. This was later helped by the development of
tools such as the steroid biosynthesis inhibitor, metyrapone and the
glucocorticoid receptor antagonist, RU486 (mifepristone).
Glucocorticoid excess, eg in Cushing's disease, results in redistribution of
body fat to a more central distribution, impaired glucose tolerance,
impaired immune responses, hypertension and degenerative changes to
muscle and connective tissue. By contrast, in Addison's disease
glucocorticoid deficiency leads to weight loss, hypoglycaemia and
hypotension.
1.1.4.1 Effects of glucocorticoids on metabolism
Glucocorticoids regulate the metabolism of carbohydrates, protein and fat
both in the liver and in the periphery. Glucocorticoids mobilise substrates
for hepatic gluconeogenesis by stimulating release of amino acids from
skeletal muscle and fatty acids and glycerol from adipose tissue, and also
increase expression of gluconeogenic enzymes eg phosphoenolpyruvate
carboxykinase (PEPCK; Sasaki et al., 1984). Peripheral glucose uptake
and utilisation are inhibited by glucocorticoids (Rizza et al., 1982), partly
by decreased translocation of glucose transporters to the cell surface
(Weinstein et al., 1995). Glycogen storage is stimulated by
glucocorticoids due to activation of glycogen synthase, and decreased
metabolism of glycogen by glycogen phosphorylase (Stalmans & Laloux,
1979).
In addition to acutely stimulating lipolysis to provide gluconeogenic
substrates, glucocorticoids also promote differentiation of pre-adipocytes
to mature adipocytes (Hauner et al., 1987). Site-specific alterations in fat
metabolism lead to the characteristic body fat redistribution observed with
glucocorticoid excess (Rebuffe-Scrive et al., 1988). The effects of
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glucocorticoids on body weight homeostasis are discussed in full in section
1.3.
Glucocorticoid-induced catabolism of muscle to produce gluconeogenic
substrates can, in the long term, lead to myopathy. Chronic glucocorticoid
excess is also associated with osteopenia and poor wound healing.
Glucocorticoids decrease new bone formation and increase osteoclast cell
numbers, stimulating bone resorption (Hahn et al., 1979). Both intestinal
calcium absorption and renal calcium reabsorption are also impaired by
glucocorticoids (Hahn et al., 1979; Laake, 1960). The deleterious effects
of glucocorticoids on connective tissue are mediated by an inhibitory
effect on fibroblast proliferation and function, and extracellular matrix
component synthesis (Pratt & Aronow, 1966).
1.1.4.2 Effects of glucocorticoids on the immune system
Glucocorticoids have profound inhibitory effects on inflammation and the
immune system. Trafficking of immune cells is altered by glucocorticoids,
with decreased peripheral lymphocyte and monocyte numbers, but
increased circulating granulocytes. Apoptosis of lymphoid cells is induced
by glucocorticoids and T-cell function and B-cell proliferation are
inhibited (Cupps et al., 1985). Glucocorticoids prevent the inflammatory
response by inhibiting neutrophil accumulation (Dale et al., 1975) and the
phagocytotic and cytotoxic effects of macrophages (Rinehart et al., 1982).
They also inhibit synthesis of prostaglandins (Kantrowitz et al., 1975),
which mediate the inflammatory response. These functions of
glucocorticoids are exploited clinically in the treatment of autoimmune
diseases and inflammatory conditions, and in the management of the
immune response to transplanted organs.
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1.1.4.3 Effects of glucocorticoids on blood pressure
Glucocorticoid excess is associated with hypertension, and deficiency with
hypotension, but the mechanisms of these changes in blood pressure are
not fully understood. Cushing's disease is associated with an enhanced
sensitivity to the pressor effects of angiotensin II and noradrenaline and a
decrease in the levels of vasodilator prostaglandins (Sartura et al., 1986).
All of these changes could contribute to hypertension, but whether they are
sufficient to account for changes in blood pressure is not clear.
Paradoxically, glucocorticoids stimulate atrial natriuretic peptide (ANP)
synthesis and secretion and potentiate ANP's actions on the kidney to
induce salt excretion (Garcia et al., 1985; Hayamizu et al., 1994), which
would be expected to lower blood pressure. Many possible mediators of
glucocorticoid-induced hypertension have been studied including the
sympathetic nervous system, sodium homeostasis and vasodilator
hormones, but few of these seem to be important (for a review see
Whitworth, 1994). However, the majority of studies have been carried out
in animal models, and the studies that have been carried out in humans
have shown discrepancies in the effects of different synthetic
glucocorticoids on cardiac output and vascular resistance (Pirpiris et al.,
1992). The varied responses to synthetic glucocorticoids make it difficult
to dissect exactly how Cortisol increases blood pressure, but there is
increasing evidence that the mechanism may be independent of classical
mineralocorticoid or glucocorticoid activity, as receptor antagonists do not
block the hypertensinogenic effects of Cortisol (Clore et al., 1988; Coghlan
et al., 1984).
1.1.4.4 Effects of glucocorticoids on mood and behaviour
Glucocorticoid exhibit a wide range of neuropsychiatric and behavioral
effects, but the mechanisms behind these is still unclear. Sleep patterns,
mood, cognition and the reception of sensory signals are all affected by
glucocorticoids (McEwen et al., 1986). Glucocorticoid excess is
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associated with increased rapid eye movement sleep and psychological
disturbances, including both mania and depression. Glucocorticoid
insufficiency is also associated with psychological disturbances, mainly
depression and apathy. The effects of glucocorticoids on the control of
appetite and feeding behaviour are discussed in section 1.3. Cells in
several parts of the central nervous system (CNS) contain glucocorticoid
receptors, but some neuronal responses occur so rapidly that they are
unlikely to be mediated by classical transcriptional effects on target genes,
and a direct membrane effect is more likely. Glucocorticoids have
transcriptional effects in the central nervous system, including
neurotoxicity (Sapolsky et al, 1985) and reducing numbers of astrocytes,
oligodendrocytes and hippocampal neurones.
1.1.4.5 Effects of glucocorticoids on growth and development
Finally, glucocorticoids have effects on growth and development. Linear
skeletal growth is inhibited by glucocorticoid excess in children. The
exact mechanism of this effect is not known as neither growth hormone
(GH) or insulin-like growth factor 1 (IGF-1) levels are changed (Frantz &
Rabkin, 1964), but it seems likely that the direct effects of glucocorticoids
on bone and muscle metabolism mentioned earlier have a role to play in
this process. Glucocorticoids stimulate the differentiation of many cell
types, and their effects on fetal lung maturation are utilised clinically to
accelerate lung development in premature babies. They also play a role in
the development of the nervous system by regulating the differentiation of
neural crest epithelial cells into chromaffin cells, and influence the
development of the adrenal medulla (Federoff et al., 1988). Increased
glucocorticoid exposure in utero retards fetal growth in rats and humans
(Benediktsson et al., 1993; Reinisch et al., 1978) and this has been linked
with "programming" effects on cardiovascular risk and control of the HPA
axis. In rats, it has been shown that perinatal manipulations in
glucocorticoid exposure can alter glucocorticoid receptor expression in the
brain to permanently alter HPA axis responses (Meaney et al., 1994) and
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can alter gluconeogenic enzymes and glucose tolerance (Nyirenda et al.,
1998).
1.1.5 Metabolism ofglucocorticoids
The metabolism of glucocorticoids involves reduction, oxidation,
hydroxylation and conjugation, and the metabolism of Cortisol is shown in
Figure 1.3. Firstly, Cortisol (or corticosterone in the rat) can be
interconverted with inactive cortisone (11-dehydrocorticosterone in the
rat) by the isozymes of 11 P-hydroxysteroid dehydrogenase. The
metabolism of Cortisol and cortisone then follow similar steps. The rate
limiting step in glucocorticoid inactivation is the reduction of the A4'5
double bond in the A ring of the steroid structure. This can be carried out
by either 5a- or 5p-reductase, resulting in two isomers differing only in
the orientation of the hydrogen atom around the carbon at position 5.
Cortisol (corticosterone) can be metabolised by either 5a- or 5p reductase,
whereas cortisone (11-dehydrocorticosterone) is only acted on by 5p-
reductase. These dihydro-metabolites are then rapidly reduced further by
the enzyme 3a-hydroxysteroid dehydrogenase (3a-HSD) to form
tetrahydro-metabolites. The tetrahydro-metabolites are the most abundant
metabolites excreted in the urine, closely followed by the cortols and
cortolones, which have been further reduced by 20a-hydroxysteroid
dehydrogenase. The oxidation of cortols and cortolones by 21-oxidase
results in the production of cortolic and cortolonic acids. Corticosteroids
and their metabolites are not very water-soluble, and the final step of
glucocorticoid metabolism is conjugation to either glucuronic acid or
sulphates, which increases their water-solubility and aids excretion.
Hydroxylation of Cortisol to form the water-soluble 6p-hydroxycortisol is
normally only a minor route of metabolism, but can become more
































Figure 1.3: Routes of Cortisol metabolism in vivo.
Enzymes are indicated by the boxes and HSD = hydroxysteroid
dehydrogenase. Both 5a- and 5(3-reduction of Cortisol occur, but cortisone
is only acted on by 5p-reductase.
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1.2 lip-Hydroxysteroid dehydrogenase
The focus of this thesis is the metabolism of glucocorticoids by the
isoenzymes of 11 (3-hydroxysteroid dehydrogenase, and their physiology is
described in this section.
1.2.1 History of11(3-hydroxysteroid dehydrogenase
Liquorice was used as a herbal remedy in ancient times, and was
rediscovered in the fifteenth century as a treatment for dyspepsia. The
active ingredient in liquorice was identified as glycyrrhetinic acid, and its
hemmisuccinate-derivative, carbenoxolone, was the most effective
treatment for peptic ulcers before the innovation of the Lb antagonist
cimetidine. Treatment with liquorice derivatives was associated with side
effects of breathlessness and peripheral oedema, and more recently it was
noted that several patients who consumed large amounts of liquorice
developed a syndrome similar to that of primary hyperaldosteronism
(Epstein et al., 1977). The patients suffered from the symptoms of
mineralocorticoid excess (sodium retention, which leads to oedema,
breathlessness, headaches and hypertension, and potassium wasting, which
leads to polyuria, proximal myopathy, lethargy and muscle cramps) in the
face of low plasma aldosterone levels. It was initially thought that
liquorice contained a direct agonist of the mineralocorticoid receptor.
Glycyrrhetinic acid does indeed bind to mineralocorticoid receptors in
vitro, but with affinity so low (approximately 4,000x lower than the
affinity for aldosterone (Armanini et al., 1983) that this is an unlikely
mechanism of action. However, liquorice-induced mineralocorticoid
effects are dependent on intact adrenocortical function (Borst et al., 1953;
Card et al., 1953), and can be inhibited by dexamethasone (Hoefnagels &
Kloppenborg, 1983). It was therefore apparent that an ACTH-dependant
product of the adrenal cortex was necessary for the effects of liquorice.
14
The congenital syndrome of apparent mineralocorticoid excess (AME) is
remarkably similar to that induced by liquorice consumption (Stewart et
al., 1988; Ulick et al., 1979). Patients present with symptoms of
mineralocorticoid excess, but have low plasma mineralocorticoid levels.
The syndrome is improved by dexamethasone and the mineralocorticoid
receptor antagonist spironolactone, and worsened by even physiological
doses of Cortisol, indicating that an adrenal mineralocorticoid agonist is
responsible.
Studies on patients suffering from AME, and on healthy volunteers treated
with the liquorice derivative glycyrrhetinic acid to induce AME, showed
similar differences in glucocorticoid metabolism. In both groups urinary
free Cortisol was higher, the ratio of Cortisol:cortisone metabolites was
higher, and the elimination half life of [ El]-cortisol was longer (Stewart et
al., 1988; MacKenzie et al., 1990). The discovery of the enzyme 11(3-
hydroxysteroid dehydrogenase (11(3-HSD) led to the description of the
mechanism of AME, and also explained the paradox of mineralocorticoid
receptor specificity in the face of equal affinity for glucocorticoids and
mineralocorticoids (Arriza et al., 1987).
11P-HSD catalyses the inter-conversion of the active glucocorticoid
Cortisol and its inactive metabolite cortisone in man (corticosterone and
11-dehydrocorticosterone respectively in the rat). This dehydrogenase
activity was co-localised with the mineralocorticoid receptor and it was
shown that 11 P-HSD inactivates glucocorticoids at these sites, preventing
them binding to mineralocorticoid receptor (Edwards et al., 1988; Funder
et al., 1988), See Figure 1.4. The 11-18 hemiacetal structure of
aldosterone is such that 11 P-HSD cannot metabolise it, and it is therefore
free to bind to its receptor. It was proposed that AME is due to a lack of





Figure 1.4: 11 P-Hydroxysteroid dehydrogenase mediated receptor
protection.
E=cortisone; F=cortisol; Aldo=aldosterone; MR=mineralocorticoid
receptor.
11 (3-HSD converts Cortisol (which can bind to the mineralocorticoid
receptor) to cortisone (which cannot) conferring mineralocorticoid
specificity to the mineralocorticoid receptor.
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Decreased 11 P-HSD action could explain the alterations in glucocorticoid
metabolism in AME. Urinary free Cortisol and cortisohcortisone ratios
would be higher, and the elimination half life of [3H]-cortisol would be
longer because Cortisol would not be metabolised to cortisone. Renal
binding studies showed that glucocorticoids bound only minimally to the
kidney. However, in the presence of liquorice derivatives (carbenoxolone
or glycyrrhizic acid) glucocorticoids bound to the kidney with the same
pattern as mineralocorticoids (Edwards et al., 1988). Furthermore, the
glucocorticoid binding to mineralocorticoid receptor was shown to activate
the receptor (Souness & Morris, 1989). The evidence for decreased lip-
HSD action being the cause of liquorice-induced apparent
mineralocorticoid excess and congenital AME is therefore strong.
1.2.2 Identification of two distinct isoenzymes
As studies on 11P-HSD progressed it become apparent that there was
evidence for the existence ofmore than one 11 P-HSD enzyme.
1) In kinetic studies of 11 P-HSD purified from the liver, the Km for
Cortisol and corticosterone was found to be in the pM range (Lakshmi &
Monder, 1988). This would not appear to be adequate to protect renal
mineralocorticoid receptor from glucocorticoids, which circulate in the nM
range. It is also unlikely that this enzyme would be able to compete with
the mineralocorticoid receptor for glucocorticoid binding, since the Kd of
the mineralocorticoid receptor for glucocorticoids is in the subnanomolar
range (Arriza et al., 1987). Further kinetic studies suggested two
kinetically distinct isoforms of 11 P-HSD in the liver (Lakshmi & Monder,
1985) and in the lung (Abramovitz et al., 1982).
2) Patients with congenital 11 P-HSD deficiency maintain the ability to
convert an oral dose of cortisone to Cortisol, suggesting that only the
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dehydrogenase and not the reductase activity of 11P-HSD was affected
(Ulick etal., 1979; Stewart etal., 1988).
3) There are differences in the alterations of glucocorticoid metabolism
induced by glycyrrhetinic acid and carbenoxolone. In contrast with
glycyrrhetinic acid, carbenoxolone does not reduce plasma Cortisol levels
or urinary tetratrahydrocortisoktetrahydrocortisone ratios (Stewart et al.,
1987; Stewart et al., 1988). This was proposed to be due to carbenoxolone
inhibiting both 11 P-reductase and 11 P-dehydrogenase activity, in contrast
to glycyrrhetinic acid inhibiting only 11 P-dehydrogenase activity (Walker
et al, 1994a). This was supported by the observation that carbenoxolone
inhibits the formation of Cortisol after an oral dose of cortisone, whereas
glycyrrhetinic acid does not (Frederich et al., 1995).
4) Immunohistochemical studies found 11 P-HSD immunoreactivity and
activity were not co-localised in the kidney (Edwards et al., 1988)
suggesting that the antibody used was binding to a form of 11 P-HSD
distinct to that which protects the mineralocorticoid receptor.
11 P-HSD was cloned from the rat liver by screening a rat liver cDNA
library with anti-serum to 11 P-HSD (Agarwal et al., 1989). The cloned
11 P-HSD encoded both dehydrogenase and reductase activities, which
initially refueled speculation that there may be only one enzyme.
Biochemical studies identified a distinct NAD-dependent 11 p-HSD
isoform in the kidney (Mercer & Krozowski, 1992; Rusvai & Naray-Fejes-
Toth, 1993) and in the placenta (Brown et al., 1993). This isoform of 1 ip-
HSD was a much higher affinity enzyme, with a Km in the nM range for
glucocorticoids, which seemed more appropriate for its postulated role in
the protection of mineralocorticoid receptors. Finally, the question of
whether 11 P-HSD was one or more enzymes was answered when a second
isoform of 11 P-HSD (termed lip*HSD2) was cloned. lip-HSD2 was
initially cloned from the kidney of sheep and man (Agarwal et al., 1994;
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Albiston et al., 1994), and human placenta (Brown et al., 1996) and its
expression was found to be predominantly confined to aldosterone target
tissues, eg kidney and colon, and the placenta (Albiston et al., 1994;
Brown et al., 1996).
1.2.3 Role of11J3-HSD2
The function of 11|3-HSD2 has been clearly defined. It is an NAD+-
dependent, high affinity, exclusive dehydrogenase, which is colocalised
with mineralocorticoid receptors (Rundle et al., 1989). The enzyme
converts active glucocorticoids (Cortisol in man and corticosterone in the
rat) to their receptor inactive 11 -keto derivatives (cortisone and 11 -
dehydrocorticostrone respectively). Mutations in the 11P-HSD2 gene
have identified in patients suffering from congenital apparent
mineralocorticoid excess (Mune et al., 1995; Wilson et al., 1995a; Wilson
et al., 1995b), and liquorice derivatives have been shown to inhibit 1113-
HSD activity (Monder et al., 1989; Stewart et al., 1990). The evidence is
conclusive that the function of 11P-HSD2 in aldosterone target tissues is to
protect the mineralocorticoid receptor from inappropriate activation by
glucocorticoids.
The role of 11P-HSD2 in the control of blood pressure and vascular
responses was confirmed by observations in mice with a transgenic
disruption of the 11P-HSD2 gene (Kotelevtsev et al., 1999). The knock¬
out mice are hypertensive and also have altered vascular responses.
Vasoconstrictor responses to noradrenaline and 5-hydroxytryptamine are
enhanced, and nitric oxide mediated endothelium dependent vasodilatation
is impaired (Hadoke et al., 1999). This had led to the suggestion that 1 ip~
HSD2 may protect the vasculature from circulating glucocorticoids.
11P-HSD2 is also highly expressed in placenta (Brown et al., 1996) where
it is thought to protect the fetus from the much higher circulating levels of
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glucocorticoids in the mother (Beitins et al., 1973). Prenatal exposure to
excessive glucocorticoids is thought to retard fetal development (Reinisch
et al., 1978). The role of 1 ip-HSD2 in protecting the fetus from maternal
glucocorticoids has been supported by the finding that inhibition of 11P-
HSD2 in pregnant rats leads to reduced birth-weight of the offspring
(Lindsay et al., 1996).
1.2.4 Role of11J3-HSD1
lip-HSDl is an NADP(H)-dependent lower affinity enzyme that is
expressed almost ubiquitously, with the highest levels found in the liver
(Mondcr & Shackleton, 1984). In vitro, hepatic lip-HSDl reductase
activity is labile, and dehydrogenase activity predominates, but in primary
cultures of rat hepatocytes the reaction direction is predominantly
reductase (Panarelli et al., 1996). In vivo, hepatic lip-HSDl also acts in
the reductase direction, as venous sampling in man has shown the ratio of
Cortisol to cortisone is increased more than five fold in the hepatic vein
compared with the general circulation (Walker et al., 1992). Hepatic 11 p~
HSD1 therefore regenerates Cortisol from cortisone, potentiating
glucocorticoid action, and so alterations in llp-HSDl would have
important implications for glucocorticoid mediated effects. Indeed,
transgenic disruption of the lip-HSDl gene in mice attenuates activation
of glucocorticoid induced gluconeogenic enzymes (Kotelevtsev et al.,
1997) and inhibition of lip-HSD activity by carbenoxolone leads to an
improvement in whole body insulin sensitivity in man (Walker et al.,
1995). Inhibition of hepatic lip-HSDl by chronic oestradiol
administration also inhibits the expression of gluconeogenic enzymes,
such as phosphoenolpyruvate carboxykinase (Jamieson et al., 1999). 1 ip~
HSD activity is also found in other metabolically active tissues such as
muscle and fat (Bujalska et al., 1997; Napolitano et al., 1998), where it
may also affect glucocorticoid action.
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The vascular system is a target for both gluco- and mineralocorticoids.
lip-HSD activity was found in arterial vessels, and lip-HSDl mRNA
localised to vascular smooth muscle (Walker et al., 1991), such that it
could modulate glucocorticoid access to the glucocorticoid receptor, and
affect vascular tone and hence peripheral resistance. However, the 11(3-
HSD1 knock-out mouse has normal vasoconstrictor responses to
noradrenaline and 5-hydroxytryptamine, and vasodilatation to acetyl
choline is unaffected (Hadoke et al., 1999). Therefore the role of 11 P~
HSD1 in the vasculature remains uncertain.
The brain is a key glucocorticoid target, and glucocorticoid effects are
mediated by both gluco- and mineralocorticoid receptors (McEwen et al.,
1986; De Kloet, 1991) eg in the hippocampus. It is thought that
glucocorticoids bind to mineralocorticoid receptors under normal
circumstances, but that when glucocorticoids rise eg at the diurnal peak or
with stress, they will bind to classical glucocorticoid receptors (Reul & De
Kloet, 1985). lip-HSDl is expressed in many brain regions, with highest
expression in hippocampal, cerebellar and cortical neurones (Moisan et al.,
1990; Lakshmi et al., 1991; Sakai et al., 1992). In primary hippocampal
cultures 1 lp-HSDl is a reductase (Rajan et al., 1996) and thus potentiates
the neurotoxic effects of glucocorticoids (Sapolsky et al., 1985). This may
be relevant to neurodegenerative diseases and aging.
The hippocampus, hypothalamus and pituitary all express 1 lp-HSDl
(Moisan et al., 1990), so there is a potential role for 1 lp-HSDl to regulate
glucocorticoid secretion via the HPA axis. This is supported by
observations in the 1 lp-HSDl knock-out mouse, which has adrenocortical
hypertrophy, increased sensitivity to ACTH and elevated plasma
corticosterone in the diurnal nadir (Kotelevtsev et al., 1997). It has been
suggested that these mice have an insensitivity of the HPA to central
glucocorticoid inhibition due to lack of amplification of glucocorticoid
levels by lip-HSDl in key sites of feedback. Impaired activity of llp-
21
HSD1 in the periphery could also have an effect on the HPA, by increasing
the metabolic clearance rate of Cortisol and thus increasing drive to the
HPA (Phillipou et al., 1996). Impairment of llp-HSD2 would be
predicted to have the opposite effect, by decreasing the clearance of
Cortisol. Therefore, both peripheral clearance and central regulation of
feedback of glucocorticoids by 11P-HSD may be important.
1.2.5 Regulation of11/3-HSDs
The expression of 11 p-HSD 1 is sexually dimorphic, at least in the rat, with
males having higher hepatic and renal enzyme activity than females (Lax
et al., 1978; Smith & Funder, 1991). The sexual dimorphism is due to a
difference in growth hormone secretion patterns, which is in turn regulated
by oestradiol (Low et al., 1994a). Male rats have high amplitude
pulsatility to their growth hormone levels, whereas this pulsatility is
dampened in female rats leading to more continuous growth hormone
levels, and decreased 11 P-HSD 1 (Low et al., 1993). Exogenous oestradiol
administration decreases hepatic and renal 11 P-HSD 1 mRNA, but has no
effect in hippocampus (Low et al., 1993), which is indicative of tissue-
specific regulation of the enzyme. Studies in man are limited to analysis
of urinary steroid metabolites, and are not conclusive. Increased, normal
and decreased 11 P-HSD activity have all been reported in women
compared with men (Andrew et al., 1998; Stewart et al., 1999; Finken et
al., 1999; Fraser et al., 1999).
Thyroid hormone decreases hepatic 11 P-HSD 1 activity in rats, but has no
effect on renal 11 P-HSD activity (Whorwood et al., 1993). This could
indicate tissue-specific regulation of 11 P-HSD, but the result is
confounded by the presence of both 11 P-HSD 1 and 2 in rat kidney.
However, in man analysis of urinary glucocorticoid metabolites indicates
that 11 P-HSD 1 activity is increased by thyroid hormone (Hellman et al.,
1961; Zumoff et al., 1983).
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There is evidence that inflammatory agents such as the interleukins and
tumour necrosis factor-a increase 11P-HSD1 activity and expression in
kidney cells (Escher et al., 1997). This is thought to be a counterbalance
mechanism to limit their pro-inflammatory effects by increasing the
activity of anti-inflammatory glucocorticoids. Interleukins 5 and 6 also
increase 11 P-HSD activity in granulosa cells (Evangelatou et al., 1997),
but this activity has not been attributed to a particular isozyme.
Glucocorticoids and insulin have antagonistic effects on lip-HSDl. Cell
culture studies on human fibroblast cells and rat vascular smooth muscle
and liver cells all showed induction of 11 P-HSD 1 by glucocorticoids while
insulin had the opposite effect (Hammami & Siiteri, 1991; Takeda et al.,
1994; Jamieson et al., 1995). Similar induction of 11 P-HSD 1 is seen in
vivo in liver and hippocampus after glucocorticoid treatment, while
adrenalectomy resulted in decreased activity and mRNA in the liver (Low
et al., 1994b; Walker et al., 1994b). By contrast 11 P-HSD activity in the
kidney is unaffected by manipulations in glucocorticoids (Smith & Funder,
1991; Walker et al., 1994b), which represents distinct regulation of the
11P-HSD2 isozyme.
As was discussed briefly in section 1.1, glucocorticoids have effects on
body weight homeostasis. Since 11 p-HSD 1 controls local glucocorticoid
levels in key target tissues such as liver, muscle and fat, alterations in 11 p-
HSD1 activity are postulated to be important in obesity. Some of the
regulators of body weight are discussed in the following section.
1.3 Regulation of body weight
Body weight is governed by the balance between energy intake, ie food
consumption, and energy expenditure, and the centre of energy
homeostasis control is thought to be the hypothalamus. Lesion studies
carried out in the 1940s and 1950s demonstrated that the ventromedial
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hypothalamus is a satiety centre, whereas the lateral hypothalamic area
stimulates feeding behaviour (Brobeck et al., 1943; Anand & Brobeck,
1951). More recently, the arcuate nucleus has also been implicated in the
regulation of food intake (Mercer et al., 1996; Ollmann et al., 1997;
Cheung et al., 1997). The control of body weight regulation is complex,
and is an expanding field with new hormones and receptors still being
identified.
1.3.1 Leptin
Leptin was recently identified as the peptide hormone product of the Ob
gene (Zhang et al., 1994), which is mutated in the ob/ob obese mouse. It
is synthesised in adipose tissue and circulates in plasma at levels
correlating to the amount of body fat present (Considine et al., 1995;
Lonnqvist et al., 1995). Leptin acts on receptors in the hypothalamus
(Tartaglia et al., 1995; Chen et al., 1996) to maintain body weight
homeostasis by inducing changes in food intake and energy expenditure
(Halaas et al., 1995; Pelleymounter & et al, 1995). Leptin receptors are
also expressed in the pancreas where they cause inhibition of glucose
stimulated insulin release (Emilsson et al., 1997), and could therefore play
a role in the dysregulation of insulin secretion observed in obese states.
Although these actions of leptin initially received most interest, the
expression of leptin receptors in reproductive tissues and the effects of
leptin therapy in restoring fertility in the ob/ob mouse (Chehab et al.,
1996) has led to studies on the role of leptin in fertility and the onset of
puberty. A wide range of other tissues such as liver, lung, heart, kidney
and adipose tissue (Tartaglia et al, 1995) also express leptin receptors, but
their function in these tissues is still to be elucidated.
When leptin was discovered in 1994 and was found to be the satiety factor
the obese ob/ob mouse lacked (Zhang et al., 1994), it was hoped that
human obesity could be explained by a lack of leptin. However, Caro and
colleagues proved this hope improbable. The analysis of the leptin gene in
24
well over one hundred obese people failed to identify a mutation except in
one individual (Considine et al., 1995; Considine et al., 1996). One
kindred with a functional mutation in the leptin gene has been described
(Montague et al., 1997), and initial reports indicate that treatment with
recombinant leptin is causing a weight reduction in these individuals
(Farooqi et al., 1999). Plasma leptin levels correlate with percentage body
fat, even in obesity (Considine et al., 1995; Lonnqvist et al., 1995) which
implies that there is not a defect in production of leptin, but that obese
humans are resistant to the actions of leptin. There is still hope that leptin
treatment may still help obese individuals to lose weight, and indeed the
preliminary results of a recent clinical trial indicate this may be the case
(Greenberg et al., 1999). However, the weight loss was achieved in this
study with the aid of a calorie-controlled diet and very high levels of
leptin, and patients were only studied for 24 weeks. Whether these effects
will persist, and the long-term effects of leptin treatment remain to be seen.
1.3.2 Neuropeptide Y
Neuropeptide Y (NPY) acts on the hypothalamus and has opposing effects
to leptin ie it stimulates appetite and decreases energy expenditure (Clark
et al., 1984; Stanley et al., 1986; Billington et al., 1991). Administration
of NPY into the paraventricular nucleus of the hypothalamus of normal
rats induces an obesity syndrome (Zarjevski et al., 1993), and infusions of
anti-NPY serum prevent feeding (Shibasaki et al., 1993). Leptin has been
shown to decrease NPY levels independently of effects on food intake and
body weight (Schwartz et al., 1996a), which implies the balance of these
hormones is important in body weight homeostasis. Glucocorticoids are
an absolute requirement for NPY to exert its effects, as NPY has no effect
in adrenalectomised animals and replacement of corticosterone leads to a
recovery ofNPY effects (Stanley et al., 1989).
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1.3.3 a-Melanocyte-stimulating hormone
POMC is the precursor for several peptides, one of which is a-
melanocyte-stimulating hormone (a-MSH). a-MSH acts through the
melanocortin receptor-4 (MC4) to inhibit food intake. There is an
endogenous receptor antagonist, agouti-related peptide, over-expression of
which leads to obesity (Ollmann et al., 1997). Loss of either POMC, MC4
or agouti peptide, by naturally occuring mutations or gene targeting, are all
associated with obesity (Yaswen et al., 1999; Huszar et al., 1997; Lu et al.,
1994).
1.3.4 The orexins
Orexin-A and -B were recently identified as the endogenous ligands of an
orphan receptor purified from brain (Sakurai et al., 1998). The peptide
hormones are specifically expressed by neurones around the lateral
hypothalamic area, and intra-cerebro-ventricular injection leads to
increased feeding and weight gain (Sakurai et al., 1998). Orexin neurones
project widely through the brain and the physiological role of the orexins
is therefore thought to be complex.
1.3.5 Glucocorticoids
The focus of this thesis is the role of glucocorticoids in obesity. A
possible role for glucocorticoids in the pathogenesis of obesity has long
been considered, primarily because chronic glucocorticoid excess
promotes accumulation of adipose tissue. Glucocorticoids act on both
lipoprotein lipase and hormone-sensitive lipase to cause an accumulation
of fat, and promote differentiation of pre-adipocytes to mature adipocytes
(Hauner et al., 1987). In man, glucocorticoids increase energy
expenditure, but this is accompanied by a larger increase in energy intake,
resulting in positive energy balance and therefore weight gain (Tataranni et
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al., 1996). It has recently been observed in rats that hyperphagia and
weight gain are induced by intracerebro-ventricular administration of the
synthetic glucocorticoid dexamethasone (Zakrzewska et al., 1999).
Glucocorticoids also increase expression of other factors that enhance food
intake, including NPY and the NPY receptor (Larsen et al., 1994). The
evidence for the involvement of glucocorticoids in obesity is discussed in
section 1.5.
1.4 The Zucker rat as a model of obesity
The animal model utilised in the majority of the work in this thesis is the
obese Zucker rat, and the physiology of this model is discussed in the
following section.
The genetically obese Zucker rat (fa/fa) has been commonly used as an
animal model of obesity and early type 2 diabetes since it was first
described by Lois and Theodore Zucker in 1961 (Zucker & Zucker, 1961).
The obese Zucker rat displays a catalogue of metabolic disturbances
similar to those observed in the human metabolic syndrome "X". The
obese rats are hyperphagic with predominantly visceral obesity (Van
Zwieten et al., 1996), which is improved, but not negated, by pair-feeding
with lean rats (Cleary et al., 1980). A defect in brown adipose tissue
thermogenesis, increasing energy efficiency, contributes to maintenance of
obesity in the face of caloric restriction (York et al., 1985). They are also
insulin resistant, and have compensatory hyperinsulinaemia (York et al.,
1972). There is a sub-strain of obese Zucker rats, known as the Zucker
diabetic fatty rats, that are overtly diabetic and suffer P-cell
decompensation and failure, and these are used as a model for type 2
diabetes (Tokuyama et al., 1995; Hirose et al., 1996). Obese Zucker rats
have altered fat metabolism, including increased synthesis and secretion of
very low density lipoproteins (Witztum & Schonfeld, 1979) which may
contribute to the high levels of plasma triglycerides observed in these
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animals (Barry & Bray, 1969). Whether they are hypertensive has been a
matter of debate. It appears that they are mildly hypertensive but whether
this reaches statistical significance depends on the number of rats in the
study and the precision of the measurements made (Kurtz et al., 1989; Van
Zwieten et al., 1996; Alonso-Garcia et al., 1996). Obese Zucker rats also
have alterations in the hypothalamic-pituitary adrenal (HPA) axis, which
are discussed in section 1.4.3. Both homo-and heterozygous lean Zucker
rats are metabolically normal (Bray & York, 1979) and are used as
controls in studies involving obese Zucker rats.
1.4.1 Leptin
The primary defect in the obese Zucker rat was recently identified to be a
recessive mutation in the leptin receptor gene (Chua et al., 1996). A
nucleotide substitution at position 880 (A->C) causes the conversion of
amino acid 269 from glutamine in the wild type to proline (Chua et al.,
1996). The mutation occurs in an area of P-sheet and proline is known to
disrupt P-sheet conformations, so it assumed that the mutation alters the
structure of the receptor (Takaya et al., 1996). This mutation occurs in the
extracellular domain of the receptor in a region that is conserved between
rat, mouse and human leptin receptor sequences and is thought to be
involved in cellular transport of the leptin receptor (Chua et al., 1996).
The mutant receptor still has the same affinity for leptin as a wild type
receptor (Tartaglia & et al, 1995) but is expressed at much reduced level
on the cell surface (Rosenblum et al., 1996), supporting the hypothesis that
the mutation affects cellular transport. The mutation results in resistance
to the actions of leptin and deficient transport of leptin across the blood
brain barrier (Wu-Peng et al., 1997).
Obese Zucker rats have been found to be resistant to the actions of leptin
in several tissues. Intracerebro-ventricular (icv) administration of leptin to
obese Zucker rats has less of a weight reducing effect than observed in
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lean Zucker rats (Cusin et al., 1996). Leptin inhibits glucose stimulated
insulin secretion in isolated pancreatic islets, and stimulates lipolysis in
isolated white fat pads by increasing activity of lipoprotein lipase, but
these effects are not observed in obese Zucker rats (Emilsson et al., 1997;
Siegrist-Kaiser et al., 1997).
1.4.2 Previous studies in the obese Zucker rat
Obese Zucker rats were studied for more than 30 years before the
discovery of leptin, and the identification of their leptin receptor mutation.
In this time several hypotheses were put forward to explain their obesity,
all of which we now know to be secondary to leptin resistance. Since
leptin resistance appears to be a common feature in human obesity,
intermediate mechanisms between leptin resistance and obesity are still
being studied in an attempt to elucidate alternative therapeutic targets.
Administration of NPY into the hypothalamus of normal rats induces
obesity (Zarjevski et al., 1993). In obese Zucker rats, NPY levels within
the hypothalamus are higher (Sanacora et al., 1990; McKibbin et al.,
1991), and secretion ofNPY from the hypothalamus is increased (Dryden
et al., 1995), compared with lean animals. However, NPY receptor levels
and responses to administration of exogenous NPY are lower in Zucker
rats (McCarthy et al., 1991; Brief et al., 1992). Lower receptor numbers in
obese animals are thought to be due to down-regulation in the face of
chronically high NPY levels, and the reduced response to exogenous NPY
may be due to receptor saturation, again due to chronically high NPY
levels. Leptin has been shown to decrease NPY levels independently of
effects on food intake and body weight (Schwartz et al., 1996b), and it is
possible that leptin resistance could contribute to higher NPY levels seen
in obese Zucker rats. Whether increased NPY secretion is physiologically
important in the face of decreased receptor numbers is still a matter of
debate.
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The role of the sympathetic nervous system in the obese Zucker rat has
also received attention. They have decreased sympathetic tone, which
results in defective brown adipose tissue thermogenesis and increased
energy efficiency (Onai et al., 1995). The (33-adrenoceptor is expressed at
lower levels in adipose tissue of obese animals (Onai et al., 1995), and it
has been shown that the potency of p3-adrenoceptor agonists is reduced in
these animals (Charon et al., 1995). Treatment of obese Zucker rats with
low doses of the P3-adrenoceptor agonist BRL35135A did not alleviate
obesity, but did lead to an improvement of hyperinsulinaemia, insulin
resistance and hypertriglyceridaemia (Hashimoto et al., 1996). In a more
recent study, obesity was attenuated by treatment with a higher dose of
BRL35135 (Savontaus et al., 1998). Glucocorticoids play a role in this
abnormality, as adrenalectomy restores P3-adrenoceptor mRNA levels to
normal (Onai et al., 1995).
Nitric oxide has also been implicated in the control of food intake in the
obese Zucker rat as inhibition of nitric oxide synthase limits both food
intake and weight gain (Squadrito et al., 1993). However, when
endogenous nitric oxide synthase activity was measured in the
hypothalamus, fundus of the stomach and skeletal muscle it was found to
be lower in obese rats than lean (Morley & Mattammal, 1996; Young &
Leighton, 1998). It has been suggested that nitric oxide synthase may be
uncoupled from its normal control mechanisms in obesity, and that
inhibitors of nitric oxide synthase may make a useful therapeutic target,
but this suggestion remains to be tested.
1.4.3 The HPA axis in obese Zucker rats
The most commonly studied aspect of the obese Zucker rat is the HPA
axis, as the evidence suggests that glucocorticoids have an important role
to play in the development and maintenance of obesity. Adrenalectomy of
young obese rats prevents obesity from developing, and of older rats
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attenuates obesity, and these effects are negated in a dose-dependent
manner by glucocorticoid replacement (Yukimura et al., 1978; Freedman
et al., 1986; Castonguay et al., 1986). Ablation of glucocorticoid action
by treatment with a glucocorticoid receptor antagonist also leads to an
improvement in obesity (Langley & York, 1990). Both adrenalectomy and
glucocorticoid antagonist treatment also lead to an improvement in other
metabolic defects in the obese Zucker rat eg plasma insulin and
triglyceride levels fall and some aspects of fat metabolism, such as brown
adipose tissue thermogenesis are normalised (York et al., 1985;
Castonguay et al., 1986; Freedman et al., 1986; Langley & York, 1990).
Studies have shown that obese rats excrete more corticosterone in their
urine than lean rats (Cunningham et al., 1986; White et al., 1989), but this
is not necessarily associated with increased plasma corticosterone levels.
While some reports have described elevated plasma corticosterone levels
in obese Zucker rats (Dubuc, 1976; Martin et al., 1978; Fletcher et al.,
1986; Guillaume-Gentil et al., 1990; Plotsky et al., 1992; Dryden et al.,
1995) other studies, including one where urinary corticosterone excretion
was elevated (Cunningham et al., 1986), have reported normal plasma
corticosterone levels (Yukimura et al., 1978; Walker et al., 1992).
Whether or not hypercorticosteronaemia is reported seems to depend on
the sex, age and source of the animals studied, and the time of sampling.
Obese Zucker rats have lower levels of CRH in the hypophyseal-portal
circulation (Plotsky et al., 1992) and are less sensitive to CRH
(Cunningham et al., 1986). Despite this, plasma ACTH levels are higher
in obese animals (Cunningham et al., 1986; Bestetti et al., 1990).
Although high circulating ACTH levels would explain increased
corticosterone secretion and adrenal hypertrophy there is no clear
explanation for increased ACTH in the face of low CRH. Leptin has been
reported to decrease CRF secretion (Heiman et al., 1997) and increase
POMC expression (the precursor of ACTH) (Thornton et al., 1997).
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However, the obese Zucker rat is resistant to the actions of leptin, and so
changes in the opposite direction may be predicted.
The sensitivity of corticosterone negative feedback is also equivocal in
these animals. The synthetic glucocorticoid dexamethasone has been
reported to cause the same degree of adrenal suppression in lean and obese
animals (Cunningham et al., 1986; Guillaume-Gentil et al., 1990). By
contrast, ACTH is less sensitive to negative feedback by corticosterone in
obese animals (Walker et al., 1992). Also, glucocorticoid receptor
antagonism fails to induce an increase in plasma AVP or corticosterone
levels (Pesonen et al., 1992a; Pesonen et al., 1992b) suggesting
dysregulation of the HPA axis.
The magnitude of the stress response in obese Zucker rats is also
unresolved. Both normal (Plotsky et al., 1992; Walker et al., 1992) and
increased (Bestetti et al., 1990; Guillaume-Gentil et al., 1990; Pacak et al.,
1995) pituitary and adrenal responses to stress have been reported. Sexual
dimorphism of the stress response was reported by one group (Guillaume-
Gentil et al., 1990) but this does not seem to account for the conflicting
reports.
1.5 The role of glucocorticoids in obesity
Increased secretion of glucocorticoids (eg in Cushing's syndrome) is
associated with obesity; and Cortisol secretion is increased in subjects with
idiopathic obesity, especially of central or android distribution (Pasquali et
al., 1993). It has long been known that total urinary glucocorticoid
metabolites are elevated in obese subjects, implying an increase in Cortisol
secretion rate (Gray et al., 1956; Migeon et al., 1963), and weight loss is
accompanied by a fall in glucocorticoid excretion (Migeon et al., 1963).
Despite an inferred increase in glucocorticoid secretion, plasma Cortisol
levels in obese humans tend to be normal, or even low (Migeon et al.,
1963; Ljung et al., 1996; Rosmond et al., 1998; Stewart et al., 1999),
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suggesting that metabolism of glucocorticoids must also be increased.
Recent studies in man have looked more carefully at the specific urinary
glucocorticoid metabolites (Andrew et al., 1998; Stewart et al., 1999;
Fraser et al., 1999). These show that metabolism of Cortisol by 5a-
reductase may be enhanced, and 11 P-hydroxysteroid dehydrogenases may
be altered in obesity. Specifically, Stewart et al suggest that hepatic
reactivation of Cortisol may be impaired in obesity as measured by
conversion of an oral dose of cortisone to Cortisol. This is backed up by a
change in urinary glucocorticoid metabolite profiles in this study and one
other (Fraser et al., 1999), but urinary profiles must be considered as a less
robust assessment of lip-HSD activity. Urinary steroids give an
impression of the "whole body balance" of 1 lp-IISD activities and, as will
be described later in this thesis, tissue specific changes in 11 p-HSD
activities may be overlooked by this method.
The majority of work linking glucocorticoids with obesity has been carried
out in animals. Obese Zucker rats have similar increases in glucocorticoid
production rates (White et al., 1989; Cunningham et al., 1986) and have
adrenal hypertrophy (Walker et al., 1992; Bestetti et al., 1990), but reports
of plasma corticosterone levels are inconclusive. Increased (Dubuc, 1976;
Martin et al., 1978; Fletcher et al., 1986; Guillaume-Gentil et al., 1990;
(Plotsky et al., 1992) and normal (Yukimura et al., 1978; Walker et al.,
1992; Cunningham 1986) plasma corticosterone levels have been reported,
as have both normal (Yukimura et al., 1978; Guillaume-Gentil et al., 1990;
Walker et al., 1992) and disrupted (Martin et al., 1978; Fletcher et al.,
1986) circadian rhythms of corticosterone. Despite this controversy,
obesity in animal models has been demonstrated to be glucocorticoid
dependent. Adrenalectomy of obese rats and mice prevents development
of obesity in young animals and reduces obesity in adult animals, while
glucocorticoid replacement induces a dose-dependant recurrence of the
obesity (Saito & Bray, 1984; Tokuyama & Himms-Hagen, 1987;
Yukimura et al., 1978; Freedman et al., 1986). A similar attenuation of
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obesity is observed in rats treated with the glucocorticoid receptor
antagonist RU486 (Hardwick et al., 1989; Langley & York, 1990).
Abnormalities of the HPA axis have been described in obese animals, but
these findings have not been conclusive and there are many conflicting
reports (Guillaume-Gentil et al., 1990; Plotsky et al., 1992; Bestetti et al.,
1990). Secretion of corticosterone under the control of the HPA axis is not
the only factor affecting glucocorticoid supply to its receptor (Figure 1.5).
Metabolic clearance of steroids will also have an impact on circulating
corticosterone levels. Any change in metabolic clearance would normally
be associated with compensatory changes in glucocorticoid secretion, but
if it was accompanied by alterations in the HPA it could result in a failure
to maintain normal plasma glucocorticoid levels. Access of
glucocorticoids to receptors is also controlled at a tissue level by the
steroid metabolising enzymes lip-HSDs, which interconvert active and
inactive glucocorticoids (see section 1.2). Alterations in 11P-HSD activity
could results in changes in glucocorticoid availability within a tissue,
independently of changes in plasma glucocorticoid levels. Altered 11P-
HSD1 activity has been reported in hypertensive, insulin-resistant animal
models, such as the Bianchi-Milan and Lyon hypertensive rat strains
(Stewart et al., 1993; Lloyd-MacGilp et al., 1999). Specifically, hepatic
11 P-HSD 1 activity is impaired, which would be predicted to decrease
exposure of the liver to glucocorticoids. However, no suggestions have
been made as to how this change relates to the pathogenesis of
hypertension or insulin resistance, and to date the importance of 11 P~
HSDs in animal models of obesity has not been assessed
The evidence for a link between glucocorticoids and obesity in both man
and animal models is strong. However, the nature of and mechanisms
underlying abnormalities of the HPA axis and / or glucocorticoid














Figure 1.5: Control of availability of glucocorticoids to receptors.
CRH=corticotrophin releasing hormone; ACTH=adrenocorticotrophic
hormone
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1.6 Aims of this thesis
The primary aim of this thesis was to study glucocorticoid metabolism in
obesity, to elucidate differences that may account for characteristics of
obesity and HPA activation. The majority of the work carried out utilised
the Zucker rat model of obesity, described in section 1.4. The following
list of aims was addressed in this thesis:
1) To study metabolic clearance of corticosterone in obese Zucker rats
by assessing urinary metabolite profiles by GC-MS, necessitating
establishment of new methodology, and to confirm inferences made on
glucocorticoid metabolising enzyme activities by assessing enzyme
activity in vitro.
2) To quantify 11(3-HSD1 activity in glucocorticoid target tissues in
obese Zucker rats, to establish whether differences in local glucocorticoid
levels could contribute to the obese phenotype. Also to measure
expression of glucocorticoid regulated genes, to assess whether any change
in enzyme activity relates to a change in glucocorticoid action.
3) To examine possible mechanisms of control of lip-HSDl in
obesity by making manipulations in obese Zucker rats, with the role of
glucocorticoids and insulin of particular interest.
4) To assess the role of lip-HSDs in obesity, by inhibiting the
enzymes with carbenoxolone in obese Zucker rats. Of particular interest
were the effects on insulin sensitivity and weight gain.
5) To assess lip-HSDl activity in human obesity, and relate this to
observations made in the obese Zucker rat, to validate the use of this






Unless otherwise stated, chemicals and reagents were purchased from
Sigma, Poole, UK.
All HPLC grade solvents were from Rathburn Chemicals, Walkerburn,
UK.
All epi-steroid standards were from Steraloids, Newport, USA.
All radioactivity was from Amersham, Bucks, UK.
Sources other than these are indicated in parenthesis.
2.2 Commonly used buffers and solutions
Acetate buffer: 0.2M sodium acetate, pH4.6. Stored at 4°C.
Alkaline SDS: 0.2M NaOH, 0.1% SDS. Freshly prepared before use.
Borate buffer: 8.25g boric acid, 2.7g NaOH, 3.5ml conc. HC1 and 5g BSA
made up to 1 litre with distilled water, pH 7.4. Stored at -20°C and thawed
at room temperature immediately before use.
Cesium Chloride/TE solution: lOOg CsCl dissolved in 100ml TE buffer
(see below).
Denaturing solution: 4M guanidium thiocyanate, 0.025M Na citrate, 0.5%
sarcosyl. (3-Mercaptoethanol (0.1M) added immediately prior to use.
DEPC-treated water: Distilled water (500ml) mixed with
diethylpyrocarbonate (DEPC; 5 drops) and left for 1 - 24 hours before
autoclaving.
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Deionised formamide: 15g Amberlite ion exchange resin (BDH,
Lutterworth, UK) mixed with 150ml formamide for 1 hour, then filtered
twice to remove Amberlite.
GTE: 50mM glucose, 25mM tris[hydroxymethyl]-aminomethane (tris),
lOmM EDTA, pH8. Freshly prepared before use.
Kreb's Ringer Bicarbonate Buffer: 118mM NaCl, 3.8mM KC1, 1.19mM
KH2P04, 2.54mMCaCl2, 1.19mM MgS04, 25mM NaHC03, pH 7.4.
Stored at 4°C and supplemented with 0.2% glucose immediately prior to
use.
LB agar: Luria-Bertoni broth with 15g agar per litre broth added before
autoclaving.
Loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol, 25 %
Ficoll made up in DEPC-treated water.
Luria-Bertoni broth: lOg bactotryptone, 5g bacto yeast extract, 5g NaCl,
made up to 1 litre with distilled water and autoclaved immediately.
lOx MOPS buffer: 0.2M 3-[N-morpholino]propanesulfonic acid, 50mM
Na acetate, 5mM EDTA, pH7. Autoclaved before use.
Orthophosphate buffer: 40 mM Na2HP04. pH 7.5.
Phosphate buffer: 0.2M NaH2P04, 0.6M Na2HP04, 5mM
ethylenediaminetetraacetic acid. Autoclaved before use.
5M Potassium Acetate: 60 ml of 5M potassium acetate, 11.5ml glacial
acetic acid, 28.5ml water.
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2Ox SSC buffer: 175.32g NaCl, 88.23g Na citrate made up to 1 litre with
distilled water. Autoclaved before use.
1 Ox TBE buffer: 56g Tris, 57.5g boric acid, 20ml 0.5M EDTA, made up to
500ml with distilled water. Autoclaved before use.
TE buffer: lOmM Tris-HCl, ImM EDTA, pH 8. Autoclaved before use.
Wash Buffer One: lx SSC buffer, 0.1% sodium dodecyl sulphate (SDS)
made with DEPC-treated water.
Wash Buffer Two: 0.3x SSC buffer, 0.1% SDS made with DEPC treated
water.
2.3 Animal maintenance
Lean and obese Zucker rats were obtained from Harlan Orlac, Bicester,
UK at five weeks-of age. Rats were maintained under controlled
conditions of light (lights on 0800 h - 2000 h) and temperature (21-22°C),
and allowed free access to standard rat chow (Special Diet Services,
Witham, UK) and drinking water. During basal conditions rats were under
the care of the animal technicians of the Biomedical Research Facility,
Western General Hospital. After surgery and during treatment periods the
day to day care of the animals was carried out by me, with the assistance
of the animal technicians, during which time the animals were observed
closely for signs of ill health. Animals were housed four per cage except
when urine collections were being made, when they were housed
individually in metabolic cages.
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2.3.1 Surgery
The surgical procedures were carried out by Dr CJ Kenyon of the
Molecular Medicine Centre, Western General Hospital. Six-week-old lean
and obese Zucker rats were anaesthetised with 4% halothane and either
bilaterally adrenalectomised (ADX) or sham-operated through dorsal
incisions and the incisions closed with staples. The animals were closely
monitored until they regained consciousness, and were not returned to
their cage until fully conscious. All rats were maintained on 0.9% saline
as drinking water to allow the ADX rats to maintain their electrolyte
balance. Rats were weighed every second day to follow the progress of
weight gain, and were killed 21 days after surgery by decapitation.
2.3.2 Glucose tolerance tests
Rats were fasted from 1700h to 0900h, weighed and a 2g/kg dose of
glucose administered by gavage. Blood samples were taken by tail nick at
0, 30 and 120 min after glucose administration. Blood samples were
collected into heparinised Eppendorfs, centrifuged at 5000 rpm for 2 min
in a bench-top centrifuge and the plasma removed into fresh Eppendorfs.
The samples were frozen on dry ice and stored at -20°C. At the end of the
glucose tolerance test, rats were allowed free access to food and water.
2.4 Plasma assays
2.4.1 Corticosterone radioimmunoassay
Plasma samples were diluted 1 in 5 in borate buffer and denatured at 65°C
for 30 min to dissociate corticosterone (B) from proteins. A range of
concentrations of B were prepared (0.6 - 320 nM) to allow construction of
a standard curve. Samples and standards were incubated in duplicate with
a mixture of [3H]-B (10,000cpm per sample) and B antibody (1 in 10,000
dilution; produced in-house by Dr CJ Kenyon) in borate buffer in a total
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volume of 70pl for 2h. Scintillation proximity assay beads (SPA;
Amersham, Bucks, UK) were then added to each sample and the samples
sealed and incubated overnight. The SPA beads bind to the primary
antibody and if the primary antibody is bound to [3H]-B the SPA beads
cause scintillation of the radioactive signal. As the concentration of
unlabelled B increases there is competition between binding of labelled
and unlabelled B to the primary antibody, and the radioactive signal
decreases. Samples were counted on a Wallac Microbeta Plus liquid
scintillation counter. The concentration of B in each sample was estimated
from the standard curve. The inter- and intra-assay coefficients of
variation were <10%.
2.4.2 11 -Dehydrocorticosterone radioimmunoassay
The 11-dehydrocorticosterone (A) radioimmunoassay (RIA) was carried
out in the same way as the B RIA except for the following changes:
samples were not diluted as A circulates at much lower levels than B; the
standard curve was constructed using A standards; [°H]-A (see below)
rather than [ H]-B was used; and an A primary antibody (a gift from Prof
Vecsei and Dr Haack, Ruprecht-Karis-Universitat, Heidelberg) was used.
The inter- and intra-assay coefficients of variation were <10%.
2.4.3 Preparation of[3H]-l 1 -dehydrocorticosterone
[3H]-A was prepared from [3H]-B using homogenates of rat kidney, which
contain high levels of 11P-HSD2 that will readily convert [3H]-B to [3H]-
A. Rat kidney also contains 11(3-HSD1 that will carry out the reverse
reaction, but by using high concentrations of the appropriate cofactor
(NAD) almost exclusive dehydrogenase activity was achieved. Kidney
homogenate (lmg/ml) was incubated at 37°C with NAD (2mM) and [3H]-
B (600nM) in a total volume of 2ml for four hours. The steroids were
extracted with 10 volumes of ethyl actetate, dried under oxygen free
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nitrogen at 60°C and re-suspended in lOOpl of ethanol. A lp.1 sample of
the re-suspended steroid was analysed by HPLC (see section 2.6.5) to
check the purity of [3H]-A, which was routinely >97%. ['H]-A was stored
at -20°C and the purity was checked by HPLC before each use as it had a
tendency to break down.
2.4.4 Insulin radio-immunoassay
The insulin radioimmunoassay was carried out using a commercially
available kit (Amersham, Bucks UK). Plasma samples were diluted 1 in 3
in the supplied buffer before assay. A range of concentrations of insulin
was prepared (0.1 - 25 ng/ml) to allow construction of a standard curve.
Samples and standards were incubated in duplicate plastic tubes with a
mixture of [l2T]-insulin (l,000cpm per sample) and insulin primary
antibody in buffer (total volume 75pl) at room temperature for 4 hours.
1 9 S
Two tubes were prepared with only [ I]-insulin to give the total counts,
19 S
and two with [ T]-insulin and buffer but no antibody to give the non¬
specific binding. Amerlex™-M magnetic separation beads (60pl) were
then added to each sample and the samples incubated for a further lOmin.
The samples were centrifuged at l,000g for lOmin at 4°C to pellet the
beads, and the supernatant discarded. The tubes were counted in a y-
counter and the concentration of insulin in the samples estimated by
comparison with the standard curve. The inter- and intra-assay
coefficients of variation were <15% and <10% respectively.
2.4.5 Glucose assay
Plasma samples were incubated in duplicate with glucose hexokinase
reagent (Sigma) for 5min. The reagent causes glucose present in the
sample to be phosphorylated and NADH to be generated, causing an
increase in absorbance at 340nM. The absorbance of the samples at
340nM was measured using a Shimadzu uv/visible recording
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spectrophotometer with a reagent blank. If the plasma sample was
haemolysed, a plasma blank (prepared by diluting the plasma sample with
water) rather than a reagent blank was used to allow correction for the
colour in the sample. The amount of glucose in the sample was calculated
by comparison with a standard curve (100 - 800 mg/dL glucose). The
inter- and intra-assay coefficients of variation were <2%.
2.5 Gas chromatography / mass spectrometry
2.5.1 Preliminary work
There was no existing protocol for the detection of rat urinary
glucocorticoid metabolites in our laboratory, so I developed one. The
starting point for the development of the assay was the assay currently
employed in out laboratory for the analysis of human urinary
glucocorticoid metabolites (Best & Walker, 1997). The complexity of the
assay necessitates the use of internal standards, which are added to the
samples / standards at the beginning of the assay. The standards used in
our laboratory for human urine assays are the non-endogenous 11 a- (epi)
isomers of Cortisol and tetrahydrocortisol. These compounds are very
structurally similar to the endogenous steroids of interest and behave in a
similar manner to the endogenous steroids throughout the assay. A ratio of
the signals for the endogenous steroid and the epi-steroid is obtained for
the range of standards and a standard curve of the ratios is drawn (epi-
cortisol is the internal standard used for Cortisol and cortisone and epi-
tetrahydrocortisol is the internal standard used for all other Cortisol
metabolites). The ratios obtained for the samples are then compared to the
ratios in the standard curve and the amount of endogenous steroid in the
samples calculated. For the rat urine assay it was necessary to use internal
standards that were more appropriate for rat steroids, therefore epi-
corticosterone (epi-B) and epi-tetrahydrocorticosterone (epi-THB) were
used. These compounds had not been used in our laboratory before so
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their use had to be validated. First it was determined that these compounds
could be detected by gas chromatography / mass spectrometry (GC-MS)
and then their fragmentation patterns were analysed to assess which ion
was the most appropriate to use (Figure 2.1). Then calibration lines were
drawn up for the ratio of endogenous steroid signal and the epi-steroid
signal to ensure that in the range used this was linear (a line with an R
value from linear regression analysis of > 0.99 was accepted as linear). An
example calibration line is shown in Figure 2.2.
One further change to the standard assay was necessary to be able to
process rat urine. In the human urine assay steroids are extracted from
urine using Sep-pak C18 columns containing 360mg of packing material
(Waters, Herts, UK). The rat urine was collected using metabolic cages,
and this allowed contamination of the urine with food and faeces. These
contaminants necessitated the use of columns with a larger amount of



































Figure 2.1: Fragmentation pattern of epi-corticosterone derivatised with
methoxyamine and trimethylsilylimidazole.
The ion monitored was m/z = 548.
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Corticosterone (fdg)
Figure 2.2: Example standard curve for corticosterone by GCMS.
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2.5.2 Extraction ofsteroids from urine
Sep-pak columns were primed by passing through 20ml of methanol then
20ml of water (all solvents used in this assay were HPLC grade). For the
standard curve the columns were loaded with 5ml of water, then lOpg of
epi-B, 5pg of epi-THB and 100 - 1750 ng of standard steroids in
methanol, followed by a further 5ml of water. For the samples the
columns were loaded with 5ml of urine, then lOpg of epi-B and 5pg of
epi-THB in methanol, followed by a further 5ml of urine. The columns
were then washed with 20ml of water, and the steroids eluted with 10ml of
methanol. The samples were dried under a stream of oxygen free nitrogen
(OFN) at 60°C.
2.5.3 Hydrolysis ofsteroids
Glucocorticoids are conjugated to glucuronic acid and sulphates to make
them more water-soluble before they are excreted. These groups need to
be removed to allow derivatisation and good chromatography. Acetate
buffer was added to the dry samples and vortexed vigorously to ensure
steroids were in solution. (3-Glucuronidase enzyme was added and the
samples incubated at 37°C for 48 hours. (3-Glucuronidase enzyme cleaves
the glucuronic acid from the steroid, and also has sulphatase action to
remove the sulphate groups.
2.5.4 Extraction ofhydrolysate
Once hydrolysis was complete, the steroids were re-extracted. Sep-pak
columns were primed as before with 20ml methanol and 20ml water; the
hydrolysate was passed through the column; the column washed with 20ml
water; and the steroids eluted with 10ml methanol. The methanol was
removed by drying the samples under a stream of OFN at 60°C. The
steroids were then further extracted by reconstituting the sample in a
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mixture of ethyl acetate and water (15:1), vortexing vigorously, removing
the organic phase and drying the sample under OFN at 60°C. The aqueous
phase was discarded.
2.5.5 Derivatisation ofsteroids
The steroids underwent two derivatisation steps to mask the polar groups
and improve chromatography. Firstly, the ketone groups were replaced by
incubating the samples in 2% methoxyamine in dry pyridine at 60°C for
30min. The samples were dried as before, and then incubated with
trimethylsilylimidazole at 100°C for 2h to replace the hydroxyl groups.
Not all of the available groups on a molecule will be derivatised, for
example the ketone group at carbon 20 is not replaced by methoxyamine,
possibly because of the stoichiometry of the reaction. The differences in
derivatisation aid in the identification of molecules by GC-MS.
2.5.6 Extraction ofderivatised steroids
The steroids were extracted from the derivative mixture on lipidex 5000
columns which were prepared by adding 1ml of lipidex 5000 (Canberra
Packard, UK) to glass pasteur pipettes loosely plugged with silanised glass
wool. The lipidex was prepared in mobile phase (cyclohexane: pyridine:
hexamethylsisilazane; 98:1:1) and the columns were washed with 3ml of
mobile phase before use. The samples were passed through the column in
2ml of mobile phase, and a further 1ml of mobile phase was passed
through to ensure all of the steroid was eluted. The samples were dried
under OFN and reconstituted in hexane in preparation for injection into the
GC-MS system.
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2.5.7 Gas chromatography /mass spectrometry
Steroids were quantified using a Voyager GC-MS system (Finnigan,
Manchester, UK) in electron impact mode fitted with a EC-5 capillary
column (length 30 metres, internal diameter 0.25mm, film thickness
0.25|um; Alltech, Carnforth, UK). The temperature programme used for
the gas chromatography consisted of an initial temperature of 200°C
maintained for lmin, temperature increased by 20°C per min for 3min,
temperature increased by 2°C per min for 20min and held at 300°C for
2min. This temperature programme was selected to give the best practical
separation of ions with the same mass. The mass-spectrometer was
programmed to monitor the selected ions with a dwell time of 0.04seconds
per ion per cycle. The mass of the ions monitored and the retention times
are shown in Table 2.1. The area under each peak was integrated using
Masslab software (Fisons, UK); the ratio of each peak to the internal
standard calculated; and the concentration of steroid calculated from the





Corticosterone (B) 548 22.070 + 22.245
11 -Dehydrocorticosterone (A) 474 21.605





Table 2.1: Mass/charge ratio of ion monitored and retention time of that




Tissues were routinely frozen on dry ice directly after dissection from the
animal and stored at -80°C until use. Tissues were roughly dissected while
frozen and 0.5 - lg of tissue was homogenised in 4 - 5ml of Kreb's Ringer
bicarbonate buffer (KRB) in an Ystral mechanical homogeniser (Scientific
Instruments Centre, Liverpool). Homogenates were centrifuged at 500g at
4°C for 5min to allow any small amounts of unhomogenised tissue to sink
to the bottom, and the supernatant was removed. Liver microsomes were
prepared by repeated centrifugation of the homogenised tissue.
Homogenates were centrifuged at 14,000g at 4°C for 20min, and the
supernatant was removed and centrifuged at 100,000g at 4°C for 60min.
The microsomes appeared as a jelly-like pellet at the bottom of the tube,
and were resuspended in 1ml KRB.
2.6.2 Protein estimation
Protein concentration of tissue homogenates and microsomal preparations
was determined colorimetrically using a Bio-Rad protein assay kit (Bio-
Rad, Hemel Hampstead, UK). A range of protein standards (0.1 - 1.2
mg/ml) was prepared in distilled water from the provided protein standard.
Protein assay dye reagent was prepared by diluting the concentrate
provided by 1 in 5 with distilled water and then filtering it through a
Whatman No 1 filter paper. Diluted protein assay dye reagent (1.96ml)
was added to 40pl of either protein standard or appropriately diluted
sample in a borosilicate tube, vortexed and left at room temperature for 15
- 30min. The absorbance of the samples at A,=595nm was measured using
a Shimadzu uv/visible recording spectrophotometer and the concentration
of protein in each sample was estimated from the standard curve.
2.6.3 In vitro assay of 11f-HSD activity
In vivo, lip-HSDl is a reductase, converting inactive 11-
dehydrocorticosterone to corticosterone. However, in vitro reductase
activity is labile and dehydrogenase activity predominates in tissue
homogenates, so lip-HSDl activity was quantified by conversion of
corticosterone to 11-dehydrocorticosterone. Preliminary studies were
carried out for each different tissue to optimise the protein concentration
and incubation time to ensure that the percentage conversion was between
10 and 40% (ie not saturated). Aliquots of tissue homogenates at the
appropriate concentration (see Table 2.2) were incubated in duplicate at
37°C in Kreb's Ringer bicarbonate buffer containing 0.2% glucose, NADP
(2 mM) and [3H]-corticosterone (50 nM) in a total volume of 250pl.
Blanks were prepared by incubating [3H]-corticosterone, NADP and buffer
with no tissue added. After the incubation period the reaction was stopped
by the addition of 10 volumes of ethyl acetate (all solvents used were
HPLC grade). The organic phase was removed and evaporated under
oxygen free nitrogen at 60°C. Extracts were re-suspended in mobile phase
(20% methanol, 30% acetonitrile and 50% water) and stored at -20°C until
analysis by high pressure liquid chromatography. The percentage of [3H]-
B converted to [ H]-A was corrected for apparent conversion in the blank
samples, which was always <3%, and was used as an index of lip-HSD
activity. Where results between different groups of animals were to be
compared all the incubations were carried out concurrently, and all
samples treated in the same way.
11 p-HSD 1 activity was assessed in human subcutaneous adipose samples
in the same way, but incubations were carried out with [3H]-Cortisol, rather
a
than [ H]-corticosterone. The protein concentration and incubation period
employed are detailed in Table 2.2.
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Tissue Protein concentration Incubation period
Kidney 50pg/ml 60 min
Liver lOpg/ml 60 min
Liver microsomes 15pg/ml 10 min
Omental fat 1000p.g/ml 60 min
Skeletal muscle 1500pg/ml 60 min
Subcutaneous fat 500pg/ml 60min
Thymus 500pg/ml 60 min
Human subcutaneous fat 750 fig/ml Up to 30 hr
Table 2.2: Protein concentrations and incubation times employed in 11(3-
HSD activity assays.
To determine 11(3-HSD2 activity in the kidney homogenates incubations
were also performed with NAD (2 mM) as cofactor and lOnM [3H]-B in a
total volume of 1ml. The percentage conversion of [JH]-B to [3H]-A was
corrected for apparent conversion in the blank samples, which was always
<3%, and was used as an index of 11P-HSD activity. Where results were
to be compared between groups of animals all incubations were carried out
concurrently.
2.6.4 In vitro assay ofhepatic 11J3-HSD1 kinetics
To determine hepatic 11 P-HSD 1 kinetics liver microsomal preparations
were incubated as for the 11 P-HSD activity assay above, but with the
addition unlabelled B (0.3 - lOpM). The percentage conversion of the
3 3
[ H]-B to ["H]-A was calculated and this percentage conversion applied to
the total amount of B present in the assay to give the total conversion of B
to A in nmol / min / mg of protein (velocity of the reaction). These values
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were used to construct a Lineweaver-Burke plot (1/velocity of reaction vs
1 /substrate concentration) to allow calculation of the maximum velocity of
the reaction (Vmax) and Michaelis constant of the reaction (concentration
of substrate at halfmaximal velocity; Km).
2.6.5 High-pressure liquid chromatography
A 200p.l aliquot of each sample in mobile phase (20% methanol, 30%
acetonitrile and 50% water) was injected into the high-pressure liquid
chromatography system (HPLC). The HPLC system comprises a Waters
(Herts, UK) auto-injector, mobile phase pump, reverse phase p-Bondapak
CI8 column in a column heater and a Berthold (Leeds, UK) radioactivity
monitor linked to a scintillation fluid pump. The system is controlled by a
computer loaded with Winflow software (JMBS Developments, France).
The flow rate of the mobile phase was set at 1.5 ml/min and the flow rate
of scintillant (Quicksafe Flow 2; Zinsser, Berks, UK) was set at 4.5 ml/min
to achieve optimal mixing, and hence efficiency of counting. The column
heater was set at 35°C to improve chromatography and maintain stability
of retention times. Initially a Waters column (3.9 x 30mm) was used, but
this was changed to a Phenomenex (Cheshire, UK) column to achieve
better chromatography. Radioactive standards were injected at the start of
every batch of samples to confirm the identity of the peaks. The retention
time for A was approximately 6 min and for B approximately 8 min, with
more than one minute of baseline between the two peaks. The peaks were
always less than one minute wide, and the amount of radioactivity used
ensured the peak height was at least 50x background. The area under each
peak was integrated using the Winflow software, and the proportion of the
area of each peak used to quantify the conversion of | H]-B to [3H]-A, and
hence 11P-HSD activity. Routinely blank incubations with no tissue were
performed for each assay, and the conversion in each sample was corrected
for the apparent conversion in the blank.
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The same method was used to quantify [3H]-cortisol and [3H]-cortisone,
except the mobile phase used was 25% methanol, 10% acetonitrile and
65% water. The retention time for cortisone was approximately 18 min
and for Cortisol approximately 20 min.
2.6.6 In vitro assay of5a-reductase activity
The enzyme 5a-reductase type 1 reduces most A4'5 unsaturated steroids
with similar efficiency. Activity of the enzyme was quantified in liver
3 3
homogenates by measuring the conversion of [ H]-testosterone ([ H]-T) to
[3H]-5a-dihydrotestosterone ([3H]-5aDHT). Liver homogenates (protein
0.5mg/ml) were incubated in duplicate at 37°C in orthophosphate buffer
(40 mM Na2HPC>4. pH 7.5) with NADPH (1 mM) and [3H]-testosterone
(50 nM) in a total volume of 1ml for 10 min. The reaction was stopped by
the addition of 10 volumes of HPLC grade ethyl acetate. The organic
phase was removed and the ethyl acetate evaporated under oxygen free
nitrogen at 60°C. The steroid extracts were re-suspended in ethanol with
unlabelled testosterone and 5a-dihydrotestosterone, and separated by thin
layer chromatography. The percentage of [3H]-T converted to [3H]-5a-
DHT was used as an index of 5a-reductase activity. Where results
between different groups of animals were to be compared all the
incubations were carried out concurrently, and all samples treated in the
same way.
2.6.7 Thin layer chromatography
The steroids were re-suspended in 100pl of ethanol containing 0.5mg/ml
each of unlabelled T and 5a-DHT. It was necessary to add unlabelled T
and 5a-DHT to enable the visualisation of steroids, as the radioactive
steroids were of too low a concentration to be visualised. Polysilicic acid
gel impregnated glass fibre sheets were divided into 2cm wide lanes and
40pl of sample was applied to each lane. The steroids were separated in
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TLC tanks (mobile phase 9:1 dichloromethane:diethylether) for one hour.
The steroid bands were identified using phosphomolybdic acid and were
scraped into scintillation vials. The radioactivity in each steroid fraction
was quantified by a P-counter using Cocktail T scintillant (BDH Ltd,
Lutterworth, UK). The proportion of the radioactivity in each fraction was
used to quantify conversion of [3H]-T to [3H]-5a-DHT, and hence 5a-
reductase activity.
2.7 Northern analysis of RNA
2.7.1 Extraction ofRNA
Tissues were dissected from the animals onto dry ice and stored at -80°C
until used. Total RNA was extracted from tissues by the guanidium
thiocyanate method of Chomczynski and Sacchi (Chomczynski & Sacchi,
1987). Approximately lOOmg of liver samples were homogenised in
500pl denaturing solution using baked Dounce glass homogenisers, and
the homogenate transferred to sterile Eppendorf tubes. To remove DNA
and protein from the sample 0.2M sodium acetate (pH 4; 50pl), citrate-
saturated phenol (500pl) and chloroform:isoamyl alcohol (49:1; lOOpl)
were added to the homogenate. The mixture was vortexed thoroughly, left
on ice for 15min then centrifuged at 14,000g for 20min. The upper
aqueous phase containing the RNA was transferred to new Eppendorfs and
the lower layers containing DNA and protein were discarded. Isopropanol
(200pl) was added to the aqueous phase, the sample left at -20°C for at
least one hour to precipitate the RNA and then centrifuged at 14,000g for
20min to pellet the RNA. The supernatant was discarded, the pellet re-
suspended in denaturing solution (60pl) and isopropanol (60pl), and the
RNA precipitated and pelleted as before. The pellet was washed in 70%
ethanol (200pl) and resuspended in DEPC treated water (50pl). The
concentration and purity of the RNA were estimated
spectrophotometrically by measuring the absorbance at A.=260nm and
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280nm. RNA was only used with a A260/ A280 of between 1.5 and 1.8.
RNA was stored at -80°C until used.
2. 7.2 RNA electrophoresis and capillary transfer
Total RNA was separated by electrophoresis on a 1.2% agarose
formaldehyde denaturing gel. A 100ml gel was prepared by melting 1.2g
of agarose in 88ml DEPC-treated water, adding 40% formaldehyde (2ml)
and lOx MOPS buffer (10ml), and pouring into a gel mould with
appropriately sized combs in place. The gel was allowed to set and was
then soaked in lx MOPS buffer in a gel tank for 30min. RNA was
prepared for electrophoresis by aliquoting 20pg of RNA, adding DEPC-
treated water to bring the total volume to lOpl, then adding deionised
formamide (lOpl), 40% formaldehyde (2.5pl) and lOx MOPS buffer
(2.5pl) to give a total volume of 25pl. The sample was mixed and the
RNA denatured by incubating at 65°C for 15min. Ethidium bromide was
added to the loading buffer (lpl per 50pl loading buffer) and 2pi of this
mix added to each sample of denatured RNA. The RNA was loaded into
the wells on the gel and electrophoresed at 100V for 2 - 4 hours until the
front band of the loading buffer was % of the way down the gel. The gel
was photographed under UV light (k=254nm) with as little exposure as
possible to minimise RNA damage. The gel was soaked in 20x SSC buffer
for 15min before blotting onto a nylon membrane (Zeta-Probe® GT, Bio-
Rad, Hemel Hampstead, UK). A wick of Whatman 3MM filter paper was
placed over an upturned gel mould in a plastic tray containing 20x SSC
buffer and the gel was placed on the top. A piece of nylon membrane cut
to the same size as the gel and pre-wetted in 20x SSC was smoothed on
top of the gel and this was covered with 3 layers of 3MM filter paper and
approximately 5cm of paper towels. A plate of glass was placed on the top
to secure the apparatus, and a light weight balanced on the top. Capillary
transfer was allowed to take place overnight at room temperature. The
next day the membrane was washed in 20x SSC to remove any gel and the
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efficiency of transfer was checked by photographing the gel and the
membrane under UV light (A,=254nm). The membrane was dried between
two sheets of 3MM filter paper at 80°C for 2 hours, and the RNA cross-
linked under UV light. The membranes were stored wrapped in cling-film
between two pieces of 3MM paper.
2. 7.3 Hybridisation to 32P-labelled cDNA
The nylon membrane was soaked in 20x SSC buffer for 5min, then placed
in Hybaid hybridisation bottle containing 3ml 20% SDS and 6ml
phosphate buffer that had been warmed to 55°C. To this was added
denatured herring testes DNA (lOmg/ml; lOOpl). The membrane was
prehybridised in a Hybaid hybridisation oven at 55°C for at least 2 hours.
The 32P-labelled cDNA probe (prepared as described in section 2.8.4) was
added to the prehybridisation buffer, and the membrane hybridised with
the probe overnight at 55°C. The probe was then disposed of and the
membrane rinsed with wash buffer one. This was followed by two washes
in wash buffer one at room temperature for 20min, and one wash in wash
buffer two at 55°C for 30min. The level of radioactive signal remaining
on the membrane was checked, and if this was too high the final wash was
repeated. The membrane was wrapped in cling-film and exposed to a
Fujifilm imaging screen for six hours and the level of hybridized probe
quantified using a Fuji FLA2000 fluorescent image analyzer. The
membranes were then rehybridised with glyceraldehydephosphate
dehydrogenase (GAPDH) cDNA in the same way to control for RNA
loading and transfer. The level of expression of the RNA of interest was
then expressed as a ratio of the signal of the RNA of interest to the signal
for GAPDH. Membranes were routinely left for at least 4 weeks before
reprobing, to allow the original signal to decay, and all the mRNA species
probed for were well separated on the membrane. If results between
groups of animals were to be compared all the samples were hybridised in
the same hybridisation bottle with the same probe.
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2.8 Preparation of 32P labelled cDNA probes
2.8.1 Bacterial transformation
Eschericia coli HB101 cells were grown in 100ml of Luria-Bertoni (LB)
broth at 37°C in a shaking incubator until they reached mid-log phase
(A6oo = 0.3 - 0.6). They were then centrifuged at 3000rpm for 5min at
4°C, the pellet re-suspended in cold calcium chloride (0.1M; 20ml) and
left on ice for between lOmin and 2 hours. The centrifugation step was
repeated to re-pellet the cells and the cells were re-suspended in cold
calcium chloride (0.1M; 2ml). The competent cells were stored on ice in
the fridge for up to 3 days before transformation.
Competent cells (lOOpl) were mixed with plasmid DNA (50ng) and left on
ice in the fridge for 20min. The cells were heat shocked at 40°C for one
minute and placed back on ice. The heat shock and the calcium chloride
lead to incorporation of the plasmid DNA into the cells. The cells were
spread onto LB agar plates containing 100pg/ml ampicillin, and the plates
incubated overnight at 37°C. Only cells that have incorporated the
plasmid DNA will grow on the ampicillin plates, as HB101 cells do not
have inherent ampicillin resistance.
2.8.2 Plasmid DNA preparation
A single transformed bacterial colony was selected from an agar plate and
incubated overnight at 37°C in 3ml LB containing lOOpg/ml ampicillin.
This was then added to 500ml LB containing lOOpg/ml ampicillin and
incubated overnight at 37°C. The culture was centrifuged at 6,000rpm for
5min at 4°C in a Beckman J14 centrifuge, and the supernatant discarded.
The cell pellet was resuspended in 12ml cold GTE buffer, 24ml of cold
alkaline SDS was added and the mixture left on ice for lOmin. Cold
potassium acetate (16ml) was added and the mixture left on ice for a
59
further lOmin before being centrifuged at 6,000rpm for 5min at 4°C in a
Beckman J14 centrifuge. The mixture was filtered through sterile gauze to
remove the precipitate, isopropanol (32ml) was added to the filtrate and
the mixture was left at room temperature for 30min to precipitate the
DNA. The DNA was pelleted by centrifugation at 10,000rpm for 3min at
4°C in a Beckman J20 centrifuge, and the supernatant discarded. The
DNA pellet was resuspended in 2.2ml TE buffer, 2.9g CsCl added and
dissolved and lOOpl ethidium bromide (lOmg/ml) added. The mixture was
transferred to Beckman Quickseal ultracentrifuge tubes, tubes topped up
with CsCl/TE solution and centrifuged at 70,000rpm for 20 hours at 20°C
in a Beckman Optima TLX ultracentrifuge. The DNA was separated into
bands that could be visualised by the pink colour of the ethidium bromide.
These DNA bands were removed using a 21-gauge needle and syringe,
transferred to fresh ultracentrifuge tubes, topped up with CsCl/TE solution
and centrifuged at 100,000rpm for 4 hours at 20°C. The DNA bands were
collected as above and the ethidium bromide was removed by extracting
repeatedly with water saturated butanol until the pink colour disappeared.
The DNA was precipitated with ethanol (2 volumes) for lOmin at room
temperature and pelleted by centrifugation for 5min at 14,000g. The
supernatant was discarded and the DNA pellet washed with 70% ethanol
then resuspended in 1ml TE buffer. The concentration and purity of the
DNA was assessed spectrophotometrically using the ratio of absorbances
at 1=260 and 280nm.
2.8.3 Restriction enzyme digestion ofplasmid, andpurification offragment
Plasmid DNA (lOpg) was digested with the appropriate restriction enzyme
(10 units) in lx restriction enzyme buffer in a total volume of lOOpl for 2
hours at 37°C (see Table 2.3). Digestion of the DNA was confirmed by
electrophoresis of 3pi of the digest through a 1.2% agarose gel (prepared
by dissolving 1.2% agarose in lx TBE buffer and adding lpl ethidium
bromide (10mg/ml)). The digest was compared with uncut plasmid and a
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lkB DNA ladder containing fragments ranging from 75bp - 12kb under
UV light at X=254nm. If the plasmid was sufficiently digested the
remaining digest was electrophoresed in a large single well of a 1.2% low
melting point agarose gel (made as above but using low melting point
agarose).
The DNA fragment was visualised under UV light (^=254nm), excised
from the gel using a scalpel, purified from the gel using a commercially
available kit (Hybaid Recovery DNA Purification kit; Hybaid, Ashford,
Middlesex) and resuspended in 50pl DNAase free/RNAase free water.
Recovery of the DNA fragment was assessed by electrophoresis of 1 pi of
the DNA solution through a 1.2% agarose gel as described above.
Fragment Restriction Enzyme(s)
11P-HSD1 EcoR 1






EcoR 1 and Xba 1
Table 2.3 Restriction enzymes used to cut plasmid DNA.
2.8.4 [32P] Labelling ofcDNA
A random primed DNA labeling kit was used to label the DNA fragments
(Boehringer Mannheim, Lewes, UK). Approximately 25ng of DNA
fragment was aliquoted into an Eppendorf, made up to lOpl with DEPC-
treated water and denatured at 100°C for lOmin. The Eppendorf was
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cooled on ice and briefly centrifuged to bring the contents to the bottom of
the Eppendorf. Hexanucleotide primer mix (2pl), dATP, dTTP and dGTP
(lpl of each), [a32P]-dCTP (4pl) and Klenow (lpl) were added to give a
total reaction volume of 20pl and the reaction incubated at 37°C for one
hour. Unincorporated radioactivity was removed by passing the mixture
over a NICK column (Pharmacia, St.Albans, UK). The NICK column was
prepared by washing with 3ml TE then the reaction mixture was applied to
the column. The column was washed with 400pl TE, the eluant discarded
and the labelled DNA eluted from the column with a further 400pl TE.
The activity of the probe was checked by mixing lpl of probe with 1ml of
Cocktail T scintillant and counting in a (3-counter. The probe was used if
the specific activity was greater than 10,000cpm/pl. The DNA probe was
denatured before use by heating to 100°C for 5min.
2.9 Statistics
All values are expressed as mean ± standard error. Data were statistically
analysed by Student's t-tests or Analysis of Variance followed by post-hoc








Increased secretion of glucocorticoids (eg in Cushing's disease) is
associated with obesity; and increased Cortisol secretion has been noted in
subjects with idiopathic obesity, especially if the obesity is of central
distribution (Pasquali et al., 1993). However, the increase in Cortisol
secretion in idiopathic obesity is not accompanied by an elevation in peak
plasma Cortisol levels (Rosmond et al., 1998), suggesting that peripheral
Cortisol metabolism may be enhanced in these subjects. It has been
suggested that, in the face of increased clearance of Cortisol, obesity may
be exaggerated because of increased local reactivation of inactive
cortisone to Cortisol in adipose tissue by 11 |3-hydroxysteroid
dehydrogenase type 1 (llp-HSDl) (Bujalska et al., 1997; Andrew et al.,
1998). Increased reactivation of Cortisol in adipose tissue would be
predicted to increase the local concentration of Cortisol, independently of
circulating Cortisol levels, and increase glucocorticoid receptor activation,
thus amplifying the actions of glucocorticoids and promoting fat
deposition.
As discussed in chapter 1, the obese Zucker rat has been used as an animal
model of obesity and non-insulin dependent diabetes for many years
(Zucker & Zucker, 1961). The primary abnormality in the obese Zucker
rat has been identified as a mutation in the leptin receptor (Chua et al.,
1996), which renders these animals resistant to the satiety factor. The
obesity in these animals has been shown to be glucocorticoid dependent, as
adrenalectomy or treatment with glucocorticoid receptor antagonists
attenuate weight gain and associated metabolic abnormalities (Yukimura et
al., 1978; Freedman et al., 1986; Castonguay et al., 1986; Langley &
York, 1990). The hypothalamic-pituitary-adrenal (HPA) axis has been
studied in the obese Zucker rat, with conflicting reports of normal
(Yukimura et al., 1978; Cunningham et al., 1986; Walker et al., 1992) and
elevated (Dubuc, 1976; Martin et al., 1978; Fletcher et al., 1986;
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Guillaume-Gentil et al., 1990; Plotsky et al., 1992; Dryden et al., 1995)
plasma corticosterone levels; normal (Cunningham et al., 1986;
Guillaume-Gentil et al., 1990) and decreased (Walker et al., 1992)
sensitivity to negative feedback}; and normal (Plotsky et al., 1992; Walker
et al., 1992) and increased (Bestetti et al., 1990; Guillaume-Gentil et al.,
1990; Pacak et al., 1995) pituitary and adrenal responses to stress.
Glucocorticoid availability to its receptors is also controlled by metabolic
clearance, and at a tissue level by the isozymes of 11 P-hydroxysteroid
dehydrogenase (lip-HSD), as discussed in chapter 1. We have examined
glucocorticoid metabolising enzymes in the obese Zucker rat, specifically
reactivation of corticosterone by llp-HSDl and inactivation of
corticosterone by 11P-HSD2 and 5a-reductase. We have also looked at
the expression of hepatic glucocorticoid regulated genes, to assess the
effect of enzyme changes on glucocorticoid action.
3.2 Methods
Five-week old male lean (Fa/?) or obese (fa/fa) Zucker rats were obtained
from Harlan Orlac, Bicester, and were placed in metabolic cages at eight
weeks of age. Animals were allowed to acclimatise to the metabolic cages
for one week before a 72-hour urine collection. At nine-weeks of age
animals were killed by decapitation at 0900-1 lOOh. Trunk blood was
collected and tissues of interest were dissected and either snap-frozen on
dry ice or were mechanically homogenised in Krebs Ringer buffer.
Corticosterone and 11 -dehydrocorticosterone were measured by
radioimmunoassay in plasma prepared from trunk blood samples, and
urinary corticosterone metabolites were assessed by GC-MS. lip-HSD
and 5a-reductase activity were estimated by conversion of [3H]-
m "2 o
corticosterone to [ H]-l 1-dehydrocorticosterone or [ H]-testosterone to
[ H]-dihydro-testosterone respectively. mRNA was quantified by
Northern blot.
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All data are expressed as mean ± standard error. Parametric data were
analysed by Student's t-tests and non-parametric data were analysed by
Mann-Whitney U tests. N=8 for both groups.
3.3 Results
3.3.1 Body and organ weights
As expected, obese Zucker rats were significantly heavier than lean Fa/?
control animals (Table 3.1). In concordance with previous reports they
also had heavier adrenal glands, although this difference was not
significant when corrected for body weight (Walker et al, 1992). The
thymus was also heavier in obese animals, but again this difference was
not significant when corrected for body weight.
Lean Obese P value
(n=8) (n=8)
Body weight at 9 weeks (g) 226 + 7 280 ±6 <0.01
Adrenal weight (mg) 38 ±2 54 ±7 0.04
Adrenal / body weight 0.17 ±0.01 0.20 ± 0.03 0.75
Thymus weight (mg) 457 ±23 593 ±37 <0.01
Thymus weight/body weight 2.03 ± 0.09 2.12 ± 0.12 0.66
Table 3.1: Body and organ weights of lean (Fa/?) and obese (fa/fa)
Zucker rats aged 9-weeks.
Data are mean ± SEM. P values are from Student's t-tests.
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3.3.2 Plasma glucocorticoid levels
Plasma concentrations of both corticosterone (B) and its inactive
metabolite 11-dehydrocorticosterone (A) were significantly elevated in
obese animals when compared to lean controls (Figure 3.1).
3.3.3 Urinary glucocorticoid metabolite excretion
The glucocorticoid metabolites measured are shown in Figure 3.2. Obese
animals had higher total urinary corticosterone metabolites when
compared with lean controls (Figure 3.3). Obese rats exhibited a larger
difference in excretion of metabolites of A (greater than 10 fold higher)
than of B (3-5 fold higher), and had significantly higher 5a-reduced B
(5a-tetrahydro-B; 5a-THB) but not 5p-reduced B (5p-tetrahydro-B; 5p-
THB). B was not detected in any of the samples due to technical problems
with sensitivity of the GC-MS and an inherently higher limit of detection
because of the fragmentation pattern of B.
3.3.4 Glucocorticoidmetabolising enzymes'
In liver of obese animals 5a-reductase type 1 activity was significantly
higher than in lean controls (Figure 3.4). By contrast, hepatic lip-HSDl
activity, and mRNA expression were significantly lower in obese rats
(Figure 3.5). However, lip-HSDl activity was not different between
groups in skeletal muscle or subcutaneous fat, and was actually higher in
omental fat from obese animals (Figure 3.6). Both NADP-dependent
(11P-HSD1) and NAD-dependent (llp-HSD2) llp-HSD activities in the
kidney were higher in obese rats than in lean controls (Figure 3.6).
1 Measurement of 5a-reductase activity was carried out by Dr Greg Jones, Department of





































Figure 3.1: Plasma glucocorticoid levels.
Panel a) shows corticosterone and panel b) shows 11-
dehydrocorticosterone levels measured in plasma prepared from trunk
blood samples.
* denotes p <0.05 from Student's t-tests.
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5a-THB / 5P-THB 5(3-THA
Figure 3.2: Corticosterone metabolites.















































Lean Obese Lean Obese
Figure 3.3: Urinary corticosterone metabolites.
Glucocorticoid metabolites were measured by GC-MS in urine collected
over a 72h period.
A=11-dehydrocorticosterone; B=corticosterone; THA=tetrahydroA; 5a-
THB=5a-tetrahydroB and 5p-THB=5p-tetrahydroB. nd = not detected
Limits of detection were 14ng/72h for THA, and 28ng/72h for A.
* denotes p <0.05 from Mann Whitney U tests.
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Figure 3.4: 5a-reductase activity.
5a-reductase activity is expressed as percent conversion of testosterone to
5a-dihydrotestosterone.






Figure 3.5: Hepatic 1 lp-HSD activity and expression.
Panel a) shows hepatic lip-HSDl activity, measured in tissue
homogenates, expressed as percent conversion of corticosterone to 11-
dehydrocorticosterone. Panel b) shows hepatic llf3HSDl mRNA levels
measured by Northern blot, expressed as a ratio of the 1 lp-HSDl signal to
the GAPDH signal.








Muscle Subcut Omental Kidney Kidney
Fat Fat NADP NAD
Figure 3.6: 11 (3-HSD activity in a range of tissues.
11 (3-HSD activity is expressed as percent conversion of corticosterone to
11-dehydrocorticosterone. All incubations were carried out in the
presence of NADP cofactor, except where indicated for kidney when the
incubations were carried out with NAD cofactor.
p-values are from Mann Whitney U tests.
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3.3.5 Hepatic glucocorticoid regulated gene expression
Hepatic phosphoenolpyruvate carboxykinase (PEPCK) mRNA expression
was not different between lean and obese animals (Figure 3.7). In
contrast, tyrosine aminotransferase (TAT) expression was significantly
higher in livers of obese than lean animals (Figure 3.7).
3.3 Discussion
These data confirm previous reports that obese Zucker rats have heavier
adrenal glands (Walker et al., 1992) and increased urinary corticosterone
secretion (Cunningham et al., 1986) compared with lean controls. This is
the first study to examine excretion of urinary corticosterone metabolites,
and link this to tissue enzyme activities. It is also the first study to
demonstrate tissue-specific differences in the peripheral metabolism of
corticosterone in obese Zucker rats compared with lean controls.
Both adrenal weight and total urinary corticosterone secretion are
increased in the obese Zucker rat suggesting chronic activation of the HPA
axis, as has been reported in obese humans (Weaver et al., 1993). Adrenal
weight is not different between groups when corrected for body weight,
but whether merely correcting for body weight in these animals is
appropriate is a matter for debate, as the body composition is so different
between the lean and obese animals. One possible approach would be to
correct organ weight for lean body mass, but unfortunately we were unable




































Figure 3.7: Hepatic glucocorticoid regulated gene expression.
Panel a) shows hepatic PEPCK mRNA expression, and panel b) shows
hepatic TAT mRNA expression, measured by Northern blot, and expresses
as a ratio of the signal of interest to the signal for GAPDH.
* denotes p<0.05 from Mann Whitney U tests.
75
Plasma corticosterone (B) levels were significantly higher in obese rats
than in lean controls. Plasma 11 -dehydrocorticosterone (A) levels were
also higher in obese rats, and this could have important implications. The
role of lip-HSDl in amplifying glucocorticoid action is dependent on the
presence of A, the substrate for the enzyme. The plasma A and B levels
presented are total levels, and this does not give a true representation of the
free steroid levels. B circulates predominantly bound to proteins, such as
corticosteroid-binding-globulin, whereas A is largely unbound, resulting in
free A levels that are much higher than free B levels. Thus, variations in A
levels could have an impact on tissue glucocorticoid levels by providing
substrate for lip-HSDl to convert into active B. Therefore, lip-HSDl
activity and A availability could have a role to play in governing
intracellular glucocorticoid levels, independently of circulating B.
The rat liver only expresses the type 1 isozyme of 5a-reductase, which
reduces most A4"5 unsaturated steroids with similar efficiency (Berman &
Russell, 1993). The enzyme assay employed monitored the 5a-reduction
of testosterone, but because of the properties of the enzyme this can be
used as an estimation of glucocorticoid 5a-reduction. Liver homogenates
from obese rats exhibited a higher degree of 5a-reduction of testosterone
than liver from lean rats, indicating an increased activity of 5a-reductase,
which would be predicted to increase metabolic clearance of B to the
inactive 5a-tetrahydroB. When urinary glucocorticoid metabolites were
measured this was found to be the case, as obese rats excreted significantly
more 5a-tetrahydroB than lean rats.
In contrast with the increased 5a-reductase activity, in vitro hepatic 11 p~
HSD activity was lower in the obese rat than in lean animals, and this was
accompanied by lower lip-HSDl mRNA levels. Lower lip-HSDl
activity in vivo would be predicted to reduce intracellular glucocorticoid
levels, as there would be less reactivation of B from A. This would
therefore have the same net effect as higher 5a-reductase activity, as both
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would lead to lower tissue levels of active glucocorticoids. However,
lower 11 P-HSD 1 levels were not found in all tissues in the obese Zucker
rat. There was no difference in 11 P-HSD 1 activity between groups in
either skeletal muscle or subcutaneous adipose tissue, and indeed 11P-
HSD1 activity was actually higher in omental adipose from obese rats
compared with controls, which could indicate enhancement of
glucocorticoid action in this tissue. 11 p-HSD activity was higher in vitro
in the kidney of obese Zucker rats, suggesting enhanced inactivation of
corticosterone in vivo to its inert metabolite 11-dehydro-corticosterone.
The urinary glucocorticoid metabolite profile indicates an alteration in the
balance of'whole body' llp-HSDs, favouring 11-dehydro-corticosterone
in obese Zucker rats. This suggests that the decreased hepatic 11 P-HSD 1
activity and increased renal 11 p-HSD2 activity predominate over changes
in 11 P-HSD activity in other tissues.
The combination of increased 5a-reductase, increased renal llp-HSD2
and decreased hepatic 11 P-HSD 1 activities together predict an increase in
the glucocorticoid metabolic clearance rate, which in normal
circumstances would result in a compensatory increase in corticosterone
production (Walker & Edwards, 1994a). This mechanism could contribute
to activation of the HPA and adrenocortical hypertrophy in obesity.
However, it does not explain why trough plasma corticosterone levels are
elevated in obese rats. Abnormalities of central control of the HPA have
been sought previously in these animals but responses to glucocorticoid
feedback and stressful stimuli have been variably reported as normal,
increased or decreased (Guillaume-Gentil et al., 1990; Plotsky et al., 1992;
Bestetti et al., 1990). Moreover, it remains unclear whether leptin
resistance alone could explain activation of the HPA, since there may be
opposing effects of increased neuropeptide Y (NPY) and decreased pro¬
opiomelanocortin (POMC) expression (Schwartz et al., 1996b; Inoue,
1988; Thornton et al., 1997). One possible explanation for central HPA
activation is that obese rats have similarly reduced 11 p-HSD 1 expression
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in sites responsible for glucocorticoid negative feedback in the brain
(hippocampus, hypothalamus and anterior pituitary). Reduced lip-HSDl
activity would be predicted to decrease intracellular glucocorticoid levels,
and would thus reduce the brain's impression of circulating glucocorticoid
levels. This would decrease negative feedback, and cause activation of the
HPA. In support of this theory, mice with transgenic disruption of the
lip-HSDl gene (Kotelevtsev et al., 1997) have increased plasma
corticosterone levels which have been attributed to a lack of 1 lp-HSDl in
sites responsible for negative feedback.
The observed changes in glucocorticoid metabolism also predict changes
in peripheral corticosteroid receptor activation. Enhanced inactivation (by
5a-reductase) and impaired reactivation (by 1 lp-HSDl) of glucocorticoids
in the liver predicts lower intracellular corticosterone concentrations.
Decreased glucocorticoid exposure would normally be associated with
enhanced insulin sensitivity and decreased gluconeogenesis, as in 11P-
HSD1 knockout mice (Kotelevtsev et al., 1997), so it may be that reduced
hepatic glucocorticoid exposure in the obese Zucker rat represents a
compensatory mechanism which limits the metabolic complications of
obesity. By contrast, 1 lp-HSDl activity was normal in other
glucocorticoid targets (skeletal muscle and subcutaneous adipose tissue) in
obese rats so the proposed compensatory mechanism may not operate in
all tissues. Moreover, lip-HSDl activity was elevated in omental fat in
obese rats and this predicts increased local glucocorticoid receptor
activation, and may promote obesity. In addition to the higher 1 lp-HSDl
activity in omental fat there is also an increase in the availability of the
substrate for reactivation in obese animals (ie A), which could further
increase local corticosterone levels and obesity.
An interesting anomaly to the activated HPA is the fact that obese Zucker
rats had heavier thymuses. The thymus is an organ that undergoes
glucocorticoid-induced regression, and thus lower thymus mass would
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normally be associated with higher circulating glucocorticoid levels.
Obese Zucker rats actually had significantly heavier thymuses in the face
of much higher plasma glucocorticoid levels. This emphasises that
circulating plasma levels of glucocorticoids are not necessarily indicative
of tissue glucocorticoid levels. Thymus mass was not significantly
different between groups when corrected for body weight, but again, the
validity of correcting thymus weight for body weight is debatable.
The expression of hepatic glucocorticoid regulated genes was also
examined in obese Zucker rats to get an impression of the net effect of the
higher plasma corticosterone and the alterations in metabolism of
corticosterone on glucocorticoid action. Phosphoenolpyruvate
carboxykinase (PEPCK) is the rate-limiting enzyme in the gluconeogenic
pathway. Expression of PEPCK is up-regulated in response to
glucocorticoids and down-regulated in response to insulin (Sasaki et al.,
1984), both of which are altered in obese animals. There was no
difference in PEPCK mRNA levels between obese and lean animals, and
there are several possible explanations for this. It is well established that
obese Zucker rats are insulin resistant, and may therefore have defective
insulin mediated down-regulation of PEPCK, ie increased PEPCK
expression. Thus, any decrease in glucocorticoid action could merely
negate the increase in PEPCK due to insulin resistance, leading to no net
change in PEPCK. Alternatively, PEPCK expression is affected by the
feeding state of the animal, with subtle differences being revealed by
fasting in prenatally programmed rats and llp-HSDl knockout mice
(Nyirenda et al., 1998; Kotelevtsev et al., 1997). Since the animals in this
study were not fasted, it is possible that subtle alterations in PEPCK
expression could have been overlooked.
Tyrosine amino transferase (TAT) converts amino acids into substrates for
gluconeogenesis, and is central to glucocorticoid-induced gluconeogenesis.
TAT is up-regulated by glucocorticoids (Omrani et al., 1980), but
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regulation by insulin seems to be transient (Krett et al., 1983). Hepatic
TAT mRNA levels were higher in obese rats than in lean controls,
indicating that these animals had a higher level of glucocorticoid receptor
activation. This does not discount the above theory that the change in
hepatic 11 P-HSD 1 is compensatory, and acts to limit the metabolic
complications of obesity. It may be that the lower hepatic 1 1 P-HSD 1 in
the obese Zucker rat is compensatory, but cannot completely negate the
greatly higher plasma B levels, and without lower 11P-HSD the animals
would display even more striking metabolic abnormalities.
The effect of altered 11 P-HSD 1 activity on glucocorticoid action in
omental fat will obviously be a key observation. This could be examined
in the same way as for liver, ie examining the expression of glucocorticoid
regulated genes. Unfortunately, due to time constraints, this issue has not
been addressed in this thesis.
The mechanism of dysregulation of 5a-reductase and 11 P-HSD activities
in obesity has not been addressed by this study. With respect to 11P-
HSD1 we have shown that hepatic mRNA levels are reduced, suggesting
that gene transcription is altered in obese animals. It is unlikely that the
altered 11 P-HSD activities are secondary to activation of the HPA, since
chronic glucocorticoid excess is associated with up-regulation (not down-
regulation) of hepatic 11 P-HSD 1 activity and expression (Low et al.,
1994b). 11 P-HSD 1 is regulated by many other factors, including some
which are altered in obesity, such as growth hormone, insulin, TNFa, and
gonadal steroids (Low et al., 1994a; Hammami & Siteri, 1991; Escher et
al., 1997). By contrast, 5a-Reductase type 1 and 11 p-HSD type 2 do not
appear to be highly regulated enzymes. Further studies will be required to
try and elucidate the mechanism behind altered peripheral glucocorticoid
metabolism in obesity.
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Finally, the differences in metabolism of glucocorticoids in obese Zucker
rats mirror observations that have been made in obese humans. It has been
reported by our research group and others that obese men and women
excrete more Cortisol as 5a-reduced metabolites (Andrew et al., 1998;
Fraser et al., 1999). Detailed dynamic tests and arteriovenous sampling
have shown that hepatic lip-HSDl activity is impaired in obese men
(Stewart et al., 1999) but adipose lip-HSDl is either maintained or
marginally increased in obesity (Katz et al., 1999). The results presented
in this chapter demonstrate that the obese Zucker rat will be a useful model
in which to explore the mechanisms of disrupted glucocorticoid









The results presented in the previous chapter describe alterations of
peripheral glucocorticoid metabolism in the obese Zucker rat that are
analogous to those described in human obesity (Andrew et al., 1998;
Fraser et al., 1999; Stewart et al., 1999).
The aim of this study was to gain insight into the possible mechanisms of
dysregulation of glucocorticoid metabolism by 11 (3-HSD1 in obese Zucker
rats. Two important regulators of lip-HSDl are glucocorticoids, which
are associated with chronic up-regulation of both activity and expression
(Low et al., 1994b) and insulin, which down-regulates llp-HSDl
expression (Hammami & Siiteri, 1991; Jamieson et al., 1995). As
discussed previously, glucocorticoids are thought to be pivotal to the
phenotype of the obese Zucker rat. To investigate whether glucocorticoids
have a role in the alterations of glucocorticoid metabolism observed in the
obese Zucker rat we assessed the effect of adrenalectomy on lip-HSDl
activity in lean and obese Zucker rats.
4.2 Methods
Groups of eight 6-week old male obese and lean Zucker rats were either
adrenalectomised or sham-operated through dorsal incisions under
halothane anaesthesia and maintained on 0.9% saline drinking water for
three weeks. At age 9-weeks animals were decapitated at 0900-1 lOOh,
trunk blood collected, and tissues dissected and either snap-frozen on dry
ice or mechanically homogenised in Krebs Ringer buffer.
Corticosterone was measured by radioimmunoassay in plasma prepared
from trunk blood. 11P-HSD activity was estimated by conversion of [3H]-
"2
corticosterone to [ H]-l 1-dehydrocorticosterone, and hepatic enzyme
kinetics were determined by assessing enzyme activity at a range of
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substrate concentrations. Levels ofmRNA were assessed by northern blot
hybridisation.
All data are expressed as mean ± standard error. Parametric data were
analysed by Student's t-test for paired data or Analysis of Variance
followed by post hoc tests (ANOVA). Non-parametric data were analysed
by Mann-Whitney U tests. N=8 for all groups except lean
adrenalectomised group where n=7.
4.3 Results
4.3.1 Body and organ weights
Obese sham-operated (sham) Zucker rats were heavier than lean sham-
operated animals at age 9-weeks (Figure 4.1), and adrenalectomy was
associated with lower body weight in both lean and obese animals. The
amount of weight gained by each animal in the three-week period
following surgery was also compared. Obese sham animals gained more
weight than lean sham animals (Figure 4.1), and this difference was
attenuated by adrenalectomy. Adrenalectomy reduced weight gain in both
lean and obese animals.
Obese sham rats had heavier adrenal glands than lean animals (Figure 4.2),
but this was not significant when corrected for body weight. Adrenal
glands were not found postmortem in any of the adrenalectomised animals.
Thymus weight was also greater in obese sham operated animals when
compared with lean (Figure 4.3), but not if corrected for body weight, and
the same differences were observed in adrenalectomised animals.
Adrenalectomy did not affect absolute thymus weight, but thymus weight




Lean Obese Lean Obese
SHAM ADX
Lean Obese Lean Obese
SHAM ADX
Figure 4.1: Body weights and weight gain.
Panel a) shows body weight at 9-weeks of age and panel b) shows weight
gained in the 3-week period following surgery.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same surgery group. # denotes p<0.05 compared with
sham-operated animals of the same phenotype.





















































Lean Obese Lean Obese
SHAM ADX
Figure 4.2: Adrenal weights.
Panel a) shows adrenal weight at 9-weeks of age and panel b) shows
adrenal weight corrected for body weight.
* denotes p<0.05 from Student's t-test. nd denotes not detected.




Lean Obese Lean Obese
SHAM ADX
Lean Obese Lean Obese
SHAM ADX
Figure 4.3: Thymus weights.
Panel a) shows thymus weight at 9-weeks of age and panel b) shows
thymus weight corrected for body weight.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same surgery group. # denotes p<0.05 compared with
sham-operated animals of the same phenotype.
Sham denotes sham-operated, and ADX denotes adrenalectomised,
animals.
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4.3.2 Plasma glucocorticoid levels
Obese rats had higher plasma levels of corticosterone (Figure 4.4) than
lean rats. Both lean and obese adrenalectomised animals had no detectable
plasma corticosterone.
4.3.3 Hepatic 11J3-HSD1 kinetics and mRNA expression
Kinetic constants for lip-HSDl were calculated from the Lineweaver-
Burke linear transformation of the Michaelis-Menten equation
(Lineweaver & Burk, 1934) for each individual animal. A Lineweaver-
Burke plot constructed from the mean data is shown in Figure 4.5 for
illustration. The Michaelis constant (Km) was not different between lean
and obese animals and was unaffected by adrenalectomy (Figure 4.5).
Maximum velocity (Vmax) values for obese animals were approximately
half those for lean animals (Figure 4.5). Adrenalectomy normalised Vmax
in obese animals but had no effect in lean animals.
Hepatic lip-HSDl mRNA levels were lower in the liver of obese sham
animals than lean (Figure 4.6). This difference was attenuated by
adrenalectomy, but adrenalectomy per se increased lip-HSDl expression
in both lean and obese animals.
4.3.4 11/3-HSD1 activity in omentalfat
11P-HSD1 activity in omental fat tended to be higher in obese than lean
rats, but this was not statistically significant (Figure 4.7). Adrenalectomy
tended to decrease omental fat lip-HSDl activity in obese rats, but
increase it in lean rats, such that after adrenalectomy enzyme activity was












Figure 4.4: Plasma corticosterone levels
nd denotes not detected: limit of detection was 6.25nM.
* denotes p<0.05 from Student's t-test.













































Figure 4.5: Hepatic 1 lp-HSDl kinetics
Panel a) shows Lineweaver-Burke plots for summarized data. Km (panel
b) and Vmax (panel c) were calculated from Lineweaver-Burke plots for
each individual animal.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese sham-operated animals. # denotes p<0.05 compared with sham-
operated animals of the same phenotype.
Sham denotes sham-operated, and ADX denotes adrenalectomised,
animals.
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Lean Obese Lean Obese
SHAM ADX
Figure 4.6: Hepatic 11|3-HSD1 mRNA expression
11 (3-HSD1 mRNA levels are expressed as a ratio of the lip-HSDl signal
to the GAPDH signal.
Data were analysed by Mann-Whitney U tests. * denotes p<0.05
comparing lean and obese sham-operated animals. # denotes p<0.05
compared with sham-operated animals of the same phenotype.







Lean Obese Lean Obese
SHAM ADX
Figure 4.7: 11J3-HSD1 activity in omental fat
1 lp-HSDl activity is expressed as percent conversion of corticosterone to
11-dehydrocorticosterone.
Data were analysed by Mann-Whitney U tests. * denotes p<0.05
comparing lean and obese animals in the same surgery group.
Sham denotes sham-operated, and ADX denotes adrenalectomised,
animals.
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4.3.5 Hepatic glucocorticoid regulated gene expression
Hepatic PEPCK mRNA levels were not different between lean and obese
animals (Figure 4.8). Adrenalectomy had no effect on PEPCK mRNA
levels in either lean or obese animals.
In contrast, as found in chapter 3, hepatic TAT mRNA levels were higher
in obese animals than lean (Figure 4.8). Adrenalectomy had no effect on
TAT mRNA in lean animals, but caused a decrease in TAT expression in
obese animals, such that there was no difference between lean and obese
adrenalectomised animals.
4.4 Discussion
This study confirms the observation that adrenalectomy normalises weight
gain in obese Zucker rats (Yukimura et al., 1978; York & Godbole, 1979;
Freedman et al., 1986). It is the first study, however, to describe the
nature of the defect in hepatic 1 lp-HSDl in the obese Zucker rat, and to
examine the effects of adrenalectomy on the tissue specific dysregulation
of lip-HSDl.
As before, obese animals were found to have heavier adrenal glands than
lean animals, although this was not significant after correction for body
weight. The validity, or otherwise, of correcting organ weights for body
weight in animals with such different body compositions was also
discussed in Chapter 3, and it was decided to present results corrected for
body weight for the sake of completeness. Animals from all groups were
checked for the presence of adrenals to confirm that adrenalectomy was
complete. Successful adrenalectomy was also confirmed by plasma
corticosterone measurements. Sham obese Zucker rats had higher plasma
corticosterone levels than lean rats, but corticosterone was not detected in










































Figure 4.8: Hepatic glucocorticoid regulated gene expression
PEPCK (panel a) and TAT (panel b) mRNA levels are expressed as a ratio
of their signal to the GAPDH signal.
Data were analysed by Mann-Whitney U tests. * denotes p<0.05
comparing lean and obese sham-operated animals; # denotes p<0.05
compared with sham-operated animals of the same phenotype.
Sham denotes sham-operated, and ADX denotes adrenalectomised,
animals.
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In this study hepatic 11(3-HSD1 was examined more closely to determine
the nature of the decrease in activity. Kinetic analysis revealed that the
Km of 11P-HSD1 for corticosterone was not different between lean and
obese sham-operated animals, indicating that there is no difference in the
affinity of the enzyme for its substrate. The Vmax calculated for obese
animals, however, was approximately half that of the Vmax calculated for
lean animals, indicating that the capacity of the enzyme is reduced in
obese animals. This explanation is supported by the observation that 11P-
HSD1 mRNA levels are lower in obese animals. Adrenalectomy is
associated with normalisation of hepatic kinetics in obese animals, ie an
increase in Vmax with no change in Km. These changes in enzyme
kinetics are paralleled by changes in lip-HSDl mRNA levels, with
adrenalectomy increasing lip-HSDl mRNA in obese animals. One
obvious explanation for this might be that the hypercorticosteronaemia in
the obese animals is responsible for the dysregulation of hepatic 11 p-
HSD1. However, there is an inherent difficulty with attributing the results
of this study to one particular factor, as adrenalectomy is not a simple
manipulation. As well as removing circulating corticosterone and other
adrenal steroids, adrenalectomy of obese Zucker rats is associated with
normalisation of many of their metabolic abnormalities, including insulin
resistance (Castonguay et al., 1986; Freedman et al., 1986). Replacement
of glucocorticoids restores the metabolic abnormalities in a dose-
dependant manner (Freedman et al., 1986). It is therefore difficult to
directly address the role of glucocorticoids in isolation in the obese Zucker
rat, as removal, and subsequent replacement of glucocorticoids affect
many of the metabolic abnormalities observed. However,
hypercorticosteronaemia does not seem to be a likely explanation for
alterations in hepatic lip-HSDl, in the light of evidence that chronic
glucocorticoid exposure is associated with up-regulation of hepatic 11P-
HSD1 activity in normal rats (Low et al., 1994b). An alternative
explanation for the effect of adrenalectomy is that reversal of
hyperinsulinaemia is important, as insulin down-regulates lip-HSDl
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activity (Hammami & Siiteri, 1991; Jamieson et al., 1995). This issue is
addressed in chapter 5.
The alterations in 1 1(3-HSD1 in omental fat in obese Zucker rats are
qualitatively different from those in liver. The current results confirm
increased 11|3-HSD1 activity in omental fat from obese animals, albeit that
this was a non-significant trend (p=0.1) in the sham-operated animals.
After adrenalectomy, this difference was reversed, so that omental fat 11 (3-
HSD1 activity was lower in obese animals. Relatively little is known
about regulation of 11(3-HSD1 expression in rat adipose tissue, but
experiments in human cultured cells suggest that both glucocorticoids and
insulin may up-regulate activity (Bujalska et al., 1997). However, our
observation that adrenalectomy up-regulates lip-HSDl activity in
omental fat of lean animals, by contrast with the lack of effect in liver of
lean Zucker rats, reinforces previous observations that regulation of this
enzyme is tissue specific (Low et al., 1994b) and suggests that it is
unlikely that chronic hypercorticosteronaemia is responsible for up-
regulation of 11 [3-HSD1 in obese Zucker rats.
As in the previous chapter, hepatic glucocorticoid-regulated gene
expression and thymus mass were assessed to try to gain an impression of
the effects of altered glucocorticoid metabolism on glucocorticoid action.
In this study there was again no difference found in expression of hepatic
phosphoenolpyruvate carboxykinase (PEPCK; the rate limiting enzyme in
gluconeogenesis) mRNA between lean and obese animals. Adrenalectomy
might have been expected to cause a decrease in PEPCK expression,
particularly in obese animals, as both the removal of glucocorticoids,
which normally stimulate PEPCK, and an improvement in insulin
sensitivity would be predicted to decrease PEPCK expression. However,
adrenalectomy had no effect on PEPCK mRNA levels in either lean or
obese animals.
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In contrast, another gluconeogenic enzyme, tyrosine aminotransferase
(TAT), was induced in the livers of obese Zucker rats. Adrenalectomy
reduced the expression of TAT mRNA in obese animals to a level not
different from lean animals, while having no effect on TAT mRNA
expression in lean animals. This would suggest that
hypercorticosteronaemia may be responsible for the induction of TAT
expression. However, glucocorticoids do not seem to be necessary for
basal expression of TAT, as adrenalectomy had no effect on TAT
expression in lean animals. It is noteworthy that hepatic TAT expression
follows the same pattern of regulation as hepatic 11 p-HSDl, albeit that the
changes are in the opposite direction.
The thymus is an organ that undergoes glucocorticoid-induced regression,
and so thymus mass can be used as an index of glucocorticoid action. As
was found in chapter 3, obese animals had significantly heavier thymuses
than lean animals. Adrenalectomy did not cause a significant increase in
thymus mass in either lean or obese animals, and obese adrenalectomised
animals had significantly heavier thymuses than lean adrenalectomised
animals. This indicates that the thymus of the obese Zucker rat undergoes
less regression than the thymus of the lean Zucker rat, whether or not the
animals have been adrenalectomised. The results had a different pattern
when corrected for body weight, in that adrenalectomy caused a significant
rise in thymus mass in both lean and obese animals, but there was no
difference between lean and obese groups.
In conclusion, the alterations in lip-HSDl in liver and fat in the obese
Zucker rat described in Chapter 3 are both reversed by adrenalectomy.
The regulation of lip-HSDl by adrenalectomy is tissue specific, as an
increase in lip-HSDl is observed in the liver and a decrease is observed
in fat. The exact mechanism behind these changes is unclear, as there are









In the previous chapter tissue-specific alterations in regulation of 11 (5-
HSD1 following adrenalectomy of Zucker rats was described. While
glucocorticoids could have a role in this regulation, the exact mechanism is
not certain, as adrenalectomy normalises many of the metabolic
abnormalities observed in the obese Zucker rat, including insulin
resistance (Yukimura et al., 1978; Freedman et al., 1986; Castonguay et
al., 1986). Insulin is an important regulator of 11(3-HSD1 (Hammami &
Siiteri, 1991; Jamieson et al., 1995) and therefore could be implicated in
the alteration to llp-HSDl following adrenalectomy. To investigate this
possibility we conducted a study in which obese Zucker rats were treated
with insulin-sensitising drugs.
The drugs employed in this study were the biguanide oral hypoglycaemic
agent, metformin, and the thiazolidinedione insulin sensitising agent,
rosiglitazone (BRL 49653)2. Both of these drugs enhance insulin
sensitivity, but have different mechanisms of action. Metformin has been
used in the management of type II diabetes for many years, but its precise
mode of action is not defined. Metformin improves hepatic and peripheral
insulin sensitivity, without affecting insulin secretion and is also thought to
improve plasma lipid profiles (Dunn & Peters, 1995). By contrast,
rosiglitazone acts as an agonist at the peroxisome proliferator-activated
receptor-y (PPARy). PPARy agonists have been shown to increase
peripheral glucose uptake while decreasing insulin secretion and
gluconeogenesis in a variety of animal models of type II diabetes, while
having no effect on normal animals (Fugita et al., 1983; Fujiwara et al.,
1988; Stevenson et al., 1990).
2
Rosiglitazone was a kind gift from SmithKiine Beecham
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5.2 Methods
Groups of eight 6-week old male lean and obese Zucker rats were treated
with either metformin (43mg/kg body weight) or rosiglitazone (lmg/kg
body weight) at 0900h daily. Drugs were dissolved in water and
administered by gavage, and a matched volume of water (1ml/kg body
weight) was administered to the control groups. Animals were weighed
daily to allow accurate dosing with drugs, and to follow the progress of
weight gain. After two weeks of treatment animals underwent an oral
glucose tolerance test which consisted of an overnight fast followed by an
oral glucose load of 2g/kg body weight administered by gavage at 0900h.
Blood samples were taken at 0, 30 and 120 min after the glucose bolus. At
nine weeks of age, after three weeks of treatment, animals were
decapitated at 0900-1 lOOh, trunk blood collected and tissues dissected and
either snap-frozen on dry ice or mechanically homogenised in Krebs
Ringer Bicarbonate buffer.
Corticosterone was measured by radioimmunoassay in plasma prepared
from trunk blood samples. Plasma prepared from blood samples taken
during the oral glucose tolerance tests was analysed for glucose, using a
hexokinase assay kit, and insulin, using a radioimmunoassay. 11 (3-HSD
activity was estimated by conversion of [3H]-corticosterone to [3H]-11-
dehydrocorticosterone.
All data are expressed as mean ± standard error, and data were analysed by




5.3.1 Body and organ weights
There were no differences in weight between any of the lean groups or any
of the obese groups at the start of the treatment period, and all the obese
groups were slightly heavier than all the lean groups. Obese Zucker rats in
all treatment groups gained more weight in the three week treatment
period when compared with lean Zucker rats (Figure 5.1). Neither of the
treatments had any effect on weight gain in lean animals, but rosiglitazone
caused a small but significant increase in weight gained by obese animals,
when compared with vehicle treated obese animals. This difference in
weight gain was paralleled by changes in food intake (Figure 5.1).
Adrenal weight was higher in obese vehicle treated animals than in lean
(Figure 5.2) but, as previously, this was not significant when corrected for
body weight. Both metformin and rosiglitazone normalised adrenal weight
in obese animals while having no effect on adrenal weight in lean animals.
When adrenal weights were corrected for body weight both treatments
caused adrenal weight to fall in obese animals, but again had no effect on
lean animals.
Thymus weight was also higher in obese vehicle treated animals than in
lean (Figure 5.3) but again, this was not significant when corrected for
body weight. Neither metformin nor rosiglitazone had any effect on
thymus weight in either lean or obese animals.
5.3.2 Oral glucose tolerance tests
Results from the glucose tolerance tests are shown in Figure 5.4. Obese
vehicle treated animals exhibited hyperglycaemia in the fasting state and







































Lean Obese Lean Obese
Metformin Rosiglitazone
Figure 5.1: Weight gain and food intake during treatment period.
Panel a) shows amount of weight gained in the three-week treatment
period and panel b) shows average food intake per animal per day during
the three-week treatment period.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared














































Lean Obese Lean Obese Lean Obese
Vehicle Metformin Rosiglitazone
Figure 5.2: Adrenal weights.
Panel a) shows adrenal weight and panel b) shows adrenal weight
corrected for body weight.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared













































Lean Obese Lean Obese Lean Obese
Vehicle Metformin Rosiglitazone
Figure 5.3: Thymus weights.
Panel a) shows thymus weight and panel b) shows thymus weight
corrected for body weight.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared










VehMetRos Veh Met Ros VehMet Ros
0 min 30 min 120 min
Veh Met Ros Veh Met Ros Veh Met Ros
0 min 30 min 120 min
Figure 5.4: Oral glucose tolerance tests.
Panel a) shows glucose levels and panel b) shows insulin levels in plasma
prepared from tail-nick blood samples taken 0, 30, and 120min after oral
glucose load.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared
with vehicle treated group of the same phenotype.
Veh denotes vehicle treated animals, met denotes metformin treated
animals and ros denotes rosiglitazone treated animals.
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Insulin levels were markedly higher in obese animals at all time points
during the glucose tolerance test (Figure 5.4). Neither metformin nor
rosiglitazone had any effect on plasma glucose or insulin in lean rats. In
obese rats the effects on plasma insulin were more striking than the effects
on plasma glucose. Metformin decreased both fasting and 30min plasma
glucose levels, and decreased 30 and 120min insulin levels, whereas
rosiglitazone decreased only the 30min glucose level, but reduced plasma
insulin at all time points.
5.3.3 Plasma corticosterone levels
Plasma corticosterone levels were rather variable in this experiment, so
that trends rather than statistically significant differences were observed.
The variability probably reflects poorly controlled stress at the time of
decapitation, as this experiment was carried out in another department's
animal unit due to the refurbishment of our own unit. It seems that obese
vehicle-treated rats had higher plasma corticosterone than lean rats (Figure
5.5). Neither metformin nor rosiglitazone had any effect on plasma
corticosterone in lean animals, but rosiglitazone tended to normalise
plasma corticosterone in obese animals.
5.3.4 11 (3-HSD activities
In vehicle treated animals, hepatic lip-HSDl activity was lower, and
omental fat lip-HSDl activity was higher, in obese rats when compared
with lean (Figure 5.6). Neither metformin nor rosiglitazone altered hepatic
or omental fat 1 lp-HSDl activity.
1 lp-HSDl activity in subcutaneous fat was not different between lean and
obese vehicle treated animals. Metformin treatment caused an increase in
11P-HSD1 activity in lean animals, but had no effect in obese animals. By
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contrast, rosiglitazone caused a decrease in 11 P-HSD 1 activity in obese
animals, while having no effect in lean animals.
There was also no difference in 1 1 P-HSD 1 activity between lean and
obese vehicle treated animals in skeletal muscle. Metformin had no effect
on 11 p-HSD 1 activity in lean animals, but there was a small, although not
statistically significant decrease in lip-HSDl activity in obese animals.
Rosiglitazone caused a rise in lip-HSDl activity in both lean and obese
animals.
Renal NAD- and NADP-dependent 11P-HSD activity was higher in obese
vehicle treated Zuckcr rats than in lean, although this was not statistically
significant for NAD-dependent activity. Neither metformin nor
rosiglitazone had any effect on renal 11 p-HSD activity, and enzyme











Lean Obese Lean Obese
Metformin Rosiglitazone
Figure 5.5: Plasma corticosterone levels.
Corticosterone levels were measured in plasma prepared from trunk blood
samples.







































































Figure 5.6: 11P-HSD activity in tissue homogenates.
11 p-HSD activity is expressed as percent conversion of corticosterone to
11-dehydrocorticosterone. All incubations were carried out in the
presence of NADP cofactor, except where indicated for kidney when the
incubations were carried out with NAD cofactor.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared
with vehicle treated group of the same phenotype.
Veh denotes vehicle treated animals, met denotes metformin treated
animals and ros denotes rosiglitazone treated animals.
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5.4 Discussion
These data confirm previous reports that obese Zucker rats have impaired
glucose tolerance and insulin resistance (York et al., 1972), and reiterate
the tissue-specific alterations in peripheral glucocorticoid metabolism
described in the previous chapters of this thesis. This study was designed
to examine the possible contribution of insulin to the alterations in 11 p-
HSD activity in the obese Zucker rat, and utilised two different insulin-
sensitising treatments. The results show that neither insulin-sensitising
treatment normalised aberrant lip-HSDl activity in liver or fat, but both
treatments reversed adrenal hypertrophy in obese rats.
While metformin had no effect on either food intake or body weight,
rosiglitazone treatment caused an increase in both food intake and weight
gain in obese animals, but had no effect in lean animals. This effect of
rosiglitazone has been reported previously, and is independent of leptin
and neuropeptide Y (Wang et al., 1997), but the mechanism is still
unknown.
Both metformin and rosiglitazone enhanced insulin sensitivity in obese,
but not in lean, Zucker rats, as demonstrated by the results of the oral
glucose tolerance tests. However, the mechanism of their action is
probably different, with metformin lowering fasting glucose and acting
principally on hepatic gluconeogenesis, while rosiglitazone may have
more important effects on glucose uptake in adipose tissue and skeletal
muscle.
Having established that both treatments have insulin sensitised the obese
Zucker rats, and had no effect on the lean animals, we could then look at
the effects of these changes on glucocorticoid metabolism. lip-HSDl
activity in vehicle treated rats followed the same pattern that has been
described in previous chapters of this thesis, with obese animals having
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lower 11P-HSD1 activity in the liver and higher 11 P-HSD 1 activity in
omental fat, when compared with lean controls. Neither metformin nor
rosiglitazone caused any change in 11 P-HSD 1 activity in either liver or
omental fat from lean or obese animals. The pattern for renal 11P-HSD2
activity was similar, with vehicle treated obese animals having higher
enzyme activity than lean animals, and neither of the insulin-sensitising
treatments having any effect. The most striking effect of the insulin-
sensitising treatments on 11 p-HSD activity was the effect of rosiglitazone
in skeletal muscle. This increase in 11 P-HSD 1 activity would be predicted
to increase local glucocorticoid levels, and thus antagonise insulin action,
negating some of the insulin-sensitising action. Interestingly, this effect
occurred in both obese animals, which have been insulin-sensitised, and in
lean animals, in which there is no effect of rosiglitazone on insulin
sensitivity. This raises the possibility that this is a direct effect of the drug,
rather than a consequence of insulin-sensitisation, and re-emphasises that
there are tissue-specific differences in 11 P-HSD 1 regulation. It would
therefore be interesting to observe whether the effects of rosiglitazone on
insulin sensitivity are enhanced when combined with 11 P-HSD 1
inhibition.
Mechanisms for activation of the HPA axis in obesity are poorly
understood. The results presented in chapter 3 of this thesis support the
possibility that enhanced peripheral clearance of glucocorticoids resulting
from enhanced 5a-reductase and impaired hepatic 11 P-HSD 1 activities
may be an important stimulus. However, both metformin and
rosiglitazone normalised the adrenal hypertrophy in obese Zucker rats
while having no effect on the altered hepatic 11 p-HSD 1 activity. In
addition, rosiglitazone tended to normalise plasma corticosterone levels,
albeit that this is contrary to a previous report where rosiglitazone
increased plasma corticosterone in obese Zucker rats (Wang et al., 1997).
This suggests that insulin-sensitising agents may exert effects on other
glucocorticoid metabolising enzymes, such as 5a-reductase, or may
ill
indicate effects of insulin resistance or hyperinsulinaemia on central
control of the HPA axis. Despite the alteration in plasma corticosterone
with rosiglitazone treatment, neither of the insulin-sensitising agents
altered thymus mass. This reinforces the point that circulating
glucocorticoid levels are not necessarily indicative of local glucocorticoid
action.
In conclusion, insulin-sensitisation does not normalise the alterations in
11P-HSD activity described in the obese Zucker rat. This suggests that the
mechanism underlying abnormal 11 P-HSD 1 activity does not relate to
hyperinsulinaemia, and that reversal of altered 11 P-HSD 1 activity
following adrenalectomy is not related to reversal of insulin resistance.
Alternative mediators of tissue-specific dysregulation of 11 p-HSD, such as
growth hormone (Low et al., 1994a) or gonadal steroids (Low et al.,
1993), may be more important in obesity. However, hyperinsulinaemia
may be a key factor contributing to activation of the HPA axis in obesity








In chapter 3, tissue-specific alterations in the activity of 1 1 p-HSD in obese
Zucker rats were described. Down-regulation of 11 P-HSD 1 in the liver is
predicted to attenuate local glucocorticoid action, and may enhance
metabolic clearance of glucocorticoids. By contrast, enhanced 11 P-HSD 1
in omental fat may maintain local glucocorticoid concentrations and
promote lipogenesis. This study was designed to examine the contribution
that these changes in enzyme activity may make to obesity and insulin
resistance.
Inhibition of 11 p-HSD with carbenoxolone treatment in healthy adult men
increases hepatic insulin sensitivity and decreases glucose production
(Walker et al., 1995), and lack of 11 p-HSD 1 in transgenic mice has
similar effects (Kotelevtsev et al., 1997). We therefore postulated that
inhibition of 11 P-HSD might improve insulin sensitivity in obese Zucker
rats. It also seemed possible that 11 P-HSD 1 inhibition would improve the
obesity in these animals, by decreasing local glucocorticoid levels and
attenuating the stimulus to lipogenesis. Zucker rats were treated with
carbenoxolone, an inhibitor of 11 P-HSD (Stewart et al., 1990), to test
these hypotheses.
6.2 Methods
Groups of eight 6-week old male lean and obese Zucker rats were treated
by gavage with either carbenoxolone (50mg/kg body weight) or a matched
volume of water (1ml/kg body weight) at 0900h daily. Animals were
weighed daily to allow accurate dosing with carbenoxolone, and to follow
the progress of weight gain. After two weeks of treatment animals
underwent an oral glucose tolerance test which consisted of an overnight
fast followed by an oral glucose load of 2g/kg body weight administered
by gavage at 0900h. Tail-nick blood samples were taken 0, 30 and 120
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min after the glucose bolus. At nine weeks of age, after three weeks of
treatment, animals were decapitated at 0900-1 lOOh, trunk blood collected
and tissues dissected and either snap-frozen on dry ice or mechanically
homogenised in Krebs Ringer buffer
Corticosterone was measured in plasma prepared from trunk blood
samples by radioimmunoassay. Plasma prepared from blood samples
taken during the oral glucose tolerance tests was analysed for glucose,
using a hexokinase assay kit, and insulin, using a radioimmunoassay. 1113-
HSD activity was estimated by conversion of H-corticosterone to H-ll-
dehydrocorticosterone.
All data are expressed as mean ± standard error, and data were analysed by
Analysis of Variance followed by post hoc tests (ANOVA). N=8 for all
groups.
6.3 Results
6.3.1 Body and organ weights
Vehicle treated obese Zucker rats gained more weight in the three-week
treatment period and had higher food consumption than lean animals
(Figure 6.1). Carbenoxolone treatment had no effect on food intake or
body weight, in either lean or obese animals.
Adrenal weight was higher in obese vehicle treated animals than in lean
(Figure 6.2), but not when corrected for body weight. Carbenoxolone
treatment had no effect on adrenal weight in lean animals, but caused a
decrease in adrenal weight in obese animals so that they were not different
to lean animals. When corrected for body weight, obese carbenoxolone




Lean Obese Lean Obese
Vehicle Carbenoxolone
Lean Obese Lean Obese
Vehicle Carbenoxolone
Figure 6.1: Weight gain and food intake during treatment period.
Panel a) shows amount of weight gained in the three-week treatment
period and panel b) shows average food intake per animal per day in the
three-week treatment period.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared
with vehicle treated group of the same phenotype.
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a)
Lean Obese Lean Obese
Vehicle Carbenoxolone
b)
Lean Obese Lean Obese
Vehicle Carbenoxolone
Figure 6.2: Adrenal weights.
Panel a) shows adrenal weight and panel b) shows adrenal weight
corrected for body weight.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared
with vehicle treated group of the same phenotype.
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Thymus weight was also higher in obese vehicle treated animals than in
lean (Figure 6.3), but again not when corrected for body weight.
Carbenoxolone treatment had no effect on thymus weight in obese
animals, but caused a slight increase in thymus mass in lean animals.
When corrected for body weight, carbenoxolone had no effect on thymus
weight in obese animals, but caused an increase in thymus mass in lean
animals.
6.3.2 11/3-HSD activity in tissue homogenates
In this study the same tissue profde of 1 lp-HSDl activity was found in the
vehicle treated animals as has been described in the previous chapters.
Carbenoxolone inhibited hepatic 1 lp-HSDl and renal 11P-HSD2 activity
in both lean and obese animals (Figure 6.4). However, there was no
demonstrable inhibition of lip-HSDl activity by carbenoxolone in
skeletal muscle homogenates, or in homogenates of subcutaneous or
omental fat.
6.3.3 Plasma corticosterone levels
Plasma corticosterone levels were variable in this experiment. This study
was carried out in the same animal unit as the study using rosiglitazone
and metformin, and the variability probably reflects uncontrolled stress at
the time of decapitation. There was a trend for plasma corticosterone to be
higher in the obese animals than in the lean (Figure 6.5), and
carbenoxolone treatment tended to increase plasma corticosterone in both




Lean Obese Lean Obese
Vehicle Carbenoxolone
b)
Lean Obese Lean Obese
Vehicle Carbenoxolone
Figure 6.3: Thymus weights.
Panel a) shows thymus weight and panel b) shows thymus weight
corrected for body weight.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared
































































Lean Obese Lean Obese
Vehicle Carbenoxolone
Kidney (NAD)
Lean Obese Lean Obese
Vehicle Carbenoxolone
Figure 6.4: 11(3-HSD activity in tissue homogenates.
11 p-HSD activity is expressed as percent conversion of corticosterone to
11-dehydrocorticosterone. All incubations were carried out in the
presence of NADP cofactor, except where indicated for kidney, when the
incubations were carried out with NAD cofactor.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared























Figure 6.5: Plasma corticosterone levels.
Corticosterone levels were measured in plasma prepared from trunk blood
samples.
There were no statistically significant differences between groups.
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6.3.4 Oral glucose tolerance tests
Results from the glucose tolerance tests are shown in Figure 6.6. Obese
vehicle treated rats had fasting hyperglycaemia and were also
hyperglycaemic 120min after glucose bolus, when compared with lean
rats. Insulin levels were markedly higher in obese animals at all time
points during the glucose tolerance test. Carbenoxolone treatment had no
significant effect on plasma glucose levels at any time point. By contrast,
carbenoxolone increased plasma insulin in the fasting state and 30min after
glucose in both lean and obese animals, and at 120min in obese animals
only.
6.4 Discussion
The results presented in this chapter suggest that carbenoxolone treatment
of obese Zucker rats did not improve obesity or insulin sensitivity, and in
fact exacerbated insulin resistance. However, inhibition of 11P-HSD was
not demonstrable in vitro in all tissues, and 11 p-HSD is not the only
enzyme inhibited by carbenoxolone.
Inhibition of 11 P-HSD 1 by carbenoxolone treatment was evident in tissue
homogenates of liver and kidney, but not in skeletal muscle or adipose
tissue. It is notoriously difficult to demonstrate in vitro inhibition of 11P-
HSD by carbenoxolone treatment, but chronic carbenoxolone has been
reported to inhibit transcription of 11 P-HSD 1 in liver and kidney
(Whorwood et al., 1993). This raises the possibility that the enzyme in
muscle and adipose tissue is being inhibited in vivo by carbenoxolone, but
that the effects are not transcriptional and therefore are difficult to
reproduce in vitro. An alternative explanation is that the distribution of
carbenoxolone varies between tissues and that the drug did not access
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0 min 30 min 120 min
Figure 6.6: Oral glucose tolerance tests.
Panel a) shows glucose levels and panel b) shows insulin levels in plasma
prepared from tail-nick blood samples taken 0, 30 and 120min after oral
glucose load.
Data were analysed by ANOVA. * denotes p<0.05 comparing lean and
obese animals in the same treatment group. # denotes p<0.05 compared
with vehicle treated group of the same phenotype.
Veh denotes vehicle treated animals and CBX denotes carbenoxolone
treated animals.
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If the latter were the case, tissue specific inhibition of the enzyme would
need to be taken into account when interpreting the results. The issue
could be resolved by measuring carbenoxolone concentrations within the
tissues, and work is in progress in our laboratory to establish such an
assay. It is also planned to quantify 11 0-HSD mRNA levels to establish
whether the changes in enzyme activity observed reflect transcriptional
effects.
Carbenoxolone had no effect on adrenal size in lean animals, but reduced
adrenal size in obese animals and had no significant effect on plasma
corticosterone. Attenuated HPA activity (as assessed by decreased adrenal
weight) in the face of no drop in plasma corticosterone suggests that the
net clearance of corticosterone must also be attenuated. As well as
inhibiting metabolism of corticosterone by 110-HSD2, carbenoxolone
inhibits other glucocorticoid metabolising enzymes, including 50-
reductase (Latif et al., 1990). Inhibition of both 110-HSD2 and 50-
reductase would decrease metabolic clearance of corticosterone.
However, despite inhibition of hepatic 110-HSD1 and attenuation of HPA
activation, no normalisation ofweight gain was observed in obese animals.
There are several explanations for this. Firstly, enhanced 110-HSD1
activity in omental fat may be important to maintaining obesity, and the
lack of effect of carbenoxolone on body weight may be due to the enzyme
not being demonstrably inhibited in this tissue. Secondly, as suggested in
chapter 3, attenuated hepatic 110-HSD1 may be compensatory, so that
further inhibition of 110-HSD1 activity cannot add to this effect. Thirdly,
it may be that neither altered 110-HSD1 nor activated HPA is causally
linked to obesity. The last explanation seems unlikely in light of the
growing body of evidence discussed in chapter 1.5 linking HPA activation,
glucocorticoids and obesity.
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The most striking result from this study was the effect of carbenoxolone on
insulin sensitivity. Inhibition of 11 (3-HSD1 in the liver would cause a
decrease in glucocorticoid receptor activation, and would therefore be
predicted to enhance insulin action, as has been reported in man (Walker et
al., 1995). However, the results of this study suggest that, if anything,
carbenoxolone treatment impaired insulin sensitivity in both lean and
obese animals. In chapter 3 it was suggested that attenuated hepatic 11 p-
HSD1 activity in obese Zucker rats may be compensatory to increased
plasma corticosterone. It may be that, as already suggested, this
compensation is maximal, and further inhibition of 1 lp-HSDl activity has
no additional effect. Alternatively, carbenoxolone also inhibits metabolic
clearance of corticosterone by 5p-reductase (Latif et al, 1990) and this
would tend to increase local corticosterone levels, possibly offsetting any
beneficial effect of inhibited reactivation of corticosterone by lip-HSDl.
The net effect of carbenoxolone on intrahepatic corticosterone levels will
therefore depend on the balance between decreased reactivation by 11 p-
HSD1 and decreased inactivation by 5p-reductase. Studying
glucocorticoid regulated gene expression would help to establish whether
hepatic glucocorticoid receptor activation is increased or decreased by
carbenoxolone. Urinary glucocorticoid metabolite profiles would enable
us to assess the effect of carbenoxolone on different steroid metabolising
enzymes, but unfortunately this was not possible in the course of this
experiment. It would be interesting to examine the effects of specifically
inhibiting hepatic lip-HSDl, for example using oestradiol (Low et al.,
1993; Jamieson et al., 1999), on insulin sensitivity.
The lack of specificity of carbenoxolone could also explain the
inconsistency between the human and rodent data, as it is possible that the
drug inhibits different enzymes to varying degrees in the different species.
Another explanation for the discrepancy could be the circumstances under
which insulin sensitivity was assessed. Euglycaemic hyperinsulinaemic
clamp studies were used to assess insulin sensitivity in men treated with
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carbenoxolone (Walker et al, 1995) and it is possible that the effects
observed in man are only apparent when insulin is clamped at a very high
level.
In conclusion, carbenoxolone treatment of Zucker rats had no effect on
either food intake or weight gain but did impair insulin sensitivity in both
lean and obese animals. This is in contrast with a previous report of
carbenoxolone enhancing insulin sensitivity and the finding that 11P-
HSD1 knock-out mice have attenuation of activation of gluconeogenic
enzymes, and some possible explanations for these discrepancies have
been discussed. However, full interpretation of the data presented should
be reserved until the tissue distribution of carbenoxolone, and its effects on
other steroid metabolising enzymes, can be clarified.
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Chapter Seven




The results presented in chapter 3 describe increased metabolic clearance
of corticosterone, and tissue-specific differences in metabolism of
corticosterone by lip-HSDl in the Zucker rat model of obesity. The
urinary glucocorticoid metabolite profiles support in vitro measurements
of glucocorticoid metabolising enzymes, and the results are also in
concordance with published data for urinary glucocorticoid metabolite
profiles in obese men (Andrew et al., 1998; Stewart et al., 1999),
validating the use of obese Zucker rats as a model of human obesity.
Previous studies have attempted to examine adipose tissue lip-HSDl
activity in man. However, these have been limited to cell culture work on
adipose stromal cells (Bujalska et al., 1997), and arteriovenous sampling,
which gives highly variable results (Katz et al., 1999). The aim of this
study was to assess whether obese men exhibit similar tissue-specific
alterations in 1 lp-HSDl activity.
7.2 Methods
Participants in the study were recruited from members of the MONICA
(Monitoring Trends and Determinants in Cardiovascular Disease) study of
Northern Sweden (Soderberg et al., 1999). Approval of Umea University
Hospital ethics committee and written informed consent were obtained.
Thirty-four men were selected from the MONICA population to provide a
group with a wide range of body composition and fasting plasma insulin
levels. Hepatic lip-HSDl activity was assessed by conversion of oral
cortisone to Cortisol after suppression of endogenous Cortisol production
with dexamethasone. Patients also collected a 24-hour urine sample for
analysis of Cortisol metabolites by GC-MS, and a sub-group of 13 patients
consented to a subcutaneous fat biopsy taken from the gluteal/buttock
region. The patients who had biopsies performed did not differ
significantly to the study population in general. The clinical portion of the
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study took part in Sweden, including the biopsies. The fat biopsy was
frozen immediately at -70°C and transported on dry ice. The fat was
mechanically homogenised in Krebs buffer and llp-HSDl activity was
3*3*
assessed by conversion of [ H]-cortisol to [ H]-cortisone.
Body mass index (BMI) was normally distributed in the sample of men.
Indices of obesity were therefore analysed as continuous variables in
regression analyses, but are presented in Tables and Figures in tertiles of
BMI for clarity. Urinary Cortisol metabolites were normalised by
logarithmic transformation before analysis, but are presented as
untransformed data for clarity. Area under the curve was calculated
according to the trapezoidal rule, and centered cumulative response was
used to compensate for different baseline hormone levels.
7.3 Results
7
7.3.1 In vivo measurements ofCortisol metabolism
Increasing obesity was associated with differences in urinary Cortisol
metabolites (Table 7.1). Obese men excreted relatively more Cortisol as
derivatives of cortisone (5p-tetrahydrocortisone; THE) than Cortisol (5a-
and 5p-tetrahydrocortisol; 5a- and 5p-THF), and tended to have higher
excretion of 5a- than 5P-THF.
Hepatic lip-HSDl activity measured in vivo was impaired in obesity, as
measured by area under the curve for plasma Cortisol concentrations after
oral cortisone (Figure 7.1). Endogenous glucocorticoid production was
suppressed with a dose of dexamethasone given the night before testing,
and by the cortisone given during testing. This is shown by plasma
3 The in vivo study was carried out in Sweden by Drs Eva Rask, Tommy Olsson, Stefan
Sodeberg and O Johnson. Analysis of plasma and urine was carried out by Inger Arnesjo,
EIse-Britt Lundstrom, and Jill Smith. Analysis of the biopsy samples was carried out by
me.
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corticosterone concentrations, which fell during the time course of the test.
Therefore, the difference in plasma Cortisol concentrations between groups
can only be explained by differences in conversion of cortisone to Cortisol.
7.3.2 In vitro 11/3-HSD1 activity in subcutaneous adipose tissue
By contrast with their lower hepatic 11 (3-HSD1 activity, obese men had
substantially higher 11 (3-HSD1 activity in subcutaneous adipose tissue
(Figure 7.2). Under the conditions used there was no evidence of

















11.3±1.5 12.8+1.6 15.3+1.0 0.01
5a-Tetrahydrocortiso 1
(cc-THF)
2.15±0.29 2.06+.0.24 3.10+.0.32 0.06
5P-Tetrahydrocortisol
(p-THF)
2.81±0.27 3.29+0.42 2.59+0.29 0.82
Tetrahydrocortisone
(THE)
4.44+0.58 4.92+0.78 7.73+0.85 0.006
(5ctTHF+5pTHF)
/THE
1.18±0.08 1.29+0.17 0.87+0.28 0.06
5aTHF/5pTHF 0.78+0.09 0.71+0.09 1.13+0.10 0.10
Table 7.1: Subject classification and urinary Cortisol metabolite
measurements
Data are mean ± SEM of untransformed data, p-values are from
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Figure 7.1: Plasma Cortisol after oral cortisone
Endogenous plasma Cortisol was suppressed, as demonstrated by plasma
corticosterone in panel a), and production of Cortisol after an oral dose of
cortisone was measured, panel b). Data are mean ± SEM for subjects from
the lowest, middle and highest tertiles of BMI. Comparison of responses
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Figure 7.2: In vitro 11(3-HSD1 activity in subcutaneous adipose tissue
Data are mean ± SEM for subjects from the lowest (n=4), middle (n=6)
and highest (n=3) tertiles of BMI. Comparison of responses by regression




The urinary Cortisol metabolite profiles described in this study confirm
previous reports of altered peripheral metabolism of Cortisol in obesity due
to a combination of enhanced 5a-reductase activity (Andrew et al., 1998)
and impaired 1 1 p-HSD 1 activity in liver (Stewart et al., 1999). This study
has also described tissue-specific alterations in 11 P-HSD 1 activity that
may not be revealed by urinary metabolite analysis alone.
In this study, the balance of 11P-HSD activity in the whole body, as
assessed by urinary Cortisol metabolites, favours cortisone. This could be
explained by decreased 11 P-HSD 1 activity in the liver, and the results of
the oral cortisone-cortisol conversion test suggest this may be the case.
Urinary cortisol/cortisone metabolite ratios are not always decreased in
obesity (Andrew et al., 1998; Stewart et al., 1999), and this may be
explained by tissue-specific disruption of 11 P-HSD 1. Tissue activity of
11 P-HSD 1 has been difficult to address in man, with studies limited to cell
culture (Bujalska et al., 1997) and variable techniques such as
arteriovenous sampling (Katz et al., 1999). The availability of fresh
subcutaneous adipose samples in this study has allowed the direct
measurement of 11 p-HSD 1 activity. Obese men had substantially higher
11 P-HSD 1 activity in subcutaneous fat, predicting enhanced reactivation
of cortisone to Cortisol in adipose tissue, and promotion of obesity. Thus,
obese men appear to exhibit similar tissue-specific differences in 11P-
HSD1 activity as those described in obese Zucker rats in previous
chapters. These results further validate the use of the obese Zucker rat as a
model in which to study the mechanisms of altered glucocorticoid
metabolism, and reinforce the potential value of specific inhibitors of 11 P~





In the introduction to this thesis a list of aims was drawn up. These aims
have been addressed and the following conclusions reached.
8.1 Glucocorticoid metabolism in obesity.
Glucocorticoid metabolism has been examined in the Zucker rat model of
obesity. Clearance of corticosterone by hepatic 5a-reductase and renal
11[3-HSD2 is enhanced in obese animals, and reactivation of
corticosterone by hepatic lip-HSDl is impaired. These changes will
result in increased metabolic clearance of corticosterone, which may
contribute to HPA activation in obesity. By contrast, 1 lp-HSDl activity is
normal in skeletal muscle and subcutaneous adipose tissue, and is
enhanced in omental adipose tissue. Increased lip-HSDl activity would
be predicted to raise local corticosterone levels and glucocorticoid receptor
activation, and may promote obesity. These results validate the use of
urinary steroid metabolite profiles to assess enzyme activity, as changes in
urinary steroids were paralleled by changes in enzyme activity measured in
vitro.
The results described in chapter 7 of this thesis indicate that obesity in man
may be associated with similar tissue specific differences in lip-HSDl
activity, with enzyme activity impaired in the liver, but enhanced in fat.
This provides further evidence that the obese Zucker rat is a valid model in
which to study glucocorticoid metabolism in obesity. This model was
therefore used to try and dissect the mechanism(s) underlying
dysregulation of 1 lp-HSDl in obesity, and to determine the physiological
effects of alterations in 11 p-HSDl.
8.2 Mechanisms ofdysregulation of11J3-HSD1 in obesity
The obese Zucker rat displays a catalogue of metabolic abnormalities, and
we were interested in whether any of these could contribute to the
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alterations in llp-HSDl described in chapter 3. Two of the primary
regulators of 1 lp-HSDl are glucocorticoids and insulin, both of which are
elevated in the obese Zucker rat. The role of adrenal steroids in the
dysregulation of lip-HSDl was assessed by studying adrenalectomised
animals, and the role of insulin by studying animals treated with insulin
sensitising agents.
Adrenalectomy attenuated weight gain in obese animals to a level not
different from lean animals, and normalised hepatic llp-HSDl kinetics.
The abnormality in omental fat lip-HSDl activity was reversed by
adrenalectomy, with activity falling in obese animals and rising in lean
animals. This highlights that not only are the abnormalities in 1 lp-HSDl
activity tissue-specific, but their regulation is also tissue-specific. Since
adrenalectomy also improves insulin sensitivity, it is possible that the
effects of adrenalectomy are mediated by changes in insulin. However, in
light of the results described in chapter 5, this seems unlikely. While both
insulin-sensitising agents improved insulin sensitivity, they had no effect
on 1 lp-HSDl activity in either liver or omental fat. Both metformin and
rosiglitazone normalised adrenal hypertrophy in obese animals, and
rosiglitazone tended to decrease plasma corticosterone levels, suggesting
that hyperinsulinaemia may contribute to HPA activation in obesity.
These results suggest that dysregulation of lip-HSDl in obesity is not
related to insulin sensitivity, and normalisation of enzyme activity by
adrenalectomy is not due to changes in insulin sensitivity.
8.3 Physiological relevance ofalterations in 11/3-HSD1
The tissue specific alterations in 1 lp-HSDl activity described in chapter 3
would be predicted to decrease local glucocorticoid levels in liver and
increase them in omental fat. To assess the effect of decreased hepatic
llp-HSDl activity on glucocorticoid activity, the expression of
glucocorticoid regulated genes was measured. Hepatic tyrosine
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aminotransferase (TAT) expression, which is induced by glucocorticoids,
was higher in obese animals than in lean. This suggests that lip-HSDl
activity is not decreased enough to compensate fully for the elevated
plasma corticosterone levels in obese animals. Due to time constraints,
glucocorticoid regulated gene expression has not been measured in fat.
We can therefore only speculate that enhanced lip-HSDl activity will
lead to increased activity of glucocorticoids in this tissue.
To ascertain the importance of alterations in 1 lp-HSDl activity to obesity
and insulin resistance, Zucker rats were treated the lip-HSD inhibitor,
carbenoxolone. Inhibition of 1 lp-HSDl by carbenoxolone treatment was
demonstrated in vitro in liver and kidney, but not in adipose tissue or
skeletal muscle. Despite normalising adrenal hypertrophy and inhibiting
hepatic lip-HSDl activity, carbenoxolone treatment did not attenuate
weight gain in obese animals, and did not improve insulin resistance. In
order to clarify the interpretation of this study some further work is
required to determine whether carbenoxolone inhibited lip-HSDl in all
tissues, and the effect of carbenoxolone on other steroid metabolising
enzymes.
In summary, tissue specific alterations in glucocorticoid metabolism have
been demonstrated in both human and rodent obesity, and the Zucker rat
has been described as a suitable model in which to study the mechanisms
and implications of these changes. The mechanisms behind altered 11P-
HSD1 are still not clear, but appear to relate to a product of the adrenal
gland, and not to insulin sensitivity. However, insulin may have a role in
HPA activation in obesity, as improved insulin sensitivity results in
normalisation of adrenal hypertrophy. Finally, the importance of enhanced
adipose tissue lip-HSDl activity to the maintenance of obesity, and its
potential for therapeutic manipulation is still a key issue to be addressed.
137
References
Abramovitz, M., Laplante-Branchaud, C. & Pearson-Murphy, B.E. (1982).
Cortisol-cortisone interconversion in human fetal lung: contrasting
results using explant and monolayer cultures suggest that 11P-
hydroxysteroid dehydrogenase (EC 1.1.1.146) comprises two
enzymes. Journal of Clinical Endocrinology and Metabolism 54,
563-568.
Agarwal, A.K., Monder, C., Eckstein, B. & White, P. (1989). Cloning and
expression of rat cDNA encoding corticosteroid 11P-
dehydrogenase. Journal of Biological Chemistry 264, 18939-
18943.
Agarwal, A.K., Mune, T., Monder, C. & White, P.C. (1994). NAD+-
dependent isoform of 11 P-hydroxysteroid dehydrogenase. Cloning
and characterisation of cDNA from sheep kidney. Journal of
Biological Chemistry 269, 25959-25962.
Albiston, A.L., Obeyesekere, V.R., Smith, R.E. & Krozowski, Z.S. (1994).
Cloning and tissue distribution of the human 11 p-hydroxysteroid
dehydrogenase type 2 enzyme. Molecular and Cellular
Endocrinology 105, R11-R17
Alonso-Garcia, M., Brands, M.W., Zappe, D.H. & Hall, J.E. (1996).
Hypertension in obese Zucker rats; Role of angiotensin II and
adrenergic activity. Hypertension 28, 1047-1054.
Anand, B.K. & Brobeck, J.R. (1951). Hypothalamic control of food intake
in rats and cats. Yale Journal ofBiological Medicine 24, 123-140.
Andrew, R., Phillips, D.I.W. & Walker, B.R. (1998). Obesity and gender
influence Cortisol secretion and metabolism in man. Journal of
Clinical Endocrinology and Metabolism 83, 1806-1809.
138
Armanini, D., Karbowiak, I. & Funder, J.W. (1983). Affinity of liquorice
derivatives for mineralocorticoid and glucocorticoid receptors.
Clinical Endocrinology 19, 609-612.
Arriza, J.L., Weinberger, C., Cerelli, G., Glaser, T.M., Handelin, B.L.,
Housman, D.E. & Evans, R.M. (1987). Cloning of human
mineralocorticoid receptor complementary DNA: Structural and
functional kinship with the glucocorticoid receptor. Science 237,
268-275.
Barry, W.S. & Bray, G.A. (1969). Plasma triglycerides in genetically
obese rats. Metabolism 18, 833-839.
Beitins, I.Z., Bayard, F., Ances, I.G., Kiwarski, A. & Migeon, C.J. (1973).
The metabolic clearance rate, blood production, interconversion
and transplacental passage of Cortisol and cortisone in pregnancy
near term. Pediatric Research 7, 509-519.
Benediktsson, R., Lindsay, R.S., Noble, J., Seckl, J.R. & Edwards, C.R.W.
(1993). Glucocorticoid exposure in utero: new model for adult
hypertension. Lancet 341 339-341.
Berman, D.M. & Russell, D.W. (1993). Cell-type-specific expression of
rat steroid 5a-reductase isozymes. Proceedings of the National
Academy ofSciences USA 90, 9359-9363.
Best, R. & Walker, B.R. (1997). Additional value of measurement of
urinary cortisone and unconjugated Cortisol metabolites in
assessing the activity of 11 p-hydroxysteroid dehydrogenase in
vivo. Clinical Endocrinology 47, 231 -236.
Bestetti, G.E., Abramo, F., Guillaume-Gentil, C., Rohner-Jeanrenaud, F.,
Jeanrenaud, B. & Rossi, G.L. (1990). Changes in the hypothalamo-
pituitary-adrenal axis of genetically obese fa/fa rats: a structural,
139
immunocytochemical and morphometrical study. Endocrinology
126, 1880-1887.
Billington, C.J., Brigs, J.E., Grace, M. & Levine, A.S. (1991). Effects of
intracerebro-ventricular injections of neuropeptide Y on energy
metabolism. American Journal ofPhysiology 260, R321-R327
Borst, J.G.G., Ten Holt, S.P. & DeVries, L.A. (1953). Synergistic action of
liquorice and cortisone in Addison's and Simmond's disease.
Lancet i, 657-663.
Brann, D.W., Hendry, L.B. & Mahesh, V.B. (1995). Emerging diversities
in the mechanism of action of steroid hormones. Journal ofSteroid
Biochemistry and Molecular Biology 52, 113-133.
Bray, G.A. & York, D.A. (1979). Hypothalamic and genetic obesity in
experimental animals: an autonomic and endocrine hypothesis.
Physiological Reviews 59, 719-809.
Brief, D.J., Sipols, A.J. & Woods, S.C. (1992). Intraventricular
neuropeptide Y injections stimulate food intake in lean, but not
obese Zucker rats. Physiology & Behavior 51, 1105-1110.
Brobeck, J.R., Tepperman, J. & Long, C.N.H. (1943). Experimental
hypothalamic hyperphagia in the albino rat. Yale Journal of
Biological Medicine 15, 831-853.
Brown, R.W., Chapman, K.E., Edwards, C.R.W. & Seckl, J.R. (1993).
Human placental 11 (3-hydroxysteroid dehydrogenase: evidence for
and partial purification of a distinct NAD-dependent isoform.
Endocrinology 132, 2614-2621.
Brown, R.W., Chapman, K.E., Murad, P., Edwards, C.R.W. & Seckl, J.R.
(1996). Purification of 11 P-hydroxysteroid dehydrogenase type 2
from human placenta utilizing a novel affinity labelling technique.
Biochemical Journal 313, 997-1005.
140
Bujalska, I.J., Kumar, S. & Stewart, P.M. (1997). Does central obesity
reflect "Cushing's disease of the omentum"? Lancet 349, 1210-
1213.
Card, W.I., Mitchell, W. & Strong, J.A. (1953). Effects of liquorice and its
derivatives on salt and water metabolism. Lancet i, 663-668.
Castonguay, T.W., Dallman, M.F. & Stern, J.S. (1986). Some metabolic
and behavioural effects of adrenalectomy on obese Zucker rats.
American Journal ofPhysiology 251, R923-933.
Charon, C., Krief, S., Diot-Dupay, F., Strosberg, D., Emorine, L.J. &
Bazin, R. (1995). Early alterations in the brown adipose adenylate
cyclase system of pre-obese Zucker rat fa/fa pups: decreased G-
proteins and P3-adrenoceptor activities. Biochemical Journal 312,
781-788.
Chehab, F.F., Lim, M.E. & Ronghua, L. (1996). Correction of the sterility
defect in homozygous obese female mice by treatment with the
human recombinant leptin. Nature Genetics 12, 318-320.
Chen, H., Charlat, O., Tartaglia, L.A., Woolf, E.A., Weng, X., Ellis, S.J.,
Lakey, N.D., Culpepper, J., Moore, K.J., Breitbart, R.E., Duyk,
G.M., Tepper, R.I. & Morgenstern, J.P. (1996). Evidence that the
diabetes gene encodes the leptin receptor: identification fo a
mutation in the leptin receptor gene in db/db mice. Cell 84, 491 -
495.
Cheung, C.C., Cllifton, D.K. & Steiner, R.A. (1997). Proopiomelanocortin
neurons are direct targets for leptin in the hypothalamus.
Endocrinology 138, 4489-4492.
Chomczynski, P. & Sacchi, N. (1987). Single-step method of RNA
isolation by guanidium thiocyanate-phenol-chloroform extraction.
Anals ofBiochemistry 162, 156-159.
141
Chua, S.C., Chung, W.K., Wu-Peng, X.S., Zhang, Y„ Liu, S.-M.,
Tartaglia, L. & Leibel, R.L. (1996). Phenotypes of mouse diabetes
and rat fatty due to mutations in the OB (leptin) receptor. Science
271, 994-996.
Clark, J.T., Kalra, P.S., Crowley, W.R. & Kalra, S.P. (1984). Neuropeptide
Y and human pancreatic polypeptide stimulate feeding behaviour
in rats. Endocrinology 115, 427-429.
Cleary, M.P., Vasselli, J.R. & Greenwood, M.R.C. (1980). Development
of obesity in Zucker obese (fa/fa) rat in absence of hyperphagia.
American Journal ofPhysiology 238, E284-E292
Clore, J.N., Estep, H., Ross-Clunis, H. & Watlington, C.O. (1988).
Adrenocorticotrophin and Cortisol induced changes in urinary
sodium and potassium excretion in man. Effects of spironolactone
and RU-486. Journal of Clinical Endocrinology and Metabolism
67,824-831.
Coghlan, J.P., Denton, D.A. & Mills, E.H. (1984). Steroid antagonism of
the hypertensinogenic activity of 9a-fluroprednisolone. Life
Sciences 35, 2609-2612.
Considine, R.V., Considine, E.L., Williams, C.J., Nyce, M.R., Magosin,
S.A., Bauer, T.L., Rosato, E.L., Colberg, J. & Caro, J.F. (1995).
Evidence against either a premature stop codon or the absence of
obese gene mRNA in human obesity. Journal of Clinical
Investigation 95, 2986-2988.
Considine, R.V., Considine, E.L., Williams, C.J., Nyce, M.R., Zhang, P.L.,
Opentanova, I., Ohannesian, J.P., Kolaczynski, J.W., Bauer, T.L.,
Moore, J.H. & Caro, J.F. (1996). Mutation screening and
identification of a sequence variation in the human Ob gene
coding. Biochemical and Biophysical Research Communications
220, 735-739.
142
Cunningham, J.J., Calles-Escandon, J., Garrido, F., Carr, D.B. & Bode,
H.H. (1986). Hypercorticosteronuria and diminished pituitary
responsiveness to corticotropin-releasing factor in obese Zucker
rats. Endocrinology 118, 98-101.
Cupps, T.R., Gerard, T.I., Falkoff, R.J.M., Whalen, G. & Fauci, A. (1985).
Effects of in vitro corticosteroids on B cell activation, proliferation
and differentiation. Journal ofClinical Investigation 75, 754-761.
Cusin, I., Rohner-Jeanrenaud, F., Stricker-Krongrad, A. & Jeanrenaud, B.
(1996). The weight-reducing effect of an intracerebroventricular
bolus injection of leptin in genetically obese fa/fa rats. Diabetes
45, 1446-1450.
Dale, D.C., Fauci, A.S., Guerry, D. & Wolss, S.M. (1975). Comparison of
agents producing a neutrophilic leucocytosis in man:
hydrocorticone, prednisone, endotoxin and etiocholanone. Journal
ofClinical Investigation 56, 808-813.
De Kloet, E.R. (1991). Brain corticosteroid receptor balance and
homeostatic control. Frontiers in Neuroendocrinology 12, 95-164.
Drouin, J., Sun, Y.L., Chamberland, M., Gauthier, Y., De, L.A., Nemer,
M. & Schmidt, T.J. (1993). Novel glucocorticoid receptor complex
with DNA element of the hormone-repressed POMC gene. EMBO
Journal 12,145-156.
Dryden, S., Pickavance, L., Frankish, H.M. & Williams, G. (1995).
Increased neuropeptide Y secretion in the hypothalamic
paraventricular nucleus of obese (fa/fa) Zucker rats. Brain
Research 690, 185-188.
Dubuc, P.U. (1976). Basal corticosterone levels in young ob/ob mice.
Hormone andMetabolism Research 9, 95-97.
143
Dunn, C.J. & Peters, D.H. (1995). Metformin - a review of its
pharmacological properties and therapeutic use in non-insulin-
dependent diabetes mellitus. Drugs 49, 721-749.
Edwards, C.R.W., Burt, D., Mclntyre, M.A., De Kloet, E.R., Stewart,
P.M., Brett, L.P., Sutanto, W.S. & Monder, C. (1988). Localisation
of 11 (3-hydroxysteroid dehydrogenase-tissue specific protector of
the mineralocorticoid receptor. Lancet 2, 986-989.
Emilsson, V., Liu, Y.L., Cawthorne, M.A., Morton, N.M. & Davenport,
M. (1997). Expression of the functional leptin receptor mRNA in
pancreatic islets and direct inhibitory action of leptin on insulin
secretion. Diabetes 46, 313-316.
Epstein, M.T., Espiner, E.A., Donald, R.A. & Elughes, H. (1977). Effect of
eating liquorice on the renin-angiotensin-aldosterone axis in
normal subjects. British Medical Journal i, 488-490.
Escher, G., Galli, I., Vishwanath, B.S., Frey, B.M. & Frey, F.J. (1997).
Tumor necrosis factor alpha and interleukin ip enhance the
cortisone/cortisol shuttle. Journal ofExperimental Medicine 186,
189-198.
Evangelatou, M., Peterson, S.L. & Cooke, B.A. (1997). Leukocytes
modulate 11 P-hydroxysteroid dehydrogenase (lip-HSD) activity
in human granulosa-lutein cell cultures. Molecular and Cellular
Endocrinology 133, 81-88.
Farooqi, I.S., Jebb, S.A., Cook, G., Cheetham, C.H., Lawrence, E.,
Prentice, A.M., Hughes, I.A., McCamish, M. & O'Rahilly, S.
(1999). Treatment of congenital leptin deficiency. Journal of
Endocrinology 160, OC17
Federoff, H.J., Grabcztk, E. & Fishman, M.C. (1988). Dual regulation of
GAP-43 gene expression by nerve growth factor and
144
glucocorticoids. Journal of Biological Chemistry 263 , 19290-
19295.
Finken, M.J.J., Andrews, R.C., Andrew, R. & Walker, B.R. (2000).
Cortisol metabolism in healthy young adults: sexual dimorphism in
activities of A-ring reductase but not 11 p-hydroxysteroid
dehydrogenases. Jouranl of Clinical Endocrinology and
Metabolism (In Press)
Fletcher, J.M., Haggarty, P., Wahle, K.W.J. & Reeds, P.J. (1986).
Hormonal studies of young lean and obese Zucker rats. Hormone
and Metabolism Research 18, 290-295.
Frantz, A.G. & Rabkin, M.T. (1964). Human growth hormone: clinical
measurements, response to hypoglycemia, and supression by
glucocorticoids. New England Journal of Medicine 271 , 1375-
1381.
Fraser, R., Ingram, M.C., Anderson, N.H., Morrison, C., Davies, E. &
Connel, J.M.C. (1999). Cortisol effects on body mass, blood
pressure and cholesterol in the general population. Hypertension
33, 1364-1368.
Frederich, R.C., Hamann, A., Anderson, S., Lollamnn, B., Lowell, B.B. &
Flier, J.S. (1995). Leptin levels reflect body lipid content in mice:
evidence for diet-induced resistance to leptin action. Nature
Medicine 1, 1311-1314.
Freedman, M.R., Horwitz, B.A. & Stern, J.S. (1986). Effect of
adrenalectomy and glucocorticoid replacement on development of
obesity. American Journal ofPhysiology 252, R595-R607
Fugita, T., Sugiyama, Y., Taketomi, S., Shoda, T., Kawamatsu, Y.,
Iwatsuka, H. & Suzuoki, Z. (1983). Reduction of insulin resistance
in obese and/or diabetic animals by 3[-4-(l
145
methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4 dione (ADD-
3870, U-63287, ciglitazone), a new antidiabetic agent. Diabetes
32, 804-810.
Fujiwara, T., Yoshioka, S., Yoshioko, T., Ushiyawa, I. & Horikoshi, H.
(1988). Characterisation of a new and antidiabetic agent, CS-045:
studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37,
1849-1888.
Funder, J.W., Pearce, P.T., Smith, R. & Smith, A.I. (1988).
Mineralocorticoid action: target tissue specificity is enzyme, not
receptor, mediated. Science 242, 583-585.
Gametchu, B., Chen, F., Sackey, F., Powell, C.S. & Watson, C.S. (1999).
Plasma membrane-resident glucocorticoid receptors in rodent
lymphoma and human leukemia models. Steroids 64, 107-119.
Gametchu, B., Watson, C.S. & Wu, S. (1993). Use of receptor antibodies
to demonstrate membrane glucocorticoid receptor in cells from
human leukemic patients. FASEB Journal 7, 1283-1292.
Garcia, R., Debinski, W. & Gutkowsa, J. (1985). Gluco- and
mineralocorticoids may regulate the natriuretic effect and the
synthesis and release of atrial natriuretic factor by the rat aorta in
vivo. Biochemical and Biophysical Research Communications
131, 806-814.
Gray, C.H., Sunnon, J.B., Pond, M.H. & Simpson, S.L. (1956). Steroid
studies in normal and adipose children. Journal of Clinical
Endocrinology 16, 473
Greenberg, A.S., Fulioka, K., Heymsfield, S.D., Lau, D., Lubina, J. &
McCamish, M. (1999). Clinical effects of leptin in obesity.
Proceedings of the Endocrine Society S43-3
146
Guillaume-Gentil, C., Rohner-Jeanrenaud, F., Abramo, F., Bestetti, G.E.,
Rossi, G.L. & Jeanrenaud, B. (1990). Abnormal regulation of the
hypothalamo-pituitary-adrenal axis in the genetically obese fa/fa
rat. Endocrinology 126, 1873-1879.
Guo, Z., Chen, Y.-Z., Xu, R.-B. & Fu, H. (1995). Binding characteristics
of glucocorticoid receptor in synaptic plasma membrane from rat
brain. Functional Neurology 10, 183-194.
Hadoke, P.W.F., Kotelevtsev, Y.V., Williams, B.C., Seckl, J.R., Mullins,
J.J. & Walker, B.R. (1999). Influence of 11 [3-hydroxysteroid
dehydrogenases (llHSDs) on vascular function: studies in mice
with transgenic deletion of 11-HSD type 1 or type 2. Proceedings
ofthe Endocrine Society
Hahn, T.J., Halstead, L.R., Teitelbaum, S.L. & Hahn, B.H. (1979). Altered
mineral metabolism in glucocorticoid induced ostopenia:effect of
25-hydroxyvitamin D administration. Journal of Clinical
Investigation 64, 21-28.
Halaas, J.L., Gajiwala, K.S., Maffei, M.M., Cohen, S.L., Chait, B.T.,
Rabinowitz, D., Lallone, R.L., Burley, S.K. & Friedman, J.M.
(1995). Weight reducing effects of the plasma protein encoded by
the obese gene. Science 269, 543-546.
Hammami, M.M. & Siiteri, P.K. (1991). Regulation of 11 p-hydroxysteroid
dehydrogenase activity in human skin fibroblasts: enzymatic
modulation of glucocorticoid action. Journal of Clinical
Endocrinology and Metabolism 73, 326-334.
Hammond, G.L., Smith, C.L., Paterson, N.A.M. & Sibbald, W.J. (1990). A
role for corticosteroid-binding globulin in delivery of Cortisol to
activated neutrophils. Journal of Clinical Endocrinology and
Metabolism 71, 34-39.
147
Hardwick, A., Linton, E. & Rothwell, N. (1989). Thermogenic effects of
the antiglucocorticoid RU-486 in the rat: involvement of
corticotropin-releasing factor and sympathetic activation of brown
adipose tissue. Endocrinology 124, 1684-1688.
Hashimoto, K., Nagao, Y„ Ida, K., Takeda, M., Murakami, N., Kato, K. &
Mizota, M. (1996). Improvement of metabolic disorders and
visceral fat obesity by the p3-adrenoceptor agonist (R*,R*)-(±)-
methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino]propyl]-
phenoxyacetate hydrobromide (BRL35135A) in genetically obese
rodents. Biochemical Pharmacology 52, 1529-1535.
Hauner, H., Schmid, P. & Pfeiffer, E.-F. (1987). Glucocorticoids and
insulin promote the differentiation of human adipocyte precursor
cells into fat cells. Journal of Clinical Endocrinology and
Metabolism 64, 832-835.
Hayamizu, S., Kanda, K., Ohmori, S., Murata, Y. & Seo,H. (1994).
Glucocorticoids potentiate the action of atrial natriuretic
polypeptide in adrenalectomised rats. Endocrinology 135, 2459-
2464.
Heiman, M.L., Ahima, R.S., Craft, L.S., Schoner, B., Stephens, T.W. &
Flier, J.S. (1997). Leptin inhibition of the hypothalamic-pituitary-
adrenal axis in response to stress. Endocrinology 138, 3859-3863.
Hellman, L., Bradlow, H.L., Zumoff, B. & Gallagher, T.F. (1961). The
influence of thyroid hormone on hydrocortisone production and
metabolism. Journal of Clinical Endocrinology and Metabolism
21, 1231-1247.
Hirose, H., Lee, Y.H., Inman, L.R., Nagasawa, Y., Johnson, J.H. & Unger,
R.H. (1996). Defective fatty acid-mediated P-cell compensation in
Zucker diabetic fatty rats; pathogenic implications for obesity-
148
dependent diabetes. Journal of Biological Chemistry 271, 5633-
5637.
Hoefnagels, W.H.L. & Kloppenborg, P.W.C. (1983).
Antimineralocorticoid effects of dexamethasone in subjects treated
with glycyrrhetinic acid. Journal ofHypertension 1, 313-315.
Huszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H., Fang, Q.,
Berkemeier, L.R., Gu, W., Keterson, R.A., Boston, B.A., Cone,
R.D., Smith, F.J., Campfield, L.A., Burn, P. & Lee, F. (1997).
Targeted disruption of the melanocortin-4 receptor results in
obesity in mice. Cell 88, 131-141.
Inoue, T. (1988). Effect of neuropeptide Y on the hypothalamic-pituitary-
adrenal axis in the dog. Medical Journal of Kobe University 49,
27-35.
Jamieson, P.M., Chapman, K.E., Edwards, C.R.W. & Seckl, J.R. (1995).
11 (3-Hydroxysteroid dehydrogenase is an exclusive 11 P-reductase
in primary cultures of rat hepatocytes: effect of physicochemical
and hormonal manipulations. Endocrinology 136, 4754-4761.
Jamieson, P.M., Nyirenda, M.J., Walker, B.R., Chapman, K.E. & Seckl,
J.R. (1999). Interactions between oestradiol and glucocorticoid
regulatory effects on liver-specific glucocorticoid-inducible genes:
possible evidence for a role of hepatic 11 P-hydroxysteroid
dehydrogenase type 1. Journal ofEndocrinology 160, 103-109.
Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H. &
Herrlich, P. (1990). Antitumour promotion and antiinflammation:
down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid
hormone. Cell 62, 1189-1204.
149
Kantrowitz, F., Robinson, D.R. & McGuire, M.B. (1975). Corticosteroids
inhibit prostaglandin production by rheumatoid synovia. Nature
258, 737-739.
Katz, J.R., Mohamed-Ali, V., Wood, P.J., Yudkin, J.S. & Coppack, S.W.
(1999). An in vivo study of the cortisol-cortisone shuttle in
subcutaneous abdominal adipose tissue. Clinical Endocrinology
50, 63-68.
Kotelevtsev, Y.V., Brown, R.W., Fleming, S., Kenyon, C.J., Edwards,
C.R.W., Seckl, J.R. & Mullins, J.J. (1999). Hypertension in mice
lacking 11 P-hydroxysteroid dehydrogenase type 2. Journal of
Clinical Investigation 103, 683-689.
Kotelevtsev, Y.V., Holmes, M.C., Burchell, A., Houston, P.M., Schmoll,
D., Jamieson, P.M., Best, R., Brown, R.W., Edwards, C.R.W.,
Seckl, J.R. & Mullins, J.J. (1997). 11 p-hydroxysteroid
dehydrogenase type 1 knockout mice show attenuated
glucocorticoid-inducible responses and resist hyperglycaemia on
obesity or stress. Proceedings ofthe National Academy ofSciences
USA 94, 14924-14929.
Krett, N.L., Heaton, J.H. & Gelehrter, T.D. (1983). Insulin resistance in H-
35 rat hepatoma cells is mediated by post-receptor mechanisms.
Molecular and Cellular Endocrinology 32, 91-100.
Kurtz, T.W., Morris, C. & Pershadsingh, H.A. (1989). The Zucker fatty rat
as a genetic model of obesity and hypertension. Hypertension 13,
896-901.
Laake, H. (1960). The actions of corticosteroids on the renal absortion of
calcium. Acta Endocrinologica 34, 60-64.
Lakshmi, V. & Monder, C. (1985). Evidence for independent 11-oxidase
and 11-reductase activities of 11 P-hydroxysteroid dehydrogenase:
150
enzyme latency, phase transitions, and lipid requiements.
Endocrinology 116, 552-560.
Lakshmi, V. & Monder, C. (1988). Purification and characterization of the
corticosteroid 11 p-dehydrogenase component of the rat liver 11 p-
hydroxysteroid dehydrogenase complex. Endocrinology 123,
2390-2398.
Lakshmi, V., Sakai, R.R., McEwan, B.S. & Monder, C. (1991). Regional
distribution of 11 P-hydroxysteroid dehydrogenase in rat brain.
Endocrinology 128, 1741-1748.
Langley, S.C. & York, D.A. (1990). Effects of antiglucocorticoid RU486
on development of obesity in obese fa/fa Zucker rats. American
Journal ofPhysiology 259, R539-544.
Larsen, P.J., Jessop, D.S., Lightman, S.L. & Mikkelsen, J.D. (1994).
Chronic administration of glucocorticoids directly upregulates
prepro-neuropeptide Y and Yi -receptor mRNA levels in the arcuate
nucleus of the rat. Journal ofNeuroendocrinology 6, 153-169.
Latif, S.A., Conca, T.J. & Morris, D.J. (1990). The effects of the licorice
derivative, glycyrrhetinic acid, on hepatic 3a- and 3P-
hydroxysteroid dehydrogenases and 5a- and 5p-reductase
pathways of metabolism of aldosterone in male rats. Steroids 55,
52-58.
Lax, E.R., Ghraf, R. & Schriefers, H. (1978). The hormonal regulation of
hepatic microsomal 11 p-hydroxysteroid dehydrogenase activity in
the rat. Acta Endocrinologica 89, 352-358.
Lindsay, R.S., Lindsay, R.M., Edwards, C.R.W. & Seckl, J.R. (1996).
Inhibition of 11 p-hydroxysteroid dehydrogenase in pregnant rats
and the programming of blood pressure in the offspring.
Hypertension 27, 1200-1204.
151
Lineweaver, H. & Burk, D. (1934). The determination of enzyme
dissociation constants. Journal of the American Chemistry Society
56, 658-666.
Liposits, Z. & Bohn, M.C. (1993). Association of glucocorticoid receptor
immunoreactivity with cell membrane and transport vesicles in
hippocampal and hypothalamic neurons of the rat. Journal of
Neuroscience Research 35, 14-19.
Ljung, T., Andersson, B., Bengtsson, B., Bjorntorp, P. & Marin, P. (1996).
Inhibition of Cortisol secretion by dexamethasone in relation to
body fat distribution: a dose-response study. Obesity Research 4,
277-282.
Lloyd-MacGilp, S.A., Nelson, S.M., Florin, M., Lo, M., McKinnell, J.,
Sassard, J. & Kenyon, C.J. (1999). 11 P-hydroxysteroid
dehydrogenase and corticosteroid action in Lyon hypertensive rats.
Hypertension 34, 1123-1128.
Lonnqvist, F., Arner, P., Nordford, L. & Schalling, M. (1995).
Overexpression of the obese (Ob) gene in adipose tissue of human
obese subjects. Nature Medicine 1, 950-953.
Low, S.C., Assaad, S.N., Rajan, V., Chapman, K.E., Edwards, C.R.W. &
Seckl, J.R. (1993). Regulation of 11 p-hydroxysteroid
dehydrogenase by sex steroids in vivo: further evidence for the
existence of a second dehydrogenase in rat kidney. Journal of
Endocrinology 139, 27-35.
Low, S.C., Chapman, K.E., Edwards, C.R.W., Wells, T., Robinson,
I.C.A.F. & Seckl, J.R. (1994a). Sexual dimorphism of hepatic 11P-
hydroxysteroid dehydrogenase in the rat: the role of growth
hormone patterns. Journal ofEndocrinology 143, 541-548.
152
Low, S.C., Moisan, M.-P., Noble, J.M., Edwards, C.R.W. & Seckl, J.R.
(1994b). Glucocorticoids regulate hippocampal 11P-
hydroxysteroid dehydrogenase activity and gene expression in vivo
in the rat. Journal ofNeuroendocrinology 6, 285-290.
Lu, D., Willard, D., Patel, I.R., Kadwell, S., Overton, L., Kost, T., Luther,
M., Chen, W., Woychik, R.P., Wilkison, W.O. & Cone, R.D.
(1994). Agouti protein is an antagonist of the melanocyte-
stimulating hormone. Nature 371, 799-802.
MacKenzie, M.A., Hoefnagels, W.H.L., Jansen, R.W.M.M., Benraad, T.J.
& Kloppenborg, P.W.C. (1990). The influence of glycyrrhetinic
acid on plasma Cortisol and cortisone in healthy young volunteers.
Journal ofClinical Endocrinology and Metabolism 70, 1637-1643.
Marin, P., Darin, M., Amemiya, T., Andersson, B., Jern, S. & Bjorntorp, P.
(1992). Cortisol secretion in relation to body fat distribution in
obese premenopausal women. Metabolism 41, 882-886.
Martin, R.J., Wangsness, P.J. & Gahagan, J.H. (1978). Diurnal changes in
serum metabolites and hormones in lean and obese Zucker rats.
Hormone andMetabolism Research 10, 187-192.
McCarthy, H.D., McKibbin, P.E., Holloway, B., Mayers, R. & Williams,
G. (1991). Hypothalamic neuropeptide Y receptor characterisation
and induced feeding behaviuor in lean and obese Zucker rats. Life
Sciences 49, 1491-1497.
McEwen, B.S., De Kloet, E.R. & Rostene, W. (1986). Adrenal steroid
receptors and actions in the nervous system. Physiological
Reviews 66, 1121-1188.
McKibbin, P.E., Cotton, S.J., McMillan, S., Holloway, B., Mayers, R.,
McCarthy, H.D. & Williams, G. (1991). Altered neuropeptide Y
153
concentrations in specific hypothalamic regions of obese (fa/fa)
Zuckerrats. Diabetes 40, 1423-1429.
Meaney, M., Tannenbaum, B., Francis, D., Bhatnagar, S., Shanks, N.,
Viau, V., ODonnell, D. & Plotsky, P.M. (1994). Early
environmental programming hypothalamic-pituitary-adrenal
responses to stress. Seminars in Neuroscience 6, 247-259.
Mercer, J.G., Hoggard, N., Williams, L.M., Lawrence, C.B., Hannah, L.T.,
Morgan, P.J. & Trayhurn, P. (1996). Coexpression of leptin
receptor and preproneuropeptide Y mRNA in arcuate nucleus of
mouse hypothalamus. Journal ofNeuroendocrinology 8, 733-735.
Mercer, W.R. & Krozowski, Z.S. (1992). Localization of an lip-
hydroxysteroid dehydrogenase activity to the distal nephron.
Evidence for the existence of two species of dehydrogenase in the
rat kidney. Endocrinology 130, 540-543.
Migeon, C.J., Green, O.C. & Eckert, J.P. (1963). Study of adrenocortical
function in obesity. Metabolism 12, 718-739.
Miller, W.L. (1988). Molecular biology of steroid hormone biosynthesis.
Endocrine Reviews 9, 295-318.
Moisan, M.-P., Seckl, J.R. & Edwards, C.R.W. (1990). llp-
Hydroxysteroid dehydrogenase bioactivity and messenger RNA
expression in rat forebrain: localization in hypothalamus,
hippocampus and cortex. Endocrinology 127, 1450-1455.
Monder, C. & Shackleton, C.H.L. (1984). 11 P-hydroxysteroid
dehydrogenase; fact or fancy? Steroids 44, 383-417.
Monder, C., Stewart, P.M., Lakshmi, V., Valentino, R„ Burt, D. &
Edwards, C.R.W. (1989). Licorice inhibits corticosteroid lip -
dehydrogenase of rat kidney and liver: in vivo and in vitro studies.
Endocrinology 125, 1046-1053.
154
Montague, C.T., Farooqi, I.S., Whitehead, J.P., Soos, M.A., Rau, H.,
Wareham, N.J., Sewter, C.P., Digby, J.E., Mohammed, S.N., Hurst,
J.A., Cheetham, C.H., Earley, A.R., Barnett, A.H., Prins, J.B. &
O'Rahilly, S. (1997). Congenital leptin deficiency is associate with
severe early-onset obesity in humans. Nature 387, 903-908.
Morley, J.E. & Mattammal, M.B. (1996). Nitric oxide synthase levels in
obese Zucker rats. Neuroscience Letters 209, 137-139.
Mune, T., Rogerson, F.M., Nikkila, H., Agarwal, A.K. & White, P. (1995).
Human hypertension caused by mutations in the kidney isozyme of
11 (3-hydroxysteroid dehydrogenase. Nature Genetics 10, 394-399.
Napolitano, A., Voice, M.W., Edwards, C.R.W., Seckl, J.R. & Chapman,
K.E. (1998). 11 P-hydroxysteroid dehydrogenase 1 in adipoytes:
Expression is differentiation-dependent and hormonally regulated.
Journal of Steroid Biochemistry and Molecular Biology 64, 251 -
260.
Nyirenda, M.J., Lindsay, R.S., Kenyon, C.J., Burchell, A. & Seckl, J.R.
(1998). Glucocorticoid exposure in late gestation permanently
programs rat hepatic phosphoenolpyruvate carboxykinase and
glucocorticoid receptor expression and causes glucose intolerance
in adult offspring. Journal of Clinical Investigation 101, 2174-
2181.
Ollmann, M.M., Wilson, B.D., Yang, Y.K., Kerns, J.S., Chen, Y., Gantz, I.
& Barsh, G.S. (1997). Antagonism of central melanocortin
receptors in vitro and in vivo by agouti-related peptide. Science
278, 135-138.
Omrani, G.R., Rosner, W. & Loeb, J.N. (1980). Induction of hepatic
tyrosine aminotransferase by physiological stress: Relation to
endogenous glucocorticoid secretion and cytosol receptor
depletion. Journal ofSteroid Biochemistry 13, 719-722.
155
Onai, T., Kilroy, G., York, D.A. & Bray, G.A. (1995). Regulation of
p3-adrenergic receptor mRNA by sympathetic nerves and
glucocorticoids in BAT of Zucker obese rats. American Journal of
Physiology 269, R519-R526
Pacak, K., McCarty, R., Palkovits, M., Cizza, G., Kopin, I.J., Goldstein,
D.S. & Chrousos, G.P. (1995). Decreased central and peripheral
catecholaminergic activation in obese Zucker rats. Endocrinology
136, 4360-4367.
Panarelli, M., Nelson, S.M., Grillo, P., Jamieson, P.M., Walker, B.R.,
Seckl, J.R. & Kenyon, C.J. (1996). Glucocorticoid receptor affinity
for endogenous steroids in obese Zucker rats is greatly reduced.
Proceedings ofthe Endocrine Society
Pasquali, R., Cantobelli, S., Casimirri, F., Capelli, M., Bortoluzzi, L.,
Flamia, R., Labate, A.M.M. & Barbara, L. (1993). The
hypothalamic-pituitary-adrenal axis in obese women with different
patterns of body fat distribution. Journal of Clinical
Endocrinology & Metabolism 77, 341-346.
Pelleymounter, M.A. Cullen, M.J., Baker, M.B., Hecht, R., Winters, D.,
Boone, T. & Collins F. (1995). Effects of the obese gene product
on body weight regulation in ob/ob mice. Science 269, 540-543.
Pesonen, U., Jolkkonen, J., Huupponen, R. & Koulu, M. (1992a).
Differential hypothalamic arginine vasopressin response to
glucocorticoid receptor antagonism in lean and obese Zucker rats.
Neuroendocrinology 56, 277
Pesonen, U., Koulu, M., Heikinheimo, O. & Huupponen, R. (1992b). The
glucocorticoid antagonist mifepristone reveals abnormal regulation
of the adrenocortical system in obese Zucker rats. Journal of
Endocrinology 132, 425-431.
156
Phillipou, G., Palermo, M. & Shackleton, C.H.L. (1996). Apparent
cortisone reductase deficiency; a unique form of hypercortisolism.
Journal ofClinical Endocrinology andMetabolism 81, 3855-3860.
Pirpiris, M., Sudhir, K., Yeung, S., Jennings, G.L. & Whitworth, J.A.
(1992). Pressor responsiveness in corticosteroid-induced
hypertension in humans. Hypertension 19, 567-574.
Plotsky, P.M., Thrivikraman, K.V., Watts, A.G. & Hauger, R.L. (1992).
Hypothalamic-pituitary-adrenal axis function in the Zucker obese
rat. Endocrinology 130, 1931-1941.
Pratt, W.B. & Aronow, L. (1966). The effect of glucocorticoids on protein
and nucleic acid synthesis in mouse fibroblasts growing in vitro.
Journal ofBiological Chemistry 241, 5244-5250.
Rajan, V., Edwards, C.R.W. & Seckl, J.R. (1996). 11 p-Hydroxysteroid
dehydrogenase in cultured hippocampal cells reactivates inert 11 -
dehydrocorticosterone, potentiating neurotoxicity. Journal of
Neuroscience 16, 65-70.
Rebuffe-Scrive, M., Krotkiewsky, M., Elfverson, J. & Bjorntorp, P.
(1988). Muscle and adipose tissue morphology and metabolism in
Cushing's syndrome. Journal of Clinical Endocrinology and
Metabolism 67, 1122-1128.
Reinisch, J.M., Simon, N.G., Karow, W.G. & Gandelman, R. (1978).
Prenatal exposure to prednisone in humans and animals retards
intrauterine growth. Science 202, 436-438.
Reul, J.M.H.M. & De Kloet, E.R. (1985). Two receptor systems for
corticosterone in rat brain: Microdistribution and differential
occupation. Endocrinology 117, 2505-2511.
157
Rinehart, J.J., Sagone, A.L., Balcerzak, S.P., Ackerman, G.A. & LoBuglio,
A.F. (1982). Effects of corticosteroids on human monocyte
function. New England Journal ofMedicine 292, 236-241.
Rizza, R.A., Mandarino, L.J. & Gerich, J.E. (1982). Cortisol-induced
insulin resistance in man: impaired supression of glucose
production and stimulation of glucose utililization due to a
postreceptor defect of insulin action. Journal of Clinical
Endocrinology and Metabolism 54, 131-138.
Rosenblum, C.I., Tota, M., Cully, D., Smith, T., Collum, R., Qureshi, S.,
Hess, J.F., Phillips, M.S., Hey, P.J., Vongs, A., Fong, T.M., Xu, L.,
Chen, H.Y., Smith, R.G., Schindler, C. & Van der Ploeg, L.H.T.
(1996). Functional STAT 1 and 3 signalling by the leptin receptor
(OB-R); reduced expression of the rat fatty leptin receptor in
transfected cells. Endocrinology 137, 5178-5181.
Rosmond, R., Dallman, M.F. & Bjorntorp, P. (1998). Stress-related
Cortisol secretion in men: relationships with abdominal obesity and
endocrine, metabolic and haemodynamic abnormalities. Journal of
Clinical Endocrinology and Metabolism 83, 1853-1859.
Rundle, S.E., Funder, J.W., Lakshmi, V. & Monder, C. (1989). The
intrarenal localization of mineralocorticoid receptors and 11 p-
dehydrogenase: immunocytochemical studies. Endocrinology
125, 1700-1704.
Rusvai, E. & Naray-Fejes-Toth, A. (1993). A new isoform of lip-
hydroxysteroid dehydrogenase in aldosterone target cells. Journal
ofBiological Chemistry 268, 10717-10720.
Saito, M. & Bray, G.A. (1984). Adrenalectomy and food restriction in the
genetically obese (ob/ob) mouse. American Journal ofPhysiology
246, R20-R25
158
Sakai, R.R., Lakshmi, V., Monder, C. & McEwen, B.S. (1992).
Immunocytochemical localization of 11 P-hydroxysteroid
dehydrogenase in hippocampus and other brain regions of the rat.
Journal ofNeuroendocrinology 4, 101 -106.
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M.,
Tanaka, H., Williams, S.C., Richardson, J.A., Kozlowski, G.P.,
Wilson, S., Arch, J.R.S., Buckingham, R.E., Haynes, A.C., Carr,
S.A., Annan, R.S., McNulty, D.E., Liu, W.S., Terrett, J.A.,
Elshourbagy, N.A., Bergsma, D.J. & Yanagisawa, M. (1998).
Orexins and orexin receptors: a family of hypothalamic
neuropeptides and G protein-coupled receptors that regulate
feeding behaviour. Cell 92, 573-585.
Sanacora, G., Kershaw, M., Finkelstein, J.A. & White, J.D. (1990).
Increase in hypothalamic content of proneuropeptide Y messenger
RNA in genetically obese Zucker rats and its regulation by food
depravation. Endocrinology 127, 730-737.
Sapolsky, R.M., Krey, L.C. & McEwen, B.S. (1985). Prolonged
glucocorticoid exposure reduces hippocampal neuron number:
implications for aging. Journal ofNeuroscience 5, 1222-1227.
Sartura, T., Suzuki, H., Handa, M., Igarashi, Y., Kondo, K. & Senba, S.
(1986). Multiple factors contribute to the pathogenesis of
hypertension in Cushing's syndrome. Journal of Clinical
Endocrinology andMetabolism 62, 275-279.
Sasaki, K., Cripe, T., Koch, S., Andreone, T., Peterson, D., Beale, E. &
Granner, D. (1984). Multihormonal regulation of
phosphoenolpyruvate carboxykinase gene transcription. Journal of
Biological Chemistry 268, 10717-10720.
Savontaus, E., Rouru, J., Boss, O., Huupponen, R. & Koulu, M. (1998).
Differential regulation of uncoupling proteins by chronic
159
treatments with (33-adrenergic agonist BRL 35135 and metformin
in obese fa/fa zucker rats. Biochemical & Biophysical Research
Communications 246, 899-904.
Schwartz, M.W., Baskin, D.G., Bukowski, T.R., Kuijper, J.L., Foster, D.,
Lasser, G., Prunkard, D.E., Porte, D., Woods, S.C., Seely, R.J. &
Weigle, D.S. (1996a). Specificity of leptin action on elevated blood
glucose levels and hypothalamic neuropeptide Y gene expression
in ob/ob mice. Diabetes 45, 531-535.
Schwartz, M.W., Baskin, D.G., Bukowski, T.R., Kuijper, J.L., Foster, D.,
Lasser, G., Prunkard, D.E., Porte, D., Jr., Woods, S.C., Seeley, R.J.
& Weigle, D.S. (1996b). Specificity of leptin action on elevated
blood glucose levels and hypothalamic neuropeptide Y gene
expression in ob/ob mice. Diabetes 45, 531-535.
Shibasaki, T., Oda, T., Imaki, T., Ling, N. & Demura, El. (1993). Injection
of anti-neuropeptide Y gamma-globulin into the hypothalamic
paraventricular nuvleus decreases food intake in rats. Brain
Research 601, 313-316.
Siegrist-Kaiser, C.A., Pauli, V., Juge-Aubry, C.E., Boss, O., Pernin, A.,
Chin, W.W., Cusin, I., Rohner-Jeanrenaud, F., Burger, A.G., Zapf,
J. & Meier, C.A. (1997). Direct effects of leptin on brown and
white adipose tissue. Journal ofClinical Investigation 100, 2858-
2864.
Smith, R.E. & Funder, J.W. (1991). Renal 11 P-hydroxysteroid
dehydrogenase activity: effects of age, sex and altered hormonal
status. Journal ofSteroid Biochemistry and Molecular Biology. 38,
265-267.
Soderberg, S., Olsson, T., Eliasson, M., Johnson, O. & Ahren, B. (1999).
Plasma leptin levels are associated with abnormal fibrinolysis in
160
men and postmenopausal women. Journal ofInternal Medicine (In
Press)
Souness, G.W. & Morris, D.J. (1989). The antinatriuretic and kaliuretic
effects of the glucocorticoids corticosterone and Cortisol following
pretreatment with carbenoxolone sodium (a liquorice derivative) in
the adrenalectomized rat. Endocrinology 124, 1588-1590.
Squadrito, F., Calapai, G., Cucinotta, D., Altavilla, D., Zingarelli, B.,
Ioculano, M., Urna, G., Sardella, A., Campo, G.M. & Caputi, A.P.
(1993). Anorectiv activity if Nr,-nitro-L-arginine, an inhibitor of
brain nitric oxide synthase in obese Zucker rats. European Journal
ofPharmacology 230, 125-128.
Stalmans, W. & Laloux, M. (1979). Glucocorticoids and hepatic glycogen
metabolism. In Glucocorticoid Hormone Action (Baxter, J.D. and
Rosseau, G.G., eds.), Spinger-Verlag, pp. 518-533.
Stanley, B.G., Kyrkouli, S.E., Lampert, S.E. & Leibowitz, S.F. (1986).
Neuropeptide Y chronically injected into the hypothalamus: a
powerful neurochemical inducer of hyperphagia and obesity.
Peptides 7, 1189-1192.
Stanley, B.G., Lanthier, D., Chin, A.S. & Leibowitz, S.F. (1989).
Suppression of neuropeptide Y-elicited eating by adrenalectomy or
hypophysectomy: Reversal with corticosterone. Brain Research
501, 32-36.
Stevenson, R.W., Hutson, N.J., Krupp, M.N., Volkmann, R.A., Holland,
G.F., Eggler, J.F., Clark, D.A., McPherson, R.K., Hell, X.L. &
Danbury, B.H. (1990). Actions of a novel antidiabetic agent
englitazone in hyperglycemic hyperinsulinemic ob/ob mice.
Diabetes 39, 1218-1227.
161
Stewart, P.M., Boulton, A., Kumar, S., Clark, P.M.S. & Shackleton,
C.H.L. (1999). Cortisol metabolism in human obesity: impaired
cortisone -> Cortisol conversion in subjects with central adiposity.
Journal ofClinical Endocrinology andMetabolism 84, 1022-1027.
Stewart, P.M., Corrie, J.E.T., Shackleton, C.H.L. & Edwards, C.R.W.
(1988). Syndrome of apparent mineralocorticoid excess: a defect in
the cortisol-cortisone shuttle. Journal ofClinical Investigation 82,
340-349.
Stewart, P.M., Wallace, A.M., Atherden, S.M., Shearing, C.H. & Edwards,
C.R.W. (1990). Mineralocorticoid activity of carbenoxolone:
contrasting effects of carbenoxolone and liquorice on 11 (3-
hydroxysteroid dehydrogenase activity in man. Clinical Science
78, 49-54.
Stewart, P.M., Wallace, A.M., Valentino, R., Burt, D., Shackleton, C.H.L.
& Edwards, C.R.W. (1987). Mineralocorticoid activity of liquorice:
11 (3-hydroxysteroid dehydrogenase deficiency comes of age.
Lancet ii, 821-824.
Stewart, P.M., Whorwood, C.B., Valentino, R., Burt, D., Sheppard, M.C.
& Edwards, C.R.W. (1993). 11 p-hydroxysteroid dehydrogenase
activity and gene expression in the hypertensive Bianchi-Milan rat.
Journal ofHypertension 11, 349-354.
Strain, G.W., Zumoff, B., Kream, J., Strain, J.J., Levin, J. & Fukushima,
D. (1982). Sex difference in the influence of obesity on the 24 hr
mean plasma concentration of Cortisol. Metabolism 31, 209-212.
Takaya, K., Ogawa, Y., Isse, N., Okazaki, T., Satoh, N., Masuzaki, H.,
Mori, K., Tamura, N., Hosoda, K. & Nakao, K. (1996). Molecular
cloning of rat leptin receptor isoform complementary DNAs -
identification of a missense mutation in Zucker fatty (fa/fa) rats.
162
Biochemical and Biophysical Research Communications 225, 75-
83.
Takeda, Y., Miyamori, I., Yoneda, T., Ito, Y. & Takeda, R. (1994).
Expression of 11 P-hydroxysteroid dehydrogenase mRNA in rat
vascular smooth muscle cells. Life Sciences 54, 281-285.
Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos,
R., Richards, G.J., Campfield, L.A., Clark, F.T., Deeds, J., Muir,
C., Sanker, S. Moriarty, A., Moore, K.J., Smutko, J.S., Mays, G.G.,
Woolk, E.A., Monroe, C.A. & Tepper, R.I. (1995). Identification
and expressional cloning of a leptin receptor, OB-R. Cell 83,
1263-1271.
Tataranni, P.A., Larson, D.E., Snitker, S., Young, J.B., Flatt, J.P. &
Ravussin, E. (1996). Effects of glucocorticoids on energy
metabolism and food intake in humans. American Journal of
Physiology 271, E317-E325
Thornton, J.E., Cheung, C.C., Clifton, D.K. & Steiner, R.A. (1997).
Regulation of hypothalamic proopiomelanocortin mRNA by leptin
in ob/ob mice. Endocrinology 138, 5063-5066.
Tokuyama, Y. & Himms-Hagen, J. (1987). Increased sensitivity of the
genetically obese mouse to corticosterone. American Journal of
Physiology 252, E202-E208
Tokuyama, Y., Sturis, J., DePauli, A.M., Takeda, J., Stoffel, M., Tang, J.,
Sun, X., Polonsky, K.S. & Bell, G.I. (1995). Evolution of p-cell
dysfunction in the male zucker diabetic fatty rat. Diabetes 44,
1447-1457.
Ulick, S., Levine, L.S., Gunczler, P., Zanconato, G., Ramirez, L.C., Rauh,
W., Rosier, A., Bradlow, H.L. & New, M.I. (1979). A syndrome of
apparent mineralocorticoid excess associated with defects in the
163
peripheral metabolism of Cortisol. Journal of Clinical
Endocrinology andMetabolism 49, 757-764.
Van Zwieten, P.A., Kam, K.L., Pijl, A.J., Beenen, O.H.M., Hendriks,
M.G.C. & Pfaffendorf, M. (1996). Hypertensive diabetic rats in
pharmacological studies. Pharmacological Research 33, 95-105.
Walker, B.R., Campbell, J.C., Fraser, R., Stewart, P.M. & Edwards,
C.R.W. (1992). Mineralocorticoid excess and inhibition of llp-
hydroxysteroid dehydrogenase in patients with ectopic ACTH
syndrome. Clinical Endocrinology 37, 483-492.
Walker, B.R., Connacher, A.A., Lindsay, M., Webb, D.J. & Edwards,
C.R.W. (1995). Carbenoxolone increases hepatic insulin sensitivity
in man: a novel role for 11 -Oxostreroid reductase in enhancing
glucocorticoid receptor activation. Journal of Clinical
Endocrinology and Metabolism 80, 3155-3159.
Walker, B.R. & Edwards, C.R.W. (1994a). Licorice-induced hypertension
and syndromes of apparent mineralocorticoid excess.
Endocrinology and Metabolism Clinics ofNorth America 23, 359-
377.
Walker, B.R., Williams, B.C. & Edwards, C.R.W. (1994b). Regulation of
11 P-Hydroxysteroid dehydrogenase activity by the hypothalamic-
pituitary-adrenal axis in the rat. Journal of Endocrinology 141,
467-472.
Walker, B.R., Yau, J.L., Brett, L.P., Seckl, J.R., Monder, C., Williams,
B.C. & Edwards, C.R.W. (1991). 11 P-Hydroxysteroid
dehydrogenase in vascular smooth muscle and heart: Implications
for cardiovascular responses to glucocorticoids. Endocrinology
129, 3305-3312.
164
Walker, C.-D., Scribner, K.A., Stern, J.S. & Dallman, M.F. (1992). Obese
Zucker (fa/fa) rats exhibit normal target sensitivity to
corticosterone and incresed drive to adrenocorticotropin during the
diurnal trough. Endocrinology 131 , 2629-2637.
Wang, Q., Dryden, S., Frankish, H.M., Bing, C., Pickavance, L., Hopkins,
D., Buckingham, R.E. & Williams, G. (1997). Increased feeding in
fatty Zucker rats by the thiazolidinedione BRL 49653
(rosiglitazone) and the possible involvement of leptin and
hypothalamic neuropeptide Y. British Journal of Pharmacology
122, 1405-1410.
Weaver, J.U., Kopelman, P.G., McLoughlin, L., Forsling, M.L. &
Grossman, A. (1993). Hyperactivity of the hypothalamo-pituitary-
adrenal axis in obesity: a study of ACTH, AVP, |3-lipotrophin and
Cortisol responses to insulin-induced hypoglycaemia. Clinical
Endocrinology 39, 345-350.
Weinstein, S.P., Paquin, T., Pritsker, A. & Haber, R.S. (1995).
Glucocorticoid-induced insulin resistance: dexamethasone inhibits
the activatioin of glucose transport in rat skeletal muscle by both
insulin- and non-insulin-related stimuli. Diabetes 44, 441-445.
White, B.D., Corll, C.B. & Porter, J.R. (1989). The metabolic clearance
rate of corticosterone in lean and obese male Zucker rats.
Metabolism 38, 530-536.
Whitworth, J.A. (1994). Studies on the mechanisms of glucocorticoid
hypertension in humans. Blood Pressure 3, 24-32.
Whorwood, C.B., Sheppard, M.C. & Stewart, P.M. (1993). Licorice
inhibits 11 (3-hydroxysteroid dehydrogenase messenger ribnucleic
acid levels and potentiates glucocorticoid hormone action.
Endocrinology 132, 2287-2292.
165
Wilson, R.C., Harbison, M.D., Krozowski, Z.S., Funder, J.W., Shackleton,
C.H.L., Hanauske-Abel, H.M., Wei, J.-Q., Hertecant, J., Moran, A.,
Neiberger, R.E., Williamson Balfe, J., Fattah, A., Daneman, D.,
Licholai, T. & New, M.I. (1995a). Several homozygous mutations
in the gene for lip -hydroxysteroid dehydrogenase type 2 in
patients with apparent mineralocorticoid excess. Journal of
Clinical Endocrinology andMetabolism 80, 3145-3150.
Wilson, R.C., Krozowski, Z.S. & Li, K.X.Z. (1995b). A mutation in the
HSD11B2 gene in a family with apparent mineralocorticoid excess.
Journal ofClinical Endocrinology andMetabolism 80, 2263-2266.
Witztum, J.L. & Schonfeld, G. (1979). Lipoprtoteins in the plasma and
hepatic perfusates of the Zucker fatty rat. Diabetes 28, 509-516.
Wu-Peng, X.S., Chua, S.C., Okada, N., Liu, S.-M., Nicolson, M. & Leibel,
R.L. (1997). Phenotype of the obese Koletsky (/) rat due to
Tyr763Stop mutation in the extracellular domain of the leptin
receptor (Lepr). Diabetes 46, 513-518.
Yamamoto, K.R. (1985). Steroid receptor regulated transcription of of
specific genes and gene networks. Annual Reviews ofGenetics 19,
209-215.
Yang-Yen, H.-F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J.,
Drouin, J. & Karin, M. (1990). Transcriptional interference
between c-Jun and the glucocorticoid receptor: mutual inhibition of
DNA binding due to direct preotein-protein interaction. Cell 62,
1205-1215.
Yaswen, L., Diehl, N., Brennan, M.B. & Hochgeschwender, U. (1999).
Obesity in the mouse model of pro-opiomelanocortin deficiency
responds to peripheral melanocortin. Natural Medicines 5, 1066-
1070.
166
York, D.A. & Godbole, V. (1979). Effect of adrenalectomy on obese fatty
rats. Hormone and Metabolism Research 11, 646
York, D.A., Marchington, D., Holt, S.J. & Allars, J. (1985). Regulation of
sympathetic activity in lean and obese (fa/fa) Zucker rats.
American Journal ofPhysiology 249, E299-E305
York, D.A., Steinke, J. & Bray, G.A. (1972). Hyperinsulinaemia and
insulin resistance in genetically obese rats. Metabolism 21, 277-
284.
Young, M.E. & Leighton, B. (1998). Evidence for altered sensitivity of the
nitric oxide/cGMP signalling cascade in insulin-resistant skeletal
muscle. Biochemical Journal 329, 73-79.
Yukimura, Y., Bray, G.A. & Wolfsen, A.R. (1978). Some effects of
adrenalectomy in the fatty rat. Endocrinology 103, 1924-1928.
Zakrzewska, K.E., Cusin, I., Stricker-Krongrad, A., Boss, O., Ricquier, D.,
Jeanrenaud, B. & Rohner-Jeanrenaud, F. (1999). Induction of
obesity and hyperleptinemia by central glucocorticoid infusion in
the rat. Diabetes 48, 365-370.
Zarjevski, N., Cusin, I., Vettor, R., Rohner-Jeanrenaud, F. & Jeanrenaud,
B. (1993). Chronic intracerebroventricular neuropeptide Y
administration to normal rats mimics hormonal and metabolic
changes of obesity. Endocrinology 133, 1753-1758.
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. & Freedman,
J.M. (1994). Positional cloning of the mouse obese gene and its
human homolog. Nature 372, 425-432.
Zucker, L.M. & Zucker, T.M. (1961). Fatty, a new mutation in the rat.
Journal ofHeredity 52, 275-278.
167
Zumoff, B., Bradlow, H.L., Levin, J. & Fukushima, D.K. (1983). Influence
of thyroid function on the in vivo cortisol-cortisone equilibrium in
man. Journal ofSteroid Biochemistry 18, 437-440.
168
Publications From This Thesis
Full papers
1) Understanding the role of glucocorticoids in obesity: tissue specific
alterations of corticosterone metabolism in obese Zucker rats. (2000)
DEW Livingstone, GC Jones, K Smith, PM Jamieson, R Andrew, CJ
Kenyon, BR Walker.
Endocrinology, 141 (2) pp560-563.
2) Mechanisms of dysregulation of 11 P-hydroxysteroid dehydrogenase
type 1 in obese Zucker rats. (2000)
DEW Livingstone, CJ Kenyon, BR Walker.
In preparation
3) The ebb and flow of Cortisol in obesity: high tide in subcutaneous fat.
(2000)
E Rask, T Olsson, S Soderberg, R Andrew, DEW Livingstone, O Johnson,
BR Walker. ^ ~
In preparation
Abstracts
1) Impaired hepatic 11 P-hydroxysteroid dehydrogenase type 1 in the obese
Zucker rat: implications for glucocorticoid metabolism in obesity. (1997)
DE Watson, CJ Kenyon, PM Jamieson, S Nelson, BR Walker.
Journal ofEndocrinology; 155 (suppl); OC3.
2) Tissue specific differences in 11 P-hydroxysteroid dehydrogenase in
Zucker obese rats. (1998)
DE Watson, CJ Kenyon, BR Walker.
Journal ofEndocrinology; 156 (suppl); OC42.
3) Altered glucocorticoid metabolism in Zucker obese rats mimics human
obesity. (1999)
DEW Livingstone. K Smith, CJ Kenyon, BR Walker, R Andrew.
Journal ofEndocrinology; 160 (suppl); P209.
4) Enhanced glucocorticoid metabolism in Obese Zucker rats: a novel
explanation for activation of the HPA in obesity. (1999)
DEW Livingstone, GC Jones, K Smith, CJ Kenyon, R Andrew, BR
Walker.
Endocrinology; Proceedings of the 81st meeting of the Endocrine Society;
P2-216.
169
5) Mechanisms of dysregulation of 11 p-hydroxysteroid dehydrogenase
type 1 in obese Zucker rats. (2000)
DEW Livingstone. CJ Kenyon, BR Walker.




Copyright © 2000 by The Endocrine Society
Vol. 141. No. 2
Printed in U.S-A.
Understanding the Role of Glucocorticoids in Obesity:
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DAWN E. W. LIVINGSTONE, GREGORY C. JONES, KEN SMITH,
PAULINE M. JAMIESON, RUTH ANDREW, CHRISTOPHER J. KENYON, and
BRIAN R. WALKER
Department ofMedical Sciences, University ofEdinburgh, Western General Hospital, Edinburgh,
United Kingdom EH4 2XU
ABSTRACT
The role of glucocorticoids in obesity is poorly understood. Obser¬
vations in obese men suggest enhanced inactivation of Cortisol by
5a-reductase and altered reactivation of cortisone to Cortisol by 110-
hydroxysteroid dehydrogenase type 1 (110HSD1). These changes in
glucocorticoid metabolism may influence corticosteroid receptor ac¬
tivation and feedback regulation of the hypothalamic-pituitary-ad-
renal axis (HPA). We have compared corticosterone metabolism in
vivo and in vitro in male obese and lean Zucker rats, aged 9 weeks (n =
8/group). Steroids were measured in 72-h urine and 0900 h trunk
blood samples. 5a-Reductase type 1 and 110HSD activities were as¬
sessed in dissected tissues. Obese animals were hypercorticosteron-
emic and excreted more total corticosterone metabolites (2264 ± 623
vs. 388 ± 144 ng/72 h; P = 0.003), with a greater proportion being
5a-reduced or 11-oxidized. 11-Dehydrocorticosterone was also ele¬
vated in plasma (73 ± 9 us. 18 - 2 nM; P = 0.001) and urine (408 ±
111 us. <28 ng/72 h;P = 0.01). In liver ofobese rats, 5a-reductase type
1 activity was greater (20.6 ± 2.7% vs. 14.1 ± 1.5%; P < 0.04), but
110HSD1 activity (maximum velocity, 3.43 ± 0.56 vs. 6.57 ± 1.13
nmol/min/mg protein; P = 0.01) and messenger RNA levels (0.56 ±
0.08 vs. 1.03 ± 0.15; P = 0.02) were lower. In contrast, in obese rats,
110HSD1 activity was not different in skeletal muscle and sc fat and
was higher in omental fat (36.4 ± 6.2 vs. 19.2 ±6.6 ;P = 0.01), whereas
110HSD2 activity was higher in kidney (16.7 ± 0.6% vs. 11.3 ± 1.5%;
P = 0.01).
We conclude that greater inactivation of glucocorticoids by 5a-
reductase in liver and 110HSD2 in kidney combined with impaired
reactivation ofglucocorticoids by 110HSD1 in liver may increase the
MCR of glucocorticoids and decrease local glucocorticoid concentra¬
tions at these sites. By contrast, enhanced 110HSD1 in omental
adipose tissue may increase local glucocorticoid receptor activation
and promote obesity. (Endocrinology 141: 560-563, 2000)
INCREASED SECRETION of glucocorticoids (e.g. inCushing's syndrome) is associated with obesity, and
Cortisol secretion is increased in subjects with idiopathic
obesity, especially of central distribution (1). However,
peak plasma Cortisol levels are not elevated in idiopathic
obesity (2), suggesting that peripheral metabolism of Cor¬
tisol may be enhanced. We recently reported that inacti¬
vation of Cortisol to 5a-tetrahydrocortisol is enhanced in
obese humans (3). Alternatively, increased activation of
glucocorticoid receptors in obesity could result from
raised local, rather than systemic, glucocorticoid concen¬
trations. We and others have suggested that obesity is
exaggerated because of increased reactivation of inactive
cortisone into Cortisol in adipose tissue by 11/3-hydroxy-
steroid dehydrogenase type 1 (11/3HSD1) (3, 4).
Obese Zucker rats are leptin resistant due to a homozy¬
gous point mutation in the leptin receptor gene (5). Glu¬
cocorticoids seem to be important in the development of their
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obesity, as adrenalectomy or glucocorticoid receptor antag¬
onists attenuate weight gain and associated metabolic ab¬
normalities (6, 7). Because of their relevance to local glu¬
cocorticoid levels and MCR, we have now examined
glucocorticoid-metabolizing enzymes in Zucker rats. Specif¬
ically, we have measured inactivation of corticosterone by
the enzymes 5a-reductase type 1 in liver and 11J3HSD type




Groups of eight 5-week-old male obese and lean Zucker rats (Harlan
Orlac, Bicester, UK) were characterized by phenotype, maintained under
controlled conditions of light (lights on, 0800-2000 h) and temperature
(21 C) and allowed free access to standard rat chow (Special Diet Ser¬
vices, Witham, UK) and drinking water. At 8 weeks of age, animals were
acdimatized in metabolic cages for 4 days before 72-h urine collection.
At 9 weeks of age, they were decapitated between 0900-1100 h, and
trunk blood was collected. Tissues were dissected, and whole adrenals
were blotted dry and weighed. Portions of other tissues were snap-
frozen on dry ice or mechanically homogenized in Krebs-Ringer buffer
(118 ma NaCl, 3.8 mM KC1, 1.19 mM KH-P04, 2.54 mMCaClj, 1.19 m.M
MgSO,,, and 25 mM NaHCOj, pH 7.4).
Measurement of endogenous steroids
Plasma corticosterone and 11-dehydrocorticosterone were measured
in trunk blood by RIAs. Urinary steroids were extracted and derivatised
from a 10-ml aliquot for each animal using methods previously de-
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scribed for human urine (8), except that epicorticosterone and epitet-
rahydrocorticosterone (Steraloids, Newport, RI) were used as internal
standards and 2-g/12-cc Sep-Pak cartridges (Waters Corp., Herts, UK)
were used. Steroids were quantified using a Voyager gas chromato-
graph-mass spectrometer (Finnigan, Manchester, UK) in electron impact
mode fitted with a EC-5 capillary column (30 m; id, 0.25 mm; film
thickness, 0.25 (am; Alltech, Camforth, UK).
Measurement of enzyme activities
In vivo 11J3HSD1 is a reductase, converting inactive 11-dehydrocor-
ticosterone to corticosterone. However, in vitro dehydrogenase activity
predominates, so we quantified 11/3HSD1 activity by conversion of
corticosterone to 11-dehydrocorticosterone. Hepatic 11/3HSD1 kinetics
were determined by preparing microsomes from tissue homogenate (by
centrifugation; 14,000 X g for 20 min, supernatant was removed and
centrifuged at 100,000 X g for 60 min, pellet was resuspended in Krebs-
Ringer buffer). The protein concentration was determined colorimetri-
cally. Microsomal preparations (15 /ag/ml protein) were incubated in
duplicate at 37 C in Krebs-Ringer buffer containing 0.2% glucose, NADP
(2 mm), [3H]corticosterone (50 hm), and unlabeled corticosterone (0.3-10
/am). After 10 min, steroids were extracted with ethyl acetate, the organic
phase was evaporated under nitrogen, and extracts were resuspended
in mobile phase (20% methanol, 30% acetonitrile, and 50% water). Ste¬
roids were separated by HPLC using a reverse phase /r-Bondapak Cl8
column (Phenomenex, Cheshire, UK) and were quantified by on-line
liquid scintillation counting.
11(3HSD1 activity was also measured in homogenates of liver (10
/Ag/mi protein), quadriceps skeletal muscle (1.5 mg/ml), sc lumbar fat
(0.5mg/ml), and omental fat (1 mg/ml) by the samemethod, except that
TABLE 1. Comparison of corticosteroids in lean and obese Zucker
rats
Lean In = 8) Obese in. = 8) P
BW at 9 weeks (g) 226 * 7 280 * 6 <0.001
Adrenal wt (mg) 38 i 2 54 ± 7 0.04
Adrenal/body wt 0.17 = 0.01 0.20 ± 0.03 0.75
Plasma (nM)
Corticosterone 78 ± 48 446 ± 91 0.002
11-Dehydrocorticosterone 18 2 73 = 9 0.001
Urine (ng/72 h)
Corticosterone (B) ND ND
11-Dehydrocorticosterone (A) ND 408 = 111 0.01
5 (S-TetrahydroB 20 * 11 60 = 21 0.53
5a-TetrahydroB 369 ± 114 1653 = 562 0.06
53-TetrahydroA ND 144 r 42 0.001
Sum of B metabolites 388 = 114 2264 = 623 0.003
Data are the mean i: sem. ND, Not detected. P values were de¬
termined by Mann-Whitney U tests. Limits of detection: 14—28 ng/72
h (urine) and 6.25 nm (plasma).
Fig. 1. Data are the mean ± sem for
eight lean (open symbols) and eight
obese (closed symbols) Zucker rats. P
values are forMann-Whitney U tests. A
shows llfiHSD activity in homogenates
of each tissue incubated with NADP,
except where indicated. B shows Line-
weaver-Burke plots for summarized
data from lean and obese liver micro¬
somes. K,„ values (2.15 z: 0.55 /am in
lean us. 1.80 z: 0.53 /am in obese; P -
0.31) and maximum velocity (V„..J val¬
ues (6.57 z: 1.13 nmol/min-mg protein in
lean us. 3.43 z 0.56 nmol/mimmg pro¬
tein in obese; P = 0.01) were calculated










incubations were performed for 60 min in the presence of 100 nM
[3H]corticosterone. Conditions were optimized for each tissue to ensure
first order kinetics. 11/3HSD activity was measured in kidney homog¬
enates by the same method (50 /Ag/ml protein). In addition, to detect
11/3HSD type 2 rather than type 1 activity, incubations were performed
with NAD (2 mM) rather than NADP as cofactor and 10 nM
[3H]corticosterone.
5a-Reductase type 1 activity was assessed in liver, as previously
described in prostate (9), by measuring the metabolism of testosterone
to 5a-dihydrotestosterone. Liver homogenate (0.5 mg/ml protein) was
incubated in duplicate at 37 C in orthophosphate buffer (40 mM
Na2HP04, pH 7.5) with NADPH (1 mM) and [3H]testosterone (50 nM) as
a substrate. After 10 min, steroids were extracted with ethyl acetate, the
organic phase was evaporated under nitrogen, and extracts were re¬
suspended in ethanol with unlabeled testosterone and 5a-dihydrotes-
tosterone and separated by TLC. Fractions containing testosterone and
5n-dihydrotestosterone were identified with phosphomolvbdic acid,
scraped from plates, and counted in Cocktail T liquid srintillant (BDH,
Dorset, UK).
Radiolabeled steroids were obtained from Amersham Pharmacia Bio¬
tech (Aylesbury, UK). Solvents were HPLC glass-distilled grade from
Rathbum Chemicals (Walkerburn, UK). Other chemicals were pur¬
chased from Sigma (Poole, UK).
Quantification ofmessenger RNA (mRNA) by Northern blot
Total mRNA was extracted from snap-frozen liver samples, and 20
/xg were separated by electrophoresis. The RNA was blotted onto a
Bio-Rad Laboratories, Inc. Zeta-Probe nylon membrane (Richmond,
CA), and llflHSDl mRNA was identified as previously described (10).
Hybridized probe was quantified using a Fuji Photo Film Co., Ltd.
FLA2000 fluorescent image analyzer (Tokyo, Japan). Membranes were
rehybridized with a glyceraldehyde-3-phosphate dehydrogenase probe
using the same method, to control for differences in mRNA loading and
transfer.
Results
In obese rats, plasma corticosterone concentrations and
total urinary corticosterone metabolites were elevated com¬
pared with those in lean Zucker rats (Table 1). Obese rats
exhibited a larger difference in excretion of metabolites of
11-dehydrocorticosterone (>10-fold higher) than of cortico¬
sterone (3- to 5-fold higher), and a more substantial differ¬
ence in 5a-reduced rather than 5/3-reduced metabolites of
corticosterone compared with lean rats. Adrenal glands were
heavier in obese animals, but this was not statistically sig¬
nificant after correction for body weight.
In liver of obese rats 5a-reductase type 1 activity was
increased (20.6 ± 2.7% in obese vs. 14.1 ± 1.5% in lean; P <




Liver Muscle Subcut Omental Kidney Kidney
Fat Fat NADP NAD
1 0.33
1/Substrate (1/pM)
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(118HSDl/glyceraldehvde-3-phosphate dehydrogenase ra¬
tio, 0.56 ± 0.08 in obese vs. 1.03 ± 0.15 in lean; P = 0.02) were
also markedly lower in obese rats, but there was no differ¬
ence in Kn, for corticosterone (Fig. 1). However, 11/3HSD1
activity was not different between groups in skeletal muscle
or sc fat and was higher in omental fat from obese rats (Fig.
1). In the kidney, both NADP-dependent (11/3HSD1) and
NAD-dependent (11/3HSD2) 11/3HSD activities were greater
in obese rats (Fig. 1).
Discussion
These data confirm previous reports that obese Zucker rats
have heavier adrenal glands (11) and increased urinary free
corticosterone excretion (12) compared with lean controls,
but this is the first study to examine the excretion of urinary
corticosterone metabolites. We also show that there are
tissue-specific differences in peripheral metabolism of cor¬
ticosterone in obese Zucker rats compared with their lean
controls.
There are two isozymes of 5a-reductase, but only the type
1 isozyme is expressed in rat liver (13). This isozyme reduces
most A4,5 unsaturated steroids with similar efficiency, in
contrast to the type 2 isozyme, which modulates androgen
receptor activation by converting testosterone to active 5a-
dihydrotestosterone (14). In obese Zucker rats we found an
increase in urinary excretion of 5a-reduced corticosterone
metabolites and increased activity of 5a-reductase in liver.
Interconversion of active corticosterone with inactive 11-
dehydrocorticosterone (or Cortisol and cortisone, respec¬
tively, in man) is catalyzed by the isozymes of 11/3HSD.
11/3HSD type 2 is NAD dependent, catalyzes the dehydro¬
genase (inactivating) reaction, and is expressed in tissues
such as distal nephron, where it protects mineralocorticoid
receptors from inappropriate activation by glucocorticoids
(15). In obese Zucker rats, we found higher renal NAD-
dependent 11/3HSD activity in vitro, predicting enhanced
inactivation of corticosterone. 11/3HSD type 1 is NADP(H)
dependent and is expressed in a wider range of tissues,
including liver, adipose tissue, and skeletal muscle, where it
is usually a reductase, reactivating glucocorticoids and main¬
taining local activation of glucocorticoid receptors (16).
11/3HSD1 activity and mRNA levels were decreased in liver
of obese animals, whereas affinity for corticosterone was not
different. By contrast with liver, 11/3HSD1 activity was
higher in omental adipose tissue from obese rats, butwas not
different in skeletal muscle and sc adipose tissue. The overall
balance between 11/3HSD activities in different tissues was
assessed by excretion of corticosterone metabolites in urine.
In obese Zucker rats we found differences in urinary me¬
tabolites consistent with an alteration in overall balance of
whole body ll/3HSDs toward inactive 11-dehydrocortico-
sterone, suggesting that decreased hepatic 11/3HSD1 and
increased renal 11/3HSD2 predominate over changes in other
tissues.
The combination of increased 5a-reductase, increased re¬
nal 11/3HSD2, and decreased hepatic 11/3HSD1 activities pre¬
dict an increased glucocorticoid MCR. In normal circum¬
stances this would result in a compensatory increase in
corticosterone production (17). This mechanism could con¬
tribute to activation of the hypothalamic-pituitary-adrenal
axis (HPA) and adrenocortical hypertrophy in obesity. How¬
ever, it does not explain why trough plasma corticosterone
levels are elevated in obese rats. Abnormalities of central
control of the HPA have been sought previously in these
animals, but responses to glucocorticoid feedback and stress¬
ful stimuli have been variably reported as normal, increased,
or decreased (18-20). Moreover, it remains unclear whether
leptin resistance alone could explain activation of the HPA,
as there may be opposing effects of increased neuropeptide
Y and decreased POMC expression (21-23). If obese rats have
similarly reduced 11/3HSD1 expression in brain and pitu¬
itary, this may explain central HPA activation. Mice with
transgenic disruption of the 11/3HSD1 gene (16) have in¬
creased plasma corticosterone levels, which have been at¬
tributed to decreased 11/3HSD1 (and hence local corticoste¬
rone levels) in sites responsible for negative feedback
(hippocampus, hypothalamus, and anterior pituitary).
The observed changes in glucocorticoid metabolism also
predict changes in peripheral corticosteroid receptor activa¬
tion. Enhanced inactivation (5a-reductase) and impaired re¬
activation (11/3HSD1) of glucocorticoids in the liver predict
lower intracellular corticosterone concentrations. Decreased
glucocorticoid exposure would normally be associated with
enhanced insulin sensitivity and decreased gluconeogenesis,
as in 11/3HSD1 knockout mice (16), so itmay be that reduced
hepatic glucocorticoid exposure in the obese Zucker rat rep¬
resents a compensatory mechanism that limits the metabolic
complications of obesity. By contrast, 11/3HSD1 activity was
normal in other glucocorticoid targets (skeletal muscle and
sc adipose tissue) in obese rats, so the proposed compensa¬
tory mechanism may not operate in all tissues. Moreover,
11/3HSD1 activity was elevated in omental fat in obese rats,
and this predicts higher local glucocorticoid receptor acti¬
vation and may promote obesity.
The current study does not address the mechanism of
dysregulation of 5a-reductase and llflHSD activities in obe¬
sity. With respect to 11/3HSD1 we have shown that there is
no difference in affinity for corticosterone in obese Zucker
rats, and that hepatic mRNA levels are reduced, suggesting
that gene transcription is altered in obese animals. It is un¬
likely that the altered 11/3HSD activities are secondary to
activation of the HPA, as chronic glucocorticoid excess is
associated with up-regulation (not down-regulation) of he¬
patic llflHSDl activity and expression (24). 11/3HSD1 is reg¬
ulated bymany other factors, including some that are altered
in obesity, such as GH, insulin, tumor necrosis factor-a, and
gonadal steroids (25-27). By contrast, 5a-reductase type 1
and 11/3HSD type 2 do not appear to be highly regulated
enzymes. Further studies will be required to elucidate these
mechanisms.
Finally, the differences inmetabolism of glucocorticoids in
obese Zucker rats mirror observations in obese humans. We
and others have reported that obese men and women excrete
more Cortisol as 5a-reduced metabolites (3, 28). Detailed
dynamic tests and arteriovenous sampling have shown that
hepatic llflHSDl activity is impaired in obese men (29), but
adipose 11/3HSD1 is either maintained or marginally in¬
creased in obesity (30). The present studies demonstrate that
the obese Zucker rat will be a useful model in which to
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explore the mechanisms of disrupted glucocorticoid metab¬
olism, its impact on bodyweight regulation, and its potential
for therapeutic manipulation.
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